Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers

ABSTRACT

A method of diagnosing a disease that includes obtaining experimental data on gene selections. The gene selection functions to characterize a cancer when the expression of that gene selection is compared to the identical selection from a noncancerous cell or a different type of cancer cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for diagnosing a cancer.

This application is a continuation in part of a U.S. patent application Ser. No. 10/133,937 entitled “METHODS FOR ANALYZING HIGH DIMENSIONAL DATA FOR CLASSIFYING, DIAGNOSING, PROGNOSTICATING, AND/OR PREDICTING DISEASES AND OTHER BIOLOGICAL STATES”, filed on Apr. 25, 2002.

FIELD OF THE INVENTION

The invention relates generally to selections of genes expressed in a cancer cell that function to characterize a cancer, and methods of using the same for diagnosis and for targeting the therapy of select cancers. The invention also relates generally to the use of supervised pattern recognition methods to classify and diagnose disease. More specifically, the invention relates to the use of supervised pattern recognition methods, such as artificial neural networks for the classification, diagnosis, prognosis and prediction of disease using high dimensional data, such as gene expression profiling data.

BACKGROUND OF THE INVENTION

Disease is generally diagnosed based on a myriad of factors, both objective and subjective, including but not limited to symptoms, laboratory test values, demographic factors and environmental factors. Diagnosis relies on a clinician such as a physician or a veterinarian being able to identify and evaluate the relevant factors. Often this task can be difficult, and becomes exceedingly more so as the number of factors to be considered increases.

An example of a disease whose diagnosis is difficult is tumors. Tumors are currently diagnosed on the basis of clinical presentation, routine histology, immunohistochemistry and electron microscopy. However the histological appearance may not reveal the genetic aberrations or underlying biologic processes that contribute to the malignancy. Monitoring global gene expression levels using DNA microarrays would provide an additional tool for elucidating tumor biology as well as the potential for molecular diagnostic classification of cancers. Several studies have demonstrated that gene expression profiling using DNA microarrays is able to classify tumors with a high accuracy, and discover new cancer classes.

A specific type of tumors which could benefit is the small, round blue cell tumors (SRBCTs) of childhood as a model. SRBCTs include, neuroblastoma (NB), rhabdomyosarcoma (RMS), Burkitt's lymphoma (also called Burkitt's) (BL) and the Ewing family of tumors (EWS), are so named because of their similar appearance on routine histology. However, accurate diagnosis of SRBCTs is essential because the treatment options, responses to therapy, and prognoses vary widely depending on the diagnosis. As their name implies, these cancers are difficult to distinguish by light microscopy, and currently no single test can precisely distinguish these cancers.

In clinical practice, several techniques are used for diagnosis, including immunohistochemistry, cytogenetics, interphase fluorescence in situ hybridization and reverse transcription (RT)-PCR. Immunohistochemistry allows the detection of protein expression, but it can only examine one protein at a time. Molecular techniques such as RT-PCR are used increasingly for diagnostic confirmation following the discovery of tumor-specific translocations such as EWS-FLI1; t(11;22)(q24;q12) in EWS, and the PAX3-FKHR; t(2;13)(q35;q14) in alveolar rhabdomyosarcoma (ARMS). However, molecular markers do not always provide a definitive diagnosis, as on occasion there is failure to detect the classical translocations, due to either technical difficulties or the presence of variant translocations.

An example of a diagnostic method replete with such problems is the diagnostic method for Ewing sarcoma. Ewing sarcoma is diagnosed by immunohistochemical evidence of MIC2 expression and lack of expression of the leukocyte common antigen CD45 (excluding lymphoma), muscle-specific actin or myogenin (excluding RMS). However, reliance on detection of MIC2 alone can lead to incorrect diagnosis as MIC2 expression occurs occasionally in other tumor types including RMS and BL.

One objective factor that can, in certain circumstances, be entirely predictive of a diseased state is the genetic makeup of the individual. Genetic makeup of an individual cell can also be considered in terms of the level of expression of the genes of that individual cell through gene expression data.

DNA microarray technology is a recently developed high throughput technology for monitoring gene expression at the transcription level. Its use is akin to performing tens of thousands of northern blots simultaneously, and has the potential for parallel integration of the expression levels of an entire genome. A DNA microarray consists of DNA probes immobilized on a solid support such as a glass microscope slide. The DNA probes can be double stranded cDNA or short (25 mers) or long (50-70 mers) oligonucleotides of known sequences. An ideal DNA microarray should be able to interrogate all of the genes expressed in an organism.

In DNA microarrays using cDNA, the probes are PCR amplified from plasmid cDNA clones that have been purified and robotically printed onto coated glass slides. DNA microarrays using oligonucleotide have an advantage over cDNA microarrays because physical clones are not necessary. The oligonucleotides can either be previously synthesized and printed on glass slides, or can be synthesized directly on the surface of silicon or glass slides. Several print-ready oligonucleotide (60-70 mers) sets are commercially available for human, mouse and other organisms (http://www.cgen.com, http://www.operon.com).

Another technique for fabricating oligonucleotides microarrays chemically synthesizes the oligonucleotides (25 mers) on a silicon surface using photolithography techniques. (Affymetrix Inc., Santa Clara, Calif.). Originally such arrays were designed to detect single-nucleotide mutations, but now have applications for gene expression profiling studies. Yet another technique delivers single nucleic acids, which ultimately form longer oligonucleotides (60 mers), by ink-jet onto glass surfaces.

One method of utilizing gene expression data from microarrays is given by Tusher et al., PNAS 98(9) p. 5116-21, April, 2001. The method of Tusher et al. is a statistical method titled Significance Analysis of Microarrays (“SAM”). The general approach in SAM is based on commonly used statistical tests, t-tests specifically, to find genes that discriminate between two classes in a gene-by-gene fashion. SAM uses replication of experiments to assign a significance to the discriminating genes in terms of a false discover rate. SAM therefore offers a method of choosing particular genes from a set of gene expression data, but does not offer a diagnosis based on those genes.

DNA microarrays would be an invaluable tool for disease diagnosis. Gene-expression profiling using DNA microarrays permits a simultaneous analysis of multiple markers, and can be used for example to categorize cancers into subgroups. The only limitation associated with the use of DNA microarrays is the vast amount of data generated thereby. A method that would allow for the easy and automated use of DNA microarray data in disease diagnosis is therefore desirable. Despite the many statistical techniques to analyze gene-expression data, none so far has been rigorously tested for their ability to accurately distinguish diseases belonging to several diagnostic categories. Such methods have also not been used to extract the genes or features that are the most important for the classification performance. Such genes would also generally be those that are of use to biologists and physicians as offering avenues to research in investigating cures.

However, these other methods have not been used to extract the genes or features that are most important for the classification performance and which also will be of interest to cancer biologists.

Therefore, there remains a need for a method of using gene expression data to diagnose, predict, or prognosticate about a disease condition.

SUMMARY OF THE INVENTION

In accordance with one embodiment of the invention, there is provided a selection of genes, expressed in a cancer cell, that functions to characterize the cancer when the expression of a gene selection from the cancer cell is compared to the expression of an identical selection of genes from a noncancerous cell or an identical selection of genes from a different type of cancer cell.

Another embodiment of the invention includes a method of targeting a product of at least one of the genes in table 5 (below) that includes administering a therapeutic agent. Another embodiment of the invention includes a method of targeting a product of at least one of the genes in tables 2, 6, 7, 8, or 9 (below) that includes administering a therapeutic agent having an effect on said gene product. Yet another embodiment of the invention includes a method of targeting a product of at least one of the genes in table 10 (below) that includes administering a therapeutic agent having an effect on said gene product.

Another embodiment of the invention includes a method of using a selection of genes expressed in a cell having a particular type of cancer, wherein the gene selection functions to characterize the particular type of cancer when the expression of the gene selection from the cell is compared to the expression of an identical selection of genes from a cell without that particular type of cancer for diagnosing the particular type of cancer. Devices for carrying out the above methods of the invention are also included within the scope of the invention.

Another embodiment of the invention provides a method of diagnosing, predicting, and/or prognosticating about a disease including obtaining experimental data, wherein the experimental data includes high dimensional data, filtering noise from the data, reducing the dimensionality of the data by using one or more methods of analysis, training a supervised pattern recognition and/or classification method, ranking individual data from the overall data based on the relevance of the individual data to the diagnosis, prediction, prognosis or classification, choosing multiple individual data members, wherein the choice is based on the relative ranking of the individual data, and using the chosen data to determine if an unknown set of experimental data indicates a particular diseased condition, prognosis, prediction, or classification.

The invention offers a method of diagnostic classification of cancers from their gene-expression signatures and also identifies the genes that contributed to this classification. One embodiment of the method diagnoses SRBCTs of childhood, which occasionally present diagnostic difficulties.

The invention also offers a method of diagnosing, predicting, and/or prognosticating about SRBCTs including obtaining gene expression data, filtering noise from the gene expression data, reducing the dimensionality of the data by using principal component analysis (PCA), training an ANN, ranking the individual genes from the gene expression data, choosing multiple genes from the gene expression data, wherein the choice is based on the relative ranking of the individual genes and using the chosen genes to determine if an unknown set of gene expression data indicates a particular diseased condition, prognosis, and/or a prediction.

Methods of the invention can be utilized in a number of different applications. For example, diagnostic chips can be fabricated based on the identification of the diagnostic genes. Such chips would be very useful in clinical settings, as it would allow clinicians to diagnose cancers from a relatively small set of genes instead of purchasing entire gene sets.

Methods of the invention can also be used to define which patients with the same types of cancers are likely to respond to treatment. This would allow a physician to intensify treatment for those with a more negative prognosis based on their gene expression profiles as detected utilizing a method of the invention.

Methods of the invention can also be used for identifying pharmaceutical targets. Pharmaceutical companies can utilize methods of the invention to determine which genes to target in efforts to target specific diseases.

Methods of the invention can also be utilized as a research tool for analyzing all types of gene expression data including cDNA and oligonucleotide microarray data.

Methods of the invention can also be utilized to identify and rank, by importance, the genes that contribute to a diagnosis. A minimal set of genes that can correctly classify and identify diagnostic categories can also be determined using methods of the invention.

Methods of the invention identify the most significant genes, by calculating the sensitivity of the classification to a change in the expression level of each gene. A list of genes, ranked by their significance to the classification, is produced thereby. In an embodiment of the invention utilized for classifying SRBCTs the most important 96 genes reduced the misclassifications to zero. This allows for cost effective fabrication of SRBCT subarrays for diagnostic use. When a method of the invention used the 96 genes on 25 unknown samples, all 20 samples of SRBCTs and 5 non-SRBCTs were correctly classified.

One embodiment of the invention calibrates ANN models on the expression profiles of 63 SRBCTs of 4 diagnostic categories. Preferred embodiments of the invention utilize linear (that is no hidden layers) ANN models because of the high performance achieved. Methods of the invention may utilize other linear methods as well, and methods of the invention can easily accommodate nonlinear features of expression data if required. Hidden layers will be utilized for non linear data. Preferably, both tumor samples and cell line samples are used in order to compensate for heterogeneity within unknown samples (which contain both malignant and stromal cells) based on possible artifacts due to growth of cell lines in tissue culture.

Data from such samples is complementary, because tumor tissue, though complex, provides a gene-expression pattern representative of tumor growth in vivo, while cell lines contain a uniform malignant population without stromal contamination. Despite using only neuroblastoma (NB) cell lines for calibrating the ANN models, all four NB tumors among the test samples were correctly diagnosed with high confidence. This not only demonstrates the high similarity of NB cell lines to the tumors of origin, but also validates the use of cell lines for ANN calibration. One embodiment of a method of the invention accurately classified all 63 training SRBCTs and showed no evidence of over-training, thereby demonstrating the robustness of this method.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 illustrates a process flow for a method to classify and diagnose diseases using artificial neural networks according to one embodiment of the invention.

FIG. 2 illustrates a general purpose computing system utilized as part of an artificial neural network according to another embodiment of the invention.

FIG. 3 illustrates a set of processing modules making up an embodiment of an artificial neural network according to the invention.

FIG. 4 represents a plot of the average classification error per sample (using a summed square error function) plotted during the training iterations (epochs) for both the training and validation samples.

FIG. 5 represents a plot of the average number of misclassified samples for all 3750 models plotted against an increasing number of used genes.

FIG. 6 represents a plot of the distance from the samples committee vote to the ideal vote for that diagnostic category.

FIG. 7 represents two projections of the MDS plot of the training samples.

FIG. 8 represents a hierarchical clustering of the samples and genes, where each row represents one of the 96 cDNA clones, and each column represents a separate sample.

FIG. 9 represents a hierarchical clustering dendrogram of the samples in FIG. 8.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention is a method of classifying, diagnosing, prognosticating about, and predicting disease conditions or other biological states using supervised pattern recognition methods to analyze high dimensional data.

One embodiment of the invention is illustrated in FIG. 1. This process flow describes an embodiment of the method that includes obtaining experimental data 101, filtering the data 102, reducing the dimensionality of the data 103, setting up a validation method 115, training a supervised pattern recognition method 111, validating the outcome of the supervised pattern recognition method 112, and once the supervised pattern recognition method is validated, ranking the data based on the outcome of the supervised pattern recognition method 113. Further detail and more specific embodiments of methods of the invention are described below.

Any diagnostic categories can be diagnosed using the technology described here. It includes distinguishing patients with multiple sclerosis, rheumatoid arthritis, and other inflammatory or autoimmune diseases. It may also diagnose other systemic diseases based on gene expression profiles of white cells, including infections with particular organisms, cancer, or myocardial infarctions.

Obtaining Experimental Data

The first step in methods of the invention is to obtain experimental data. Experimental data utilized in methods of the invention is high dimensional data. High dimensional data is data that has at least hundreds of individual pieces of information associated with one sample. An example of high dimensional data useful in methods of the invention is gene expression data. Gene expression data is high dimensional data because each sample or person has a large number of gene expression levels. Generally speaking, gene expression data generally has thousands of gene expression levels for each sample. Other examples of high dimensional data useful in the invention include but are not limited to protein arrays and protein chips, cell array based expression analysis, analysis of patterns of single nucleotide polymorphisms in disease conditions, and comparative genomic hybridization on methaphase, BAC genomic, cDNA and oligonucleotide arrays.

Preferably, the gene expression data is obtained through use of DNA microarray technology. DNA microarrays are preferred as a source of data because they generally offer a more complete picture of the interactions of a large number of genes with a limited number, or even one experiment. An example of a general description of how gene expression data can be obtained by using cDNA microarray technology is given below.

DNA microarrays, although a relatively new technology, have already been saddled with a number of different names, biochip, DNA chip, gene chip, genome chip, cDNA microarray, and gene array. The use of any of these terms herein refers generally to DNA microarrays. The underlying principle of DNA microarrays is base pairing or hybridization i.e., A-T and G-C for DNA, and A-U and G-C for RNA.

DNA microarrays provide a medium for matching known and unknown DNA samples based on the base pairings given above. DNA microarrays can either be fabricated by high-speed robotics or can be fabricated in a laboratory setting. They are generally patterned on glass, but can also be fabricated on nylon substrates. Microarrays generally have sample spot sizes of less than 200 μm diameter, and generally contain thousands of DNA spots on one microarray.

One method of fabricating cDNA microarrays begins by first producing gene-specific DNA by polymerase chain reaction (PCR) amplification of purified template plasmid DNAs from cloned expressed sequence tags (ESTs). The PCR product is then purified, resuspended and printed onto a substrate. DNA microarrays are also commercially available from a number of sources, including but not limited to Affymetric, Inc. (Santa Clara, Calif.), Agilent Technologies (Palo Alto, Calif.), and Research Genetics (Huntsville, Ala.).

One general procedure for a cDNA microarray experiment begins by preparing DNA samples and arraying them (either with an arraying robot, or by hand), to form a DNA microarray. Next, the RNA samples are extracted from the cells of interest, purified, reverse transcribed into cDNA and differentially fluorescently labeled to create probes. Then, the fluorescently labeled cDNA probes are hybridized to the cDNA microarray. If a probe contains a cDNA whose sequence is complementary to the DNA on a given spot, the cDNA probe will hybridize to that spot. After the cDNA probes are hybridized to the array, and any loose probe has been washed away, the microarray is imaged to determine how much of each probe is hybridized to each spot. This indicates how much of each gene from the microarray is expressed in the two samples. If the amount of starting material is small, for example from needle biopsies, the RNA can first be subject to amplification by modified Eberwine methods as described by Gelder et al. (Amplified RNA synthesized from limited quantities of heterogeneous cDNA.Proc Natl Acad Sci U S A 1990 Mar;87(5):1663-7).The experimental high dimensional data, preferably obtained from gene expression experiments, preferably performed using cDNA microarrays, is then further analyzed by a method of the invention.

Filtering the Data

The next step in a method of the invention is filtering the data 102 to remove individual pieces of data that are deemed undesirable. This filtering step functions to eliminate weak and/or problematic data from further use in the method. Accomplishment of the step of filtering depends greatly on the type of high dimensional data utilized. Any method known to those of ordinary skill in the art can be used to eliminate data determined to be undesirable.

One basis for carrying out this filtering, if a DNA microarray is being utilized for obtaining the high dimensional data, is the intensity of the fluorescence from the individual microarray spots. This basis of omitting data is based on failure or error in the imaging of the specific spots. A preferred method of performing initial data filtering on cDNA microarray data to remove those spots where imaging was a problem is to utilize the intensity of the various spots and utilize only those spots that have an intensity over a certain threshold value. Other methods of filtering DNA microarray data include but are not limited to eliminating spots in which the number of pixels represented is less than a threshold defined by the user, eliminating spots in which the standard deviation of the signal on the spots is too large, as defined by the user, eliminating spots in which the background intensity of a single spot is too high, or any combination thereof. In addition quality values based on intensity, can be assigned to each spot, standard deviation of intensity, background and/or size of each spot, then a spot could be eliminated if its quality value falls below a threshold as defined by the user.

Reducing the Dimensionality of the Data

The next step in methods of the invention is reducing the dimensionality of the data 103. The number of samples needed to calibrate a classifier with good predictive ability, depends critically on the number of features used in the design of the classifier. In the case of high-dimensional data, such as microarray data, where the number of samples is much smaller than the number of individual pieces of data there exists a large risk of over-fitting. There are two different solutions to this problem. First, the calibration process can be carefully monitored using a cross-validation scheme to avoid over-fitting (see below). Second, the dimension of the data can be reduced, either by using a dimensional reduction algorithm or by selecting a smaller set of data for input to the supervised pattern recognition method. Dimensionality reduction allows the number of parameters representing each sample to be reduced. This allows for the design of a classifier that has less risk of over-fitting, thereby increasing its predictive ability. Examples of methods of reducing the dimensionality of the data include but are not limited to principal component analysis (PCA), weighted gene analysis, t-test, rank based Wilcoxon or Mann-Whitney tests, signal-to-noise statistic, Fisher's discriminant analysis, or ANOVA tests.

In a preferred embodiment of the invention, PCA is used to reduce the dimensionality of the data.

In the case of PCA on gene expression data, reduction of the dimensionality is achieved by rotating gene expression space, such that the variance of the expression is dominated by as few linear combinations of genes as possible. Even though the formal dimension of the problem is given by the number of individual data points, the effective dimension is just one less than the number of samples. Hence the eigenvalue problem underlying PCA can be solved without diagonalizing 2308×2308 matrices by using singular value decomposition. Thus each sample is represented by 88 numbers, which are the results of projections of the data using the PCA eigenvectors.

A potential risk when using PCA on relatively few samples is that components might be singled out due to strong noise in the data. It could be argued that the outputs (labels) should be included in the dimensional reduction, using e.g. the Partial Least Squares (PLS) algorithm, in order to promote components with strong relevance for the output. However, based on explorations with similar data sets, this is not optimal; bias is introduced and implicitly “over-trains” from the outset by including the outputs in the procedure.

Setting Up a Validation Method for the Supervised Pattern Recognition Method

Once the data has been filtered 102 and its dimensionality reduced 103, a validation method is set up for monitoring and validating the training of the supervised pattern recognition method 115. Any method commonly used by those of skill in the art for validating the training of a supervised pattern recognition method can be used.

In one embodiment, the first step in setting us a validation method is to randomly divide the data into three groups of data, 105, 106, and 107. Then, one of those groups is chosen as a validation group 108. The first two of the groups 105 and 106 are combined into a training group 109, which is used to train the supervised pattern recognition method 111 and the third group 107 is used to validate the performance of the supervised pattern recognition method 111, once trained, and is called a validation group 110.

In this specific preferred embodiment, the 3-fold cross validation procedure (steps 104 through 110) is performed on all of the samples. A data group having 63 samples is given as an example. The 63 known (labeled) samples are randomly shuffled 104 and split into 3 equally sized groups (105, 106, and 107). The supervised pattern recognition method 111 is then calibrated as discussed below using the training group 109. The third group, a validation group 110, is reserved for testing predictions. Comparisons with the known answers refer to the results from the validation group 110 (i.e. when using a model, the samples used for training the model are never used in predictions). This procedure is repeated 3 times, each time with a different group used for validation. The random shuffling 104 is done about 100 to 10000 times. For each shuffling, one supervised pattern recognition method 111 model is generated. Thus, in total each sample belongs to a validation group 110, 1250 times and 3750 supervised pattern recognition methods 111 have been calibrated.

Training the Supervised Pattern Recognition Method

The supervised pattern recognition method 111 is then trained. The specific method of training the supervised pattern recognition method 111 is dependent on the specific form that the supervised pattern recognition method 111 takes. The choice of the supervised pattern recognition method 111 and the training thereof is well within one of skill in the art, having read this specification.

One example of a supervised pattern recognition method is an artificial neural network (ANN). ANNs are computer-based algorithms that are modeled on the structure and behavior of neurons in the human brain and can be trained to recognize and categorize complex patterns. Pattern recognition is achieved by adjusting parameters of the ANN by a process of error minimization through learning from experience. They can be calibrated using any type of input data, such as gene-expression levels generated by cDNA microarrays, and the output can be grouped into any given number of categories. ANNs have been recently applied to clinical problems such as diagnosing myocardial infarcts and arrhythmias from electrocardiograms and interpreting radiographs and magnetic resonance images. However, ANNs have not been used to decipher gene-expression signatures of SRBCTs or for diagnostic classification.

In embodiments where an artificial neural network (ANN) is employed as the supervised pattern recognition method 111, calibration is preferably performed using JETNET (C. Peterson, T. Roegnvaldsson and L. Loennblad, “JETNET 3.0—A versatile artificial neural network package,” Computer Physics Communications 81, 185-220 (1994)). Preferably, the software is used with a learning rate η=0.7, momentum coefficient p=0.3 and the learning rate is decreased with a factor 0.99 after each iteration. Initial weight values are chosen randomly from [−r, r], where r=0.1/max_(i) F_(i) and the “fanin” F_(i) is the number of nodes connecting to node i. The calibration is performed using a training set and it is monitored both for the training set and a validation set, which is not subject to calibration (see below). The weight values are updated after every 10 samples and the calibration is terminated after 100 passes (epochs) through the entire training set. In one embodiment of a method of the invention, the resulting parameters for the completed training of a supervised pattern recognition method 111 defines a “model”.

In preferred embodiments, due to the limited amount of calibration data and the fact that four output nodes are needed (Ewing's sarcoma (EWS), Burkitt's lymphoma (BL), neuroblastoma (NB) and rhabdomyo sarcoma (RMS)), linear perceptrons (LP) with 10 input nodes representing the PCA components described above are utilized. In other words, the supervised pattern recognition method 111 generally contains 44 parameters including four threshold units. Since 10 components could be used without risking “over-training” the optimization of the number of components to a smaller number is generally not necessary.

The possibility of using all the PCA components as inputs followed by a subsequent pruning of weights to avoid “over-fitting” is also one alternative. This resulted in the dominant 4-8 PCA components (depending on the composition of the training set 107) being the surviving inputs. Generally, the less dominant PCA components contain variance not related to separating the four cancers, but rather to, for example, experimental conditions (noise) or variance related to sub-groupings within a cancer type.

Verifying the Outcome of the Supervised Pattern Recognition Method

Once the supervised pattern recognition method 111 is trained, the next step is to determine whether the validation of the supervised pattern recognition method 111 is successful 112. This step determines whether the supervised pattern recognition method 111 adequately predicted the results for the validation data set 110 using any number of performance measurements and error measurements.

Any method known to those of ordinary skill in the art can be utilized to evaluate the performance of the training of the supervised pattern recognition method 111. Generally speaking, the performance is evaluated by comparison with some predetermined level of correct predictions that the user has determined is acceptable.

If the performance of the supervised pattern recognition method 111 is sufficiently poor, and a measure of error is greater than an allowable threshold, the processing may return to module 103 where the dimensionality of the data is reduced in a different manner and the entire training and validation process is repeated.

Ranking the Data

Once module 112 determines that the network 111 has been adequately trained, the processing proceeds to rank the output of the supervised pattern recognition method 113.

The outcome of the supervised pattern recognition method 111 can be looked at either independently or in a compiled form. Each supervised pattern recognition method 111 gives a number between 0 (not this disease type) and 1 (this disease type) as an output for each disease type. If the predictions are viewed independently, the maximal output is forced to 1 while the other outputs are forced to 0. Then it is determined how many of the predictions are correct. If the predictions are viewed in a compiled form, all of the predicted outputs are considered in their numerical form, after which all of the numbers are averaged and the resulting average is forced to 0 or 1.

In one embodiment of the method, the predictions, as compiled, are used to classify samples. For validation samples the compilation is based on 1250 models, while for additional unknown samples all 3750 models are used in the compilation.

In one embodiment, each sample is classified as belonging to the disease type corresponding to the largest average in the compilation. In addition, it is desirable to be able to reject the second largest vote as well as test samples that do not belong to any of the disease types. In order to reject those samples that do not belong, a distance d_(c) from a sample to the ideal vote for each disease type is defined as

$\begin{matrix} {d_{c} = {\frac{1}{2}{\sum\limits_{i = 1}^{4}\left( {o_{i} - \delta_{i,c}} \right)^{2}}}} & (1) \end{matrix}$

where c is a disease type, o_(i) is the average from the compilation for disease type i, and δ_(i,c) is unity if i corresponds to disease type c and zero otherwise. The distance is normalized such that the distance between two ideal samples belonging to different disease categories is unity. Based on the validation group, an empirical probability distribution of its distances is generated for each disease type.

The empirical probability distributions are preferably built using each supervised pattern recognition method 111 independently (not the average from the compilation). Thus, the number of entries in each distribution is given by 1250 multiplied by the number of samples belonging to the disease type. For a given test sample, the possible classifications based on these probability distributions can be rejected. This means that for each disease category a cutoff distance from an ideal sample is defined, within which, based on the validation samples, a sample of this category is expected to be. The distance given by the 95th percentile of the probability distribution is preferably chosen as a cutoff, which means that if a sample is outside of this cutoff distance it cannot be confidently diagnosed. It should be noted that the classification as well as the extraction of important genes (see below) converges using less than 100 supervised pattern recognition method 111 models. 3750 supervised pattern recognition method 111 models are preferred is because sufficient statistics exist for these empirical probability distributions.

For each disease category the sensitivity and specificity of the diagnosis may be calculated (see Table 1 below). Table 1 gives sensitivity, specificity and ROC curve areas for both validation and test samples. Both the sensitivity and the specificity are very high for all categories. It should be noted, that they generally depend on the kind of samples that are used as test samples.

TABLE 1 Category Sensitivity Specificity ROC curve area EWS  93% 100% 1.0 BL 100% 100% 1.0 NB 100% 100% 1.0 RMS  96% 100% 1.0

For example, in the case of SRBCT classification, using normal muscle samples as tests makes it harder to separate out RMS samples. If only samples from the four categories were used as blind distance cutoffs, it could easily have been designed such that both the sensitivity and the specificity would have been 100% for all diseases. However, it is preferred that the method is tested using a variety of blind tests. If it is desirable to improve rejection of for example normal muscle samples, one could incorporate them as a fifth category in the training process. However, using more samples of all four categories in the training is initially probably the best way to improve the diagnostic separation.

The Receiver Operator Characteristic (ROC) curve area is identical to another more intuitive and easily computed measure of discrimination: the probability that in a randomly chosen pair of samples, one belonging to and one not belonging to the disease category, the one belonging to the category is the one with the closest distance to the ideal for that particular category. Since the ROC curve areas are unity for all disease categories (see Table 1), it is possible to define cutoff distances such that both the sensitivity and the specificity are 100% for all diseases. However, based on the training and validation groups it is difficult to motivate such cutoff distances.

The next step in a method in accordance with the invention is to actually rank the data. This step can in principle be done in two ways; (1) model-independent and (2) model-dependent analysis respectively. Due to the relative small number of samples, the model-dependent analysis is preferred when using ANN models.

The sensitivity (S) of the outputs (o) with respect to any of the 2308 input variables (x_(k)) is defined as:

$\begin{matrix} {S_{k} = {\frac{1}{N_{s}}\frac{1}{N_{o}}{\sum\limits_{s = 1}^{N_{s}}{\sum\limits_{i - 1}^{N_{o}}{\frac{\delta \; o_{i}}{\delta \; x_{k}}}}}}} & (2) \end{matrix}$

where N_(s) is the number of samples (63 or 88) and N_(o) is the number of outputs (4). The procedure for computing S_(k) involves a committee of 3750 models. In addition we have defined a sensitivity for each output i (S_(i)), which is analogous to Eq. (2) but without the sum over outputs. Furthermore, a sensitivity can be defined for each sample (or subsets of samples) individually, by only using that sample(s) in the sum over samples in Eq. (2). For all these sensitivities the sign of the sensitivity has also been defined. The sign signals whether the largest contribution to the sensitivity stems from positive or negative terms. A positive sign implies that increasing the expression rate of the gene increases the possibility that the sample belongs to this cancer type, while a negative sign means that decreasing the expression rate of the gene increases the same possibility. In other words, the sign does not tell whether a gene is up- or down-regulated but if it is more or less expressed in this cancer type as compared to the others. This means the genes are ranked not only according to their importance for the total classification, but also according to their importance for the different disease categories separately. The genes are preferably given a total rank as well as a separate rank for each disease category. Based on these ranks each gene is classified according to which disease category it is highly expressed in.

In one embodiment, once ranked, a relevant set of data can be selected module 114 by minimizing the amount of data to be used to classify and identify a particular disease. In one embodiment, a pre-determined amount of data having the highest ranking are selected. Of course, other selection methods may be employed without deviating from the spirit and scope of the present invention as recited in the attached claims.

Implementation of Methods of the Invention

In embodiments of the method in which the supervised pattern recognition method 111 is an artificial neural network, a general purpose computing system as depicted in FIG. 2 can be utilized. An exemplary ANN processing system 200 provides an artificial neural network that also receives experimental data to train the artificial neural network, to verify the output of an artificial neural network, and to identify relevant genes using the neural network.

Those of ordinary skill in the art will appreciate that the ANN processing system 200 may include many more components than those shown in FIG. 2. However, the components shown are sufficient to disclose an illustrative embodiment for practicing the present invention. As shown in FIG. 2, the ANN processing system 200 is connected to a WAN/LAN, or other communications network, via network interface unit 210. Those of ordinary skill in the art will appreciate that network interface unit 210 includes the necessary circuitry for connecting the ANN processing system 200 to a WAN/LAN, and is constructed for use with various communication protocols including the TCP/IP protocol. Typically, network interface unit 210 is a card contained within the ANN processing system 200.

The ANN processing system 200 also includes processing unit 212, video display adapter 214, and a mass memory, all connected via bus 222. The mass memory generally includes RAM 216, ROM 232, and one or more permanent mass storage devices, such as hard disk drive 228, a tape drive, CD-ROM/DVD-ROM drive 226, and/or a floppy disk drive. The mass memory stores operating system 220 for controlling the operation of ANN processing system 200. It will be appreciated that this component may comprise a general purpose server operating system as is known to those of ordinary skill in the art, such as UNIX, LINUX, MAC OS®, or Microsoft WINDOWS NT®. Basic input/output system (“BIOS”) 218 is also provided for controlling the low-level operation of ANN processing system 200.

The mass memory as described above illustrates another type of computer-readable media, namely computer storage media. Computer storage media may include volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storage of information, such as computer readable instructions, data structures, program modules or other data. Examples of computer storage media include RAM, ROM, EEPROM, flash memory or other memory technology, CD-ROM, digital versatile disks (DVD) or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium which can be used to store the desired information and which can be accessed by a computing device.

The mass memory also stores program code and data for providing an ANN processing and network development. More specifically, the mass memory stores applications including ANN processing module 230, programs 234, and other applications 236. ANN processing module 230 includes computer executable instructions which, when executed by ANN processing system 200, performs the logic described above.

The ANN processing system 200 also comprises input/output interface 224 for communicating with external devices, such as a mouse, keyboard, scanner, or other input devices not shown in FIG. 2. Likewise, ANN processing system 200 may further comprise additional mass storage facilities such as CD-ROM/DVD-ROM drive 226 and hard disk drive 228. Hard disk drive 228 is utilized by ANN processing system 200 to store, among other things, application programs, databases, and program data used by ANN processing module 230. For example, customer databases, product databases, image databases, and relational databases may be stored. The operation and implementation of these databases is well known to those skilled in the art.

A set of processing modules making up an embodiment of an artificial neural network according to the invention is illustrated in FIG. 3. The artificial neural network disclosed herein corresponds to a generic neural network of no particular topology for the network of nodes contained therein. The neural network typically utilizes a form of competitive learning for the operation of the nodes within the network. Within competitive learning networks, a large number of data vectors are distributed in a highly dimensional space. These data vectors represent known values for experimental data that typically reflect a probability distribution of the input experimental data. From this probability distribution representation, predictions for unknown values for similar input data may be determined.

In all of these competitive learning networks, the networks are typically presented a set of input data that possesses a corresponding set of results data. From these data values, the network of nodes “learns” a relationship between the input data and its corresponding results data. In this process, the probability distribution relationship is estimated using the multi-dimensional network of nodes. This relationship is represented within a set of artificial neural network coefficients for a particular topology of nodes.

One skilled in the art will recognize that competitive learning networks include a nearly infinite number of network topologies that may be used to represent a particular probability distribution relationship without deviating from the spirit and scope of the present invention as recited within the attached claims. In addition, artificial neural networks may utilize various well-known algorithm architectures, including hard-competitive learning (i.e. “winner-take-all” learning), soft competitive learning without a fixed network dimensionality, and soft competitive learning with a fixed network dimensionality, to specify an artificial neural network according to the invention as recited within the attached claims. Each of these algorithm architectures represents the same probability distribution relationship; however each of the various algorithm architectures better optimize corresponding processing parameters, which are often mutually exclusive with each other. These parameters include error minimization or the minimization of an expected quantization error, entropy maximization for the reference vectors used within a network, and topology-preserving or feature mapping architectures that attempt to map high-dimensional inputs signals onto lower-dimensional structures in a manner that attempts to preserve similar relationships found within the original data within the post-mapping data. As such, any of these types of algorithm architectures may be used to construct an artificial neural network without deviating from the spirit and scope of the present invention as recited within the attached claims.

Now referring to FIG. 3, an artificial neural network processing system 301 comprises a learning module 311, a prediction module 321, and a database of network node coefficients 313. The learning module 311 is used with a set of experimental data 315 that possesses a corresponding set of experimental results 316 to generate a set of network node coefficients that represent a probability distribution relationship for the experimental data 315-experimental result 316 data set for a particular neural network topology and algorithm architecture. The learning module 311 includes a data learning input module 312 that receives the experimental data 315-experimental result 316 data set generated using the process described above. The learning module 311 also includes an ANN training module 313 that processes the experimental data 315-experimental result 316 data set to generate the coefficients used to specify the probability distribution relationship and an ANN coefficient storage module 314 for storing the coefficients that have been previous generated within the database 313 for later use.

The data processing within the learning module 311 may proceed in a batch processing fashion in which all of the vectors within the experimental data 315-experimental result 316 data set are processed at a single time. In such a process, the experimental data 315-experimental result 316 data set is received by the input module 312, processed by the training module 313, and the generated coefficients are placed within the database 313 by the storage module 314. Alternatively, the experimental data 315-experimental result 316 data set may be processed as a sequence of smaller data sets in which the experimental data 315-experimental result 316 data set data values are generated at different times. In such a process, the training module 313 uses the previously stored coefficients retrieved by the storage module along with a new small data set provided by the input module 312 to generate an updated set of coefficients. These updated coefficients may be once again stored within the database 313 for use at a later time.

Once an artificial neural network 301 has been trained, the prediction module 321 may be used to predict, or classify, a particular test data value 325. The prediction module 321 includes a data prediction input module 322, an ANN prediction module 323, and an ANN curve slope module 324. The data prediction input module 322 receives the input test data generated as described above for use in the prediction module. The ANN prediction module 323 receives and utilizes the network coefficient values for the neural network from the ANN coefficient database 313 to predict the possible result for the probability distribution relationship specified within the neural network. This output value is used by the ANN curve slope module 324 to determine all possible values for a given gene, in the manner discussed above, to determine a curve slope value. This slope value is then output for later use in ranking and classifying the individual genes used to determine the presence, or lack there of, for a disease.

The embodiments described herein are implemented as logical operations performed by a computer. The logical operations of these various embodiments of the present invention are implemented (1) as a sequence of computer implemented steps or program modules running on a computing system and/or (2) as interconnected machine modules or hardware logic within the computing system. The implementation is a matter of choice dependent on the performance requirements of the computing system implementing the invention. Accordingly, the logical operations making up the embodiments of the invention described herein can be variously referred to as operations, steps, or modules.

While the above embodiments of the invention describe the use of an artificial neural network to identify relevant genes associated with diseases and use the identified genes to classify and identify diseases, one skilled in the are will recognize that the use of the processing system discussed above are merely example embodiments of the invention. As long as experimental data is used to self-train a processing system using competitive learning processing, the present invention to would be useable in other data processing systems. It is to be understood that other embodiments may be utilized and operational changes may be made without departing from the scope of the present invention as recited in the attached claims.

Devices and Methods for Detecting, Monitoring and Treating SRBCTs

The genes given in table 2, 2b, or 5 below can be used to make up a selection of genes for detection of any one of the four SRBCT types of cancers: neuroblastoma (NB), rhabdoymosarcoma (RMS), Burkitt's lymphoma (BL), or the Ewing family of Tumors (EWS). The gene selection can be used to distinguish a SRBCT type cancer cell from a non-cancerous cell, from a cell of a different type of SRBCT cancer, or from a cell of any other different type of cancer. The cancer type of a gene indicates which cancer that it is differentially expressed in.

TABLE 2 Image Gene E S RMS NB BL Cancer SEQ. ID. Id. symbol Rank Sign Rank Sign Rank Sign Rank Sign Type NO. 812105 AF1Q 670 − 934 − 2 + 51 − NB SEQ. ID. NO. 32 383188 RCV1 478 − 808 + 13 + 42 − NB SEQ. ID. NO. 38 82225 SFRP1 160 − 264 + 17 + 85 − NB SEQ. ID. NO. 42 878280 CRMP1 602 − 1255 + 12 + 45 − NB SEQ. ID. NO. 33 135688 CATA2 354 + 155 − 37 + 88 − NB SEQ. ID. NO. 44 308231 EST 524 − 1015 + 10 + 117 − NB SEQ. ID. NO. 39 486110 PFN2 1554 + 1500 + 31 + 31 − NB SEQ. ID. NO. 45 377048 EST 733 − 560 + 23 + 102 − NB SEQ. ID. NO. 40 784257 KIF3C 577 + 1099 − 64 + 44 − NB SEQ. ID. NO. 34 395708 DPYSL4 1269 + 591 − 28 + 91 − NB SEQ. ID. NO. 30 292522 EST 221 − 667 + 32 + 189 − NB SEQ. ID. NO. 36 813266 FHL1 1045 + 1610 − 91 + 46 − NB SEQ. ID. NO. 47 244618 EST 22 − 3 + 273 − 86 − RMS SEQ. ID. NO. 77 298062 TNNT2 43 − 4 + 95 − 475 − RMS SEQ. ID. NO. 74 324494 HSPB2 1605 − 13 + 7 − 420 − RMS SEQ. ID. NO. 62 122159 COL3A1 791 + 29 + 1062 − 16 − RMS SEQ. ID. NO. 66 788107 AMPHL 74 − 14 + 817 + 108 − RMS SEQ. ID. NO. 52 377671 ITGA7 1044 + 24 + 66 − 135 − RMS SEQ. ID. NO. 68 784224 FGFR4 36 − 5 + 431 − 604 + RMS SEQ. ID. NO. 71 293500 EST 262 − 9 + 1084 − 138 − RMS SEQ. ID. NO. 80 42558 GATM 379 − 12 + 25 − 1020 − RMS SEQ. ID. NO. 79 246377 EST 719 − 36 + 641 + 75 − RMS SEQ. ID. NO. 51 809901 COL15A1 1516 − 23 + 35 − 385 − RMS SEQ. ID. NO. 67 769959 COL4A2 1575 + 66 + 1786 − 26 − RMS SEQ. ID. NO. 69 755750 NME2 1840 + 26 + 591 − 82 − RMS SEQ. ID. NO. 49 770394 FCGRT 3 + 186 − 79 − 18 − EWS SEQ. ID. NO. 20 866702 PTPN13 2 + 74 − 230 − 62 − EWS SEQ. ID. NO. 16 357031 TNFAIP6 5 + 119 − 103 − 60 − EWS SEQ. ID. NO. 18 377461 CAV1 6 + 91 − 90 − 101 − EWS SEQ. ID. NO. 19 52076 NOE1 7 + 33 − 1673 + 37 − EWS SEQ. ID. NO. 13 1473131 TLE2 10 + 1884 − 16 − 217 − EWS SEQ. ID. NO. 15 208718 ANXA1 12 + 827 − 1202 − 33 − EWS SEQ. ID. NO. 2 80338 SELENBP1 20 + 1316 + 42 − 151 − EWS SEQ. ID. NO. 14 377731 GSTM5 13 + 310 − 34 − 381 − EWS SEQ. ID. NO. 23 814260 FVT1 9 + 61 − 330 − 335 − EWS SEQ. ID. NO. 17 364934 DAPK1 42 + 1481 + 707 − 40 − EWS SEQ. ID. NO. 12 755599 IFI7 16 + 177 − 30 − 918 − EWS SEQ. ID. NO. 25 291756 TUBB5 17 + 31 − 1325 + 245 − EWS SEQ. ID. NO. 1 308497 EST 27 + 1971 − 43 − 231 − EWS SEQ. ID. NO. 24 609663 PRKAR2B 198 − 55 − 550 + 29 + BL SEQ. ID. NO. 95 868304 ACTA2 1286 − 151 − 122 − 71 + BL SEQ. ID. NO. 86

TABLE 2b EWS RMS NB BL Cancer Rank Image Id. Gene Rank Sign Rank Sign Rank Sign Rank Sign Type SEQ. ID. NO. 1 296448 IGF2 8 − 1 + 918 − 19 − RMS SEQ ID NO 72 2 207274 IGF2 19 − 2 + 1152 − 11 − RMS SEQ ID NO 73 3 841641 CCND1 11 + 38 − 118 + 6 − EWS/NB SEQ ID NO 5 4 365826 GAS1 25 + 69 + 22 − 9 − EWS/RMS SEQ ID NO 59 5 486787 CNN3 130 − 39 + 14 + 17 − RMS/NB SEQ ID NO 43 6 770394 FCGRT 3 + 186 − 79 − 18 − EWS SEQ ID NO 20 7 244618 EST 22 − 3 + 273 − 86 − RMS SEQ ID NO 77 8 233721 IGFBP2 148 + 43 + 598 + 1 − Not BL SEQ ID NO 28 9 43733 GYG2 4 + 261 − 99 − 21 − EWS SEQ ID NO 21 10 295985 EST 1 − 51 + 9 + 522 + Not EWS SEQ ID NO 26 11 629896 MAP1B 360 − 893 + 1 + 23 − NB SEQ ID NO 37 12 840942 HLA-DPB1 1161 + 383 − 6 − 12 + BL SEQ ID NO 87 13 80109 HLA-DQA1 226 − 1589 − 20 − 3 + BL SEQ ID NO 88 14 41591 MN1 257 + 18 + 4 − 169 − EWS/RMS SEQ ID NO 60 15 866702 PTPN13 2 + 74 − 230 − 62 − EWS SEQ ID NO 16 16 357031 TNFAIP6 5 + 119 − 103 − 60 − EWS SEQ ID NO 18 17 782503 EST 26 + 219 − 104 + 14 − EWS/NB SEQ ID NO 7 18 377461 CAV1 6 + 91 − 90 − 101 − EWS SEQ ID NO 19 19 52076 NOE1 7 + 33 − 1673 + 37 − EWS SEQ ID NO 13 20 811000 LGALS3BP 24 + 246 − 257 + 13 − EWS/NB SEQ ID NO 6 21 308163 EST 49 + 88 + 191 − 22 − RMS/EWS SEQ ID NO 57 22 812105 AF1Q 670 − 934 − 2 + 51 − NB SEQ ID NO 32 23 183337 HLA/DMA 317 − 1574 − 24 − 8 + BL SEQ ID NO 89 24 714453 IL4R 208 − 20 + 8 − 238 + RMS/BL SEQ ID NO 83 25 298062 TNNT2 43 − 4 + 95 − 475 − RMS SEQ ID NO 74 26 39093 MNPEP 46 + 224 + 21 − 103 − EWS/RMS SEQ ID NO 63 27 212542 EST 62 + 993 + 1086 + 2 − Not BL SEQ ID NO 53 28 204545 EST 471 + 49 + 1455 + 5 − Not BL SEQ ID NO 58 29 383188 RCV1 478 − 808 + 13 + 42 − NB SEQ ID NO 38 30 82225 SFRP1 160 − 264 + 17 + 85 − NB SEQ ID NO 42 31 44563 GAP43 693 − 191 − 3 + 166 − NB SEQ ID NO 35 32 289645 APLP1 41 + 102 − 107 + 61 − EWS/NB SEQ ID NO 4 33 324494 HSPB2 1605 − 13 + 7 − 420 − RMS SEQ ID NO 62 34 563673 ATQ1 35 + 1527 − 523 + 7 − Not BL SEQ ID NO 10 35 1473131 TLE2 10 + 1884 − 16 − 217 − EWS SEQ ID NO 15 36 1416782 CKB 134 + 416 + 851 + 4 − Not BL SEQ ID NO 3 37 417226 MYC 63 + 222 − 29 − 110 + EWS/BL SEQ ID NO 81 38 878280 CRMP1 602 − 1522 + 12 + 45 − NB SEQ ID NO 33 39 812965 MYC 23 + 296 − 11 − 308 + EWS/BL SEQ ID NO 82 40 122159 COL3A1 791 + 29 + 1062 − 16 − RMS SEQ ID NO 66 41 609663 PRKAR2B 198 − 55 − 550 + 29 + BL SEQ ID NO 95 42 461425 MYL4 98 − 7 + 80 − 419 − RMS SEQ ID NO 75 43 1469292 PIM2 1007 + 242 − 53 − 36 + BL SEQ ID NO 92 44 809910 1-8U 52 + 168 + 159 − 56 − RMS/EWS SEQ ID NO 55 45 824602 IFI16 336 + 149 − 33 − 89 + EWS/BL SEQ ID NO 84 46 245330 IGF2 65 − 6 + 147 − 434 − RMS SEQ ID NO 78 47 135688 GATA2 354 + 155 − 37 + 88 − NB SEQ ID NO 44 48 1409509 TNNT1 141 − 8 + 153 − 313 − RMS SEQ ID NO 70 49 788107 AMPHL 74 − 14 + 817 + 108 − RMS SEQ ID NO 52 50 784593 EST 224 − 299 + 39 + 68 − RMS/NB SEQ ID NO 41 51 756556 C1NH 90 + 238 + 284 − 38 − RMS/EWS SEQ ID NO 65 52 208718 ANXA1 12 + 827 − 1202 − 33 − EWS SEQ ID NO 2 53 308231 EST 524 − 1015 + 10 + 117 − NB SEQ ID NO 39 54 486110 PFN2 1554 + 1500 + 31 + 31 − NB SEQ ID NO 45 55 21652 CTNNA1 104 + 117 + 2245 − 15 − Not BL SEQ ID NO 56 56 377671 ITGA7 1044 + 24 + 66 − 135 − RMS SEQ ID NO 68 57 745343 REG1A 166 + 93 − 40 − 153 + EWS/BL SEQ ID NO 85 58 241412 ELF1 882 − 1473 − 60 − 27 + BL SEQ ID NO 90 59 504791 GSTA4 276 + 2003 + 108 + 24 − Not BL SEQ ID NO 11 60 841620 DPYSL2 51 + 100 − 366 + 70 − EWS/NB SEQ ID NO 8 61 859359 PIG3 58 − 28 + 288 + 152 − RMS/NB SEQ ID NO 50 62 45542 IGFBP5 991 + 89 + 1661 − 10 − RMS SEQ ID NO 64 63 80338 SELENBP1 20 + 1316 + 42 − 151 − EWS SEQ ID NO 14 64 45291 DRPLA 532 + 81 + 872 − 28 − Not BL SEQ ID NO 54 65 323371 APP 1689 − 90 + 594 + 65 − Not BL SEQ ID NO 27 66 897788 PTPRF 59 + 1358 − 734 + 20 − Not BL SEQ ID NO 9 67 377731 GSTM5 13 + 310 − 34 − 381 − EWS SEQ ID NO 23 68 784224 FGFR4 36 − 5 + 431 − 604 − RMS SEQ ID NO 71 69 293500 EST 262 − 9 + 1084 − 138 − RMS SEQ ID NO 80 70 767183 HCLS1 1481 − 1424 − 50 − 32 + BL SEQ ID NO 91 71 297392 MT1L 1361 − 483 − 113 − 30 + BL SEQ ID NO 93 72 325182 CDH2 590 − 919 − 5 + 260 − NB SEQ ID NO 31 73 1435862 MIC2 14 + 518 − 371 − 97 − EWS SEQ ID NO 22 74 377048 EST 733 − 560 + 23 + 102 − NB SEQ ID NO 40 75 814260 FVT1 9 + 61 − 330 − 335 − EWS SEQ ID NO 17 76 784257 KIF3C 577 + 1099 − 64 + 44 − NB SEQ ID NO 34 77 42558 GATM 379 − 12 + 25 − 1020 − RMS SEQ ID NO 79 78 814526 HSRNASEB 164 − 198 + 98 − 105 + RMS/BL SEQ ID NO 96 79 839736 CRYAB 516 + 67 + 51 − 183 − EWS/RMS SEQ ID NO 61 80 395708 DPYSL4 1269 + 591 − 28 + 91 − NB SEQ ID NO 30 81 416959 NFIB 1420 − 86 + 160 + 72 − RMS/NB SEQ ID NO 29 82 364934 DAPK1 42 + 1481 + 707 − 40 − EWS SEQ ID NO 12 83 868304 ACTA2 1286 − 151 − 122 − 71 + BL SEQ ID NO 86 84 755599 IFI17 16 + 177 − 30 − 918 − EWS SEQ ID NO 25 85 246377 EST 719 − 36 + 641 + 75 − RMS SEQ ID NO 51 86 291756 TUBB5 17 + 31 − 1325 + 245 − EWS SEQ ID NO 1 87 809901 COL15A1 1516 − 23 + 35 − 385 − RMS SEQ ID NO 67 88 769959 COL4A2 1575 + 66 + 1786 − 26 − RMS SEQ ID NO 69 89 796258 SGCA 30 − 10 + 521 − 758 − RMS SEQ ID NO 76 90 854899 DUSP6 774 + 150 + 838 + 39 − Not BL SEQ ID NO 48 91 755750 NME2 1840 + 26 + 591 − 82 − RMS SEQ ID NO 49 92 292522 EST 221 − 667 + 32 + 189 − NB SEQ ID NO 36 93 308497 EST 27 + 1971 − 43 − 231 − EWS SEQ ID NO 24 94 813266 FHL1 1045 + 1610 − 91 + 46 − NB SEQ ID NO 47 95 200814 MME 639 − 1081 + 78 − 66 + BL SEQ ID NO 94 96 768370 TIMP3 547 + 1132 + 606 + 25 − Not BL SEQ ID NO 46

One embodiment of the invention offers a selection of genes that are expressed in a cancer cell. Such selections of genes function to characterize the cancer when the gene selection from the cancer cell is compared to the expression of an identical selection of genes from a noncancerous cell, or a different type of cancer cell. As used herein, the phrase “function to characterize” can mean to identify, to be indicative of, to be highly and/or differentially expressed in. The cancer to be identified can be neuroblastoma, rhabdomyosarcoma, Burkitt's, Ewing family of tumors, or combinations thereof. In one embodiment, at least one of the genes is chosen from table 5. In another embodiment, at least one of the genes is chosen from table 2, or 2b. In yet another embodiment, at least one of the genes is chosen from at least one of tables 6, 7, 8, or 9. In a further embodiment, there are at least 9 genes chosen from table 5, preferentially selected from the top ranked genes. In an even further embodiment, there are at least 9 genes chosen from at least one of tables 2, 2b, 6, 7, 8, or 9, preferentially selected from the top ranked genes.

As used herein, “Image ID” or “Clone ID” refer to particular genes that are given in various tables. In some embodiments of the invention, gene selections include one or more genes with a given Image ID. In one embodiment, the cancer to be identified is neuroblastoma, and the gene selection includes at least one of the genes with the following Image Id: 812105 (SEQ. ID. NO. 32), 383188 (SEQ. ID. NO. 38), 82225 (SEQ. ID. NO. 42), 878280 (SEQ. ID. NO. 33), 135688 (SEQ. ID. NO. 44), 308231 (SEQ. ID. NO. 39), 486110 (SEQ. ID. NO. 45), 377048 (SEQ. ID. NO. 40), 784257 (SEQ. ID. NO. 34), 395708 (SEQ. ID. NO. 30), 292522 (SEQ. ID. NO. 36), or 813266 (SEQ. ID. NO. 47). In another embodiment, the cancer to be identified is rhabdomyosarcoma and the gene selection includes at least one of the genes with the following Image Id: 244618 (SEQ. ID. NO. 77), 298062 (SEQ. ID. NO. 74), 324494 (SEQ. ID. NO. 62), 122159 (SEQ. ID. NO. 66), 788107 (SEQ. ID. NO. 52), 377671 (SEQ. ID. NO. 68), 784224 (SEQ. ID. NO. 71), 293500 (SEQ. ID. NO. 80), 42558 (SEQ. ID. NO. 79), 246377 (SEQ. ID. NO. 51), 809901 (SEQ. ID. NO. 67), 769959 (SEQ. ID. NO. 69), or 755750 (SEQ. ID. NO. 49). In yet another embodiment, the cancer to be identified is Burkitt's, and the gene selection includes at least one of the genes with the following ImageID: 609663 (SEQ. ID. NO. 95), or 868304 (SEQ. ID. NO. 86). In a further embodiment, the cancer to be identified is a Ewing family of tumors cancer, and the gene selection includes at least one of the genes with the following Image Id: 770394 (SEQ. ID. NO. 20), 866702 (SEQ. ID. NO. 16), 357031 (SEQ. ID. NO. 18), 377461 (SEQ. ID. NO. 19), 52076 (SEQ. ID. NO. 13), 1473131 (SEQ. ID. NO. 15), 208718 (SEQ. ID. NO. 2), 80338 (SEQ. ID. NO. 14), 377731 (SEQ. ID. NO. 23), 814260 (SEQ. ID. NO. 17), 364934 (SEQ. ID. NO. 12), 755599 (SEQ. ID. NO. 25), 291756 (SEQ. ID. NO. 1), 308497 (SEQ. ID. NO. 24), or combinations thereof.

Another embodiment of the invention includes a selection of least one product of a selection of genes. As used herein, the term “product of a gene” or “gene product” can include entities that are naturally produced by the cancer cell. Examples of gene products include, but are not limited to, DNA, mRNA, and proteins. Gene products can be utilized in methods of the invention for diagnosing a cancer or as a target for therapeutic treatment.

The invention includes gene selections that can include one or more genes chosen from Table 2, 2b or 5. Table 2 lists 41 genes that are specifically expressed in one of the four types of SRBCTs that have not been previously reported to relate to cancer, and which could be used, in any combination, to make up a selection of genes in accordance with the invention. Table 2b shows the 96 top ranked genes, including the 41 genes of Table 2. Alternatively, Table 5 lists the top 200 ranked genes that also include those of Table 2b.

One embodiment of the invention includes a method of targeting a product of at least one of the genes in table 5 that includes administering a therapeutic agent having a therapeutic effect on said gene product. Another embodiment includes a method of therapeutic treatment of a cancer by using a selection of genes or their products that are expressed in a cancer cell, wherein the genes and/or their products function to characterize the cancer when the gene selection from the cancer cell is compared to the expression of an identical selection of genes from a noncancerous cell, or a different type of cancer cell. Another embodiment includes a method of targeting a product of at least one of the genes in table 2. Yet another embodiment includes a method of targeting a product of at least one of the genes of in table 6, 7, 8 or 9. A therapeutic agent is a biological or chemical entity that are based on some aspect of a gene. Examples of therapeutic agents include, but are not limited to, vaccines, antibodies, oligonucelotide DNA antisense, RNAi, chemical molecules, proteins, inhibitors, antagonists, or combinations thereof Having a therapeutic effect on a gene product can include, but is not limited to, inhibition of some activity or process of a cell, cessation of some activity or process of a cell, an increase in some activity or process of a cell, interference with some process or activity of a cell, modification of the expression of at least one gene, modification of the expression of at least one gene product, modification of the function of at least one gene, and modification of the function of at least one gene product.

Administration of a therapeutic agent can include delivery of the therapeutic agent to the cell, to the vicinity of the cell, to the vicinity of a tumor, to a patient that has a tumor, or any combination thereof. In one embodiment of the invention, a method of targeting the product of at least one gene is undertaken in order to have an effect on a cancer cell or tumor. To have an effect on a cancer cell means to alter the course of progression, development, or metastasis of a cancer cell. Cancer cells that can be affected by methods of the invention include, but are not limited to, neuroblastoma, rhabdomyosarcoma, Burkitt's, and the Ewing family of tumors. Methods of having an effect on these various types of cancers can be accomplished by having an effect on a product of at least one gene of tables 6, 7, 8, and 9 respectively.

Another embodiment of the invention includes a method of targeting the product of at least one gene of table 10 that includes administering a therapeutic agent having a therapeutic effect on said gene product. A therapeutic agent is a biological or chemical entity that are based on some aspect of a gene. Examples of therapeutic agents include, but are not limited to, vaccines, antibodies, oligonucelotide DNA antisense, RNAi, chemical molecules, proteins, inhibitors, antagonists, or combinations thereof Having a therapeutic effect on a gene product can include, but is not limited to, inhibition of some activity or process of a cell, cessation of some activity or process of a cell, an increase in some activity or process of a cell, and interference with some process or activity of a cell.

Administration of a therapeutic agent can include delivery of the therapeutic agent to the cell, to the vicinity of the cell, to the vicinity of a tumor, to a patient that has a tumor, or any combination thereof. In one embodiment of the invention, a method of targeting the product of at least one gene is undertaken in order to have an effect on a cancer cell or tumor. To have an effect on a cancer cell means to alter the course of progression, development, or metastasis of a cancer cell. Cancer cells that can be affected by methods of the invention include, but are not limited to, neuroblastoma, rhabdomyosarcoma, Burkitt's, and the Ewing family of tumors. Methods of having an effect on these various types of cancers can be accomplished by having an effect on a product of at least one gene of tables 6, 7, 8, and 9 respectively.

Another embodiment of the invention includes methods of using a selection of genes that function to characterize the cancer when the gene selection from a cancer cell is compared to the expression of an identical selection of genes from a noncancerous cell or an identical selection of genes from a different type of cancer cell expressed in a cell for diagnosing a cancer. As used herein, diagnosing can include detection, prognosis and prediction, classification, and or monitoring.

One embodiment of the invention includes such a method for diagnosis that includes use of a gene selection that includes at least one gene in Table 5. Another embodiment includes such a method for diagnosis that includes use of a gene selection that includes at least one gene from Table 2. The cancer to be diagnosed can include neuroblastoma, rhabdomyosarcoma, Burkitt's, Ewing family of tumors, or combinations thereof.

As used herein, “Image ID” or “Clone ID” refer to particular genes that are given in the various tables. In some embodiments of the invention, methods for diagnosing include use of a gene selection that includes one or more genes with a given Image ID. In one embodiment, the cancer to be diagnosed is neuroblastoma, and the gene selection includes at least one of the genes with the following Image Id: 812105 (SEQ. ID. NO. 32), 383188 (SEQ. ID. NO. 38), 82225 (SEQ. ID. NO. 42), 878280 (SEQ. ID. NO. 33), 135688 (SEQ. ID. NO. 44), 308231 (SEQ. ID. NO. 39), 486110 (SEQ. ID. NO. 45), 377048 (SEQ. ID. NO. 40), 784257 (SEQ. ID. NO. 34), 395708 (SEQ. ID. NO. 30), 292522 (SEQ. ID. NO. 36), or 813266 (SEQ. ID. NO. 47). In another embodiment, the cancer to be diagnosed is rhabdomyosarcoma and the gene selection includes at least one of the genes with the following Image Id: 244618 (SEQ. ID. NO. 77), 298062 (SEQ. ID. NO. 74), 324494 (SEQ. ID. NO. 62), 122159 (SEQ. ID. NO. 66), 788107 (SEQ. ID. NO. 52), 377671 (SEQ. ID. NO. 68), 784224 (SEQ. ID. NO. 71), 293500 (SEQ. ID. NO. 80), 42558 (SEQ. ID. NO. 79), 246377 (SEQ. ID. NO. 51), 809901 (SEQ. ID. NO. 67), 769959 (SEQ. ID. NO. 69), or 755750 (SEQ. ID. NO. 49). In yet another embodiment, the cancer to be diagnosed is Burkitt's, and the gene selection includes at least one of the genes with the following ImageID: 609663 (SEQ. ID. NO. 95), or 868304 (SEQ. ID. NO. 86). In a further embodiment, the cancer to be diagnosed is a Ewing family of tumors cancer, and the gene selection includes at least one of the genes with the following Image Id: 770394 (SEQ. ID. NO. 20), 866702 (SEQ. ID. NO. 16), 357031 (SEQ. ID. NO. 18), 377461 (SEQ. ID. NO. 19), 52076 (SEQ. ID. NO. 13), 1473131 (SEQ. ID. NO. 15), 208718 (SEQ. ID. NO. 2), 80338 (SEQ. ID. NO. 14), 377731 (SEQ. ID. NO. 23), 814260 (SEQ. ID. NO. 17), 364934 (SEQ. ID. NO. 12), 755599 (SEQ. ID. NO. 25), 291756 (SEQ. ID. NO. 1), 308497 (SEQ. ID. NO. 24), or combinations thereof. Another embodiment of the invention includes use of a product of at least one of those genes for diagnosis of a cancer.

Another embodiment of the invention includes devices for use in a method of diagnosis. Examples of such devices can include protein arrays, cell arrays, a device to detect single polymorphisms in disease conditions, devices containing metaphase BAC genomes, cDNA arrays, and oligonucleotide arrays.

WORKING EXAMPLES

The following examples provide a nonlimiting illustration of various embodiments of the invention.

Example 1 Preparation of Microarrays

Preparation of glass cDNA microarrays, probe labeling, hybridization and image acquisition were performed according to the protocol given below, which is a standard NHGRI protocol (http://www.nhgri.nih.gov/DIR/LCG/15K/HTML/protocol.html).

Gene-specific DNA was produced by PCR amplification of purified template plasmid DNAs from cloned ESTs. The PCR product was purified by ethanol precipitation, thoroughly resuspended in 3×SSC, and printed onto a poly-L-lysine coated slide.

The materials, reagents, and solutions used include: 96 well alkaline lysis miniprep kit (Edge BioSystems, Gaithersburg, Md.); LB Broth (Biofluids, Rockville, Md.); Superbroth (Biofluids, Rockville, Md.); dATP, dCTP, dGTP, dTTP, 100 mM each #27-2035-02, store frozen, −20° C. (Pharmacia, Peapack, N.J.); PCR primer AEK M13F (5′-GTTGTAAAACGACGGCCAGTG-3′) (SEQ. ID. NO. 97) and AEK M13R (5′-CACACAGGAAACAGCTATG-3′) (SEQ. ID. NO. 98) at 1 mM concentration, store frozen, −20° C.; 10× PCR Buffer, #N808-0189, and Ampli-Taq DNA polymerase, #N808-4015 store frozen, −20° C. (Perkin Elmer, Norwalk, Conn.); Carbenicillin (Gibco-BRL, Rockville, Md.); Ethanol (200 Proof USP Ethyl Alcohol); 1M Tris-HCl (pH 8); 0.5M NAEDTA (pH 8); T Low E; Buffer; 20×SSC; Glycerol (enzyme grade); Sodium Acetate (tri-hydrate); Boric Acid; Sodium Hydroxide (1M); Glacial Acetic Acid; Succinic anhydride, #23969-0 and 1-methyl-2-pyrrolidinone, #32863-4 (Aldrich Chemical Co., St. Louis, Mo.); Diethyl Pyrocarbonate (DEPC) treated H₂O; Master set of clone-purified, sequence verified human ESTs (e.g. gf211 release, Research Genetics, Huntsville, Ala.); 96 pin inoculating block (#VP 4088, V&P Scientific, Inc, San Diego, Calif.); Airpore Tape Sheets, (#19571, QIAGEN Inc., Valencia, Calif.); Sterile 96-well plate seals, (e.g. # SEAL-THN-STR (Elkay Products, Inc., Shrewsbury, Mass.); 96-well U-Bottom Microtiter Plates, #3799 and 96-well V-Bottom Microtiter Plates, #3894 (Corning Inc., Corning, N.Y.); Thin wall PCR plate and Cylcleseal PCR plate sealer (e.g. #1038-50-0 and #1044-39-4, Robbins Scientific Corp. Sunnyvale, Calif.); household one-gallon sealable storage bags (e.g. Glad Lock); heat sealable storage bags and heat sealer; 0.2 mm Sterile Filtration unit; Diamond scribe for writing on slides; Pyrex baking dish (˜24×34×5 cm); UV transparent plastic wrap (e.g. Glad Cling Wrap); 30 slide rack (stainless steel) #113 and 30 slide glass tank, #122 (Shandon Lipshaw, Pittsburgh, Pa.); 1 L glass tank; 1 L glass beaker; 1 L graduated; cylinder; Stir bar; Slide Box (plastic with no paper or cork liners), (e.g. #60-6306-02, PGC Scientific, Gaithersburg, Md.); PCR heat cycler (e.g. DNA Engine Tetrad, MJ Research, Waltharn, Mass.); Centrifuge with a horizontal (“swinging bucket”) rotor with a depth capacity of 6.2 cm for spinning microtiter plates and filtration plates (e.g. Sorvall Super T 21, Sorvall Inc., Newtown, Conn.); 37° C. Shaker incubator with holders for deep-well plates; 37° C. Waterbath; 65° C. Incubator; Vortex mixer; Immunowash microtiter plate washer, #1575 (BioRad, Hercules, Calif.); pH Meter; Platform Shaker; UV Stratalinker 2400, (Stratagene La Jolla, Calif.); Stirrer/Hotplate; Robotic slide printer; −80° C. Freezer; −20° C. Freezer; 45% (w/v) Sterile Glycerol; 450 grams enzyme grade glycerol per liter 9 Autoclave and store at room temperature); T low E Buffer; 1M Tris-HCl (pH 8.0) 10 mL; 0.5 M EDTA (pH 8.0) 0.2 mL; DEPC treated H₂O 990 mL (Autoclave and store at room temperature); Carbenicillin stock solution (1 gram of carbenicillin in 10 mls of sterile water, Sterile filter with a 0.2 micron filter, Store frozen at −20° C.); LB with 100 μg/ml carbenicillin (Add 1 ml of carbenicillin stock solution to 1 liter of LB, Make fresh); 3M Sodium Acetate pH=6.0 (408.24 grams sodium acetate (tri-hydrate) per liter, 3M acetic acid (172.4 ml per liter), Titrate the pH of the 3M sodium acetate solution to pH 6.0 with the 3M acetic acid solution, Filter sterilize using a 0.2 micron filter, Store at room temperature); Ethanol/acetate mix (Ethanol (100%) 950 ml, Sodium acetate pH=6.0, 50 ml); 1000 ml 3×SSC; DEPC H₂O 42.5 ml; 20×SSC 7.5 ml; 50 ml 70% Ethanol; Ethanol (100%) 350 ml; DEPC H₂O 150 ml; 500 ml.

The first step was to grow the EST clones. The cDNA clones were obtained from Research Genetics (Huntsville, Ala.) and were their standard microarray set, which consisted of 3789 sequence-verified known genes and 2778 sequence-verified ESTs.

The sealed master plates were incubated over night at 37° C. Most suppliers provide low density bacterial cultures. Replicating directly from these dilute stocks frequently results in non-growth in the secondary culture. If making the template from a plate that had previously been cultured to high density before freezing, this initial growth step should not be used, as it will reduce the viability of the cultures.

A set of standard 96 well round (U) bottom plates were then prepared by labeling all plates and placing 100 μl of LB broth containing 100 μg/ml carbenicillin in each well. These plates were used as working copies. To preserve the master set of plates, it was useful to make replicate copies of the master plate to serve as working copies when the master plate was first replicated. The EST clones were then checked to insure that they were in a vector conferring ampicillin resistance, as is common with human IMAGE clones.

The master plates were spun briefly (about two minutes) at 1000 rpm in a horizontal microtiter plate rotor to remove condensation and droplets from the seals before opening. Bacterial culture fluid on the sealers can easily be transferred from one well to others, cross-contaminating the stocks.

Then a container was partially filled with 100% alcohol. The 96 pin-replicating tool was dipped in the alcohol, removed and then the pins were flamed.

The inoculation block was allowed to cool briefly, then the replicating tool was dipped in the master plate and then into the daughter plate. This was repeated as necessary for each plate inoculated. It is useful to color the plate corner near the A-1 well of all master and daughter plates with a marker pen before beginning the replication process in order to reduce mistakes in the relative orientation of the plates. The suggested plates have a notch at this corner as well.

The inoculated LB plates, with the lids on, were placed into a one gallon sealable bag containing a moistened paper towel and grow overnight at 37° C. Many 37° C. incubators tend to dry out microtiter plate cultures. Placing the plates in a highly humidified bag avoids this problem.

Next, deep well plates were filled with 1 ml of Superbroth (100 μg/ml carbenicillin) per well. These plates served as the source of culture for template preparation. Using the replicating tool, the deep well plates were then inoculated directly from the freshly grown LB plates. Next, the openings of the deep well plates were covered with Qiagen Airpore Tape Sheets and the plastic lids were placed over the sheet. The plates were then placed in a 37° C. shaker incubator at 200 RPM for twenty-four hours. 50 μl of 45% (w/v) sterile glycerol was added to each well of any working plates that are to be frozen (−80° C.) and subsequently used as culture sources.

After the EXT clones were grown, the plasmid templates have to be isolated. First, the lysis buffer (Edge Biosystems Kit) was warmed to 37° C. to dissolve the SDS. Then the RNAse solution was added to the resuspension buffer (Edge Biosystems Kit), 1 ml/100 ml, and stored at 4° C. The receiving plates were prepared from the Edge Biosystems Kit by adding 350 μl of ethyl alcohol to each well of the receiving plates. The filter plate was then placed on top and secured with tape. The bacterial cultures in the deep well plates were centrifuged at 1500×g for seven minutes in a centrifuge equipped with a horizontal rotor for 96-well plates. They were then briefly inverted and excess media was tapped out on a clean paper towel. The pellets will loosen and may be lost when pouring off excess media if this step is delayed.

The pellet was then resuspended in 100 μl of Resuspension Buffer, and Vortexed until the entire pellet was re-suspended. This step is critical. Poor resuspension of the cells results in clumps of cells that do not lyse in subsequent steps. This reduces the yield and decreases the purity of the product. 100 μl of Lysis Buffer was then added and the solution was mixed gently by rocking the plates from side to side, to avoid shearing the bacterial chromosomal DNA. 100 μl of Precipitation buffer was added to each well and briefly mixed. Then, 100 μl of Neutralization buffer was added to each well and Vortexed.

The contents of the deep wells were then transferred to the waiting filter plates/receiving plate stacks using the wide bore pipette tips provided in the kits. The stacked plates were then centrifuged at 1500×g for twelve minutes in a centrifuge equipped with a horizontal rotor for 96-well plates. The stacked plates were then removed from the centrifuge. The filter plates were removed and discarded. The alcohol and filtrate were decanted from the receiver plate and the excess alcohol was touched off on clean paper towels. 500 μl of 70% ethanol was added to each well and immediately decanted and excess alcohol was touched off with a clean paper towel. Then, the plates were placed in a clean drawer without their lids, covered with a clean paper towel and allowed to dry overnight.

The next day, the DNA was resuspended in 200 μl of T Low E Buffer. The top was sealed with plate sealer and rehydrated at 4° C. for at least two days before using. They were stored at −20° C. in the interim.

After the plasmid templates have been isolated, the EST inserts were amplified. For each 96 well plate to be amplified, a PCR reaction mixture was prepared containing the following ingredients: 1000 μl of 10× PCR Buffer, 20 μL of dATP (100 mM), 20 μL of dGTP (100 mM), 20 μL of dCTP (100 mM), 20 μL of dTTP (100 mM), 5 μL of AEK M13F primer (1 mM), 5 μL of AEK M13R primer (1 mM), 100 μL of Ampli-Taq polymerase (5 U/μl), and 8800 mL of H₂O. The 96-well PCR plates were then labeled and 100 μl of the PCR reaction mixture from above was aliquotted to each well. The plates were then gently tapped to insure that no air bubbles were trapped at the bottom of the wells. 1 μl of purified EST plasmid template from above was then added to each well. The donor and recipient plates were then marked at the corner, near the A1 well to facilitate correct orientation during transfer of the template. It was important to make sure that the pipette tips were all submerged in the PCR reaction mix when delivering the template. Missing the liquid was easier when multi-channel pipettes were used.

The following thermal cycle series was then performed: 1 initial cycle of heating to 96° C. and holding for 30 sec, 25 cycles of denaturing at 94° C. for 30 sec, reannealing at 55° C. for 30 sec, and extending at 72° C. for 150 sec, one final cycle of holding at 72° C. for 5 minutes, then cooling to ambient temperature. After the above cycle, the plates were held at 4° C. while quality controls were performed.

The quality control was done by agarose gel electrophoresis of the ESTs. If this was the first time the template for these ESTs was being amplified, 2 μl of each PCR product was analyzed on a 2% agarose gel. If amplified products from this template had been previously tested, then one row of wells from each plate amplified was analyzed. Gel imaging allowed a rough quantitation of product while giving an excellent characterization of the product. Band size, as well as the number of bands observed in the PCR products, contributed to an understanding of the final results of the hybridization. The use of gel well formats suitable for loading from 96 well plates and programmable pipetters made this form of analysis feasible on a large scale.

The materials, reagents and solutions for the quality control check included: Electrophoresis apparatus with capacity for four 50 well combs, (e.g. #D3, Owl Scientific, Woburn, Mass.); 50×Tris-Acetate Electrophoresis BufferM; Agarose; Dye Solution (Xylene Cyanol/Bromophenol Blue) (e.g. #351-081-030, Quality Biological Inc., Gaithersburg Md.); Glycerol (enzyme grade); Ethidium Bromide solution (10 mg/ml); 100 base-pair ladder size standard; Programmable, 12-channel pipetter (e.g. #2019, Matrix Technologies, Lowell, Mass.); Disposable microtiter mixing trays (e.g. Falcon #353911, Becton Dickinson, Franklin Lake, N.J.); Electrophoresis power supply; 1× TAE Buffer; 50× TAE Buffer 40 ml; Ethidium Bromide (10 mg/ml) 0.1 ml and Water 960 ml; 1000 ml; Loading Buffer; Glycerol (enzyme grade) 4.0 ml, DEPC Water 0.9 ml, and Dye Solution* 0.1 ml for a total of 5.0 ml (*This solution is 0.25% (w/v) Xylene Cyanol and 0.25% (w/v) Bromophenol Blue); 100 bp Size Standards; DNA ladder (1 mg/ml) 50 μL, I M Tris-HCl (pH 8.0) 5 μl, 0.5 M EDTA (pH 8.0) 5 μl, and Loading Buffer 440 μl for a total of 500 μl.

The electrophoresis was carried out with a 2% agarose gel (1× TAE) with four combs (50 tooth) that was submerged in an electrophoresis apparatus with sufficient 1× TAE buffer to just cover the surface of the gel. A reservoir of Loading Buffer was prepared, using 12 wells of a microtiter plate. Then a pipetter was programmed to sequentially carry out the following steps: fill with 2 μl, fill with 1 μL, fill with 2 μl, mix a volume of 5 μl five times, expel 5 μl. Twelve (12) disposable tips were then placed on the pipetter. 2 μl of PCR product from wells A1-A12 of the PCR plate were loaded, followed by 1 μl of air, then 2 μl of Loading Buffer from the reservoir. The tips were then placed in clean wells of a disposable mixing tray and the pipette was allowed to mix the sample and loading dye. The pipette tip was then placed in a 50 well row so that the tip containing the PCR product from well Al is in the second well of the row, and the other tips are in every other succeeding well.

The process was repeated (changing tips each time), to load PCR plate row B starting in the 3rd well, interleaved with the A row, the C row starting at well 26, and the D row at well 27, interleaved with the C row. Then 5 μl of 100 bp Size Standards were placed in wells 1 and 50. This process was repeated, to load samples from rows E, F, G, and H in the second, 50 well row of gel wells, to load samples from two 96 well PCR plates per gel, or single row samples from 16 PCR plates. To reduce diffusion and mixing, a voltage was applied to the gel for a minute between loading each well strip. This caused the DNA to enter the gel, and reduced band spreading and sample loss.

A voltage was then applied to the gel and it was run until the bromophenol blue (faster band) had nearly migrated to the next set of wells. For a gel that is 14 cm in the running dimension, and 3 cm between each row of wells, 200 volts were applied for 15 minutes. Digital photos of the gel were taken and the images stored for future reference. The gels should show bands of fairly uniform brightness distributed in size between 600 to 2000 base-pairs. Further computer analysis of such images can be carried out with image analysis packages to provide a list of the number and size of bands. Ideally this information can be made available during analysis of the data from hybridizations involving these PCR products.

After the quality control checks are run on the plates, the next step involves purifying the PCR products. 96 well V-bottom plates were filled with 200 μl per well of ethanol/acetate mix. The ethanol acetate solution used for precipitation is less acidic (pH 6) than is typically used. In this instance, more acidic solutions produce precipitates which are harder to resuspend without improving yield.

100 μl per well of PCR product was transferred into V-bottom plates and mixed by pipetting a volume of 75 μl per well four times. The plates were then placed in a −80° C. freezer for one hour or stored overnight at −20° C. The plates were stored at −20° C. if they were to be left for more than one hour, because aggressive precipitation produces precipitates which are hard to resuspend. The plates were then thawed to reduce brittleness and melt any ice, which may have formed in the wells.

The plates were loaded into a centrifuge with a horizontal microtiter plate rotor and spun at 2600×g for 40 minutes at 4° C. Next, the supernatant from each well was aspirated using the Immunowash plate washer. Settings for the depth of aspiration by the plate washer needed to be adjusted to suit the microtiter plates used. It is advisable to leave approximately 10-20 ml in the bottom of the well to avoid disturbing the pellet.

200 μl of 70% ethanol was delivered to each well in the plate using the Immunowash plate washer, and the plates were centrifuged at 2600×g for 40 minutes. The supernatant was aspirated from each well using the Immunowash plate washer, and the plates were dried overnight in a closed drawer. They should not be dried in a speed-vac because desiccated PCR products are hard to resuspend.

After the PCR products were purified, they were then resuspended by adding 40 μl of 3×SSC per well. The plates were then sealed with a foil sealer, taking care to achieve a tight seal over each well. The plates were then placed in heat sealable bags with paper towels moistened with 3×SSC and the bag was sealed with a heat sealer. The high external humidity within the sealed bag helped to keep the volumes in the individual wells from varying. The bags were then placed in a 65° C. incubator for 2 hours. The heat in the incubator was then turned off, and the plates were allowed to cool gradually in the incubator to avoid condensation on the sealers. The plates were stored at −20° C.

The yield of the PCR suspension was then checked by fluorometric determination of DNA concentration. 1 μl of resuspended PCR product from one row of wells from each plate on a 2% agarose gel was analyzed as previously described. Adequate precipitation and resuspension produced very intense bands, with no material failing to leave the loading well, and no smear of material from the band towards the loading well.

While it would be ideal to be able to exactingly quantify each EST PCR product and spot each DNA species at equivalent concentrations, it is impractical for most labs to do so when thousands of ESTs must be prepared. Fortunately, it is possible to use a strategy where excess DNA is spotted, so that the exact quantities used do not produce much variation in the observed results. When using this strategy, it is necessary to track the average productivity of the PCR reactions. Fluorometry provides a simple way to obtain an approximate concentration of the double-stranded PCR product in the PCR reaction mix.

Next, the double stranded DNA was quantified. The materials, reagents, and solutions necessary include: reference double-stranded DNA (0.5 mg/ml) (e.g. #15612-013 Gibco/BRL, Bethesda, Md.), 96 well plates for fluorescent detection (e.g. #7105, Dynex, Chantilly, Va.), Fluorometer (e.g. #LS50B, Perkin Elmer, Norwalk, Conn.), FluoReporter Blue dsDNA Quantitation Kit (#F-2962, Molecular Probes, Eugene, Oreg.), TE, 12 channel multi-pipetters, Computer equipped with Microsoft Excel software, Ds-DNA Standards: 50 μg/ml, 100 μg/ml, 250 μg/ml, 500 μg/ml, μl TE 90, 80, 50, 0 μl ds-DNA (0.5 mg/ml) 10, 20, 50, 100, (It is good practice to check both the integrity (agarose gel) and the concentration (absorbance) of the standard before use); Fluor Buffer (Hoechst 33258 solution (contains the dye at an unspecified concentration in a 1:4 mixture of DMSO:H₂O) (from kit) 25 μl, TNE Buffer (TNE Buffer is 10 mM Tris-HCl (pH 7.4), 2 M NaCl, 1 mM EDTA) (from kit) 10 ml.

The double stranded DNA was quantified as follows. 96 well plates were labeled for fluorescence assay. 200 μl of Fluor Buffer was added to each well. 1 μl of PCR product from each well in a row of a PCR plate was added to a row of the fluorometry plate. Samples were added to rows A through G of the fluorometry plate. In the final row of the fluorometry plate 1 μl of each of the series of ds-DNA standards 0 μg/ml (TE only), 50, 100, 250 and 500 μg/ml ds-DNA were added. This series was repeated twice in the final row.

The fluorometer was set for excitation at 346 nm and emission at 460 nm, and adjusted as necessary to read the plate. If the fluorometer used did not support automated analysis, the data table was exported to Excel. The response for the standards was tested to see that it was linear and reproducible from the range of 0 to 500 μg/ml of ds-DNA.

Next, the concentration of ds-DNA in the PCR reactions was calculated using the following equation, after subtracting the average 0 μg/ml value from all other sample and control values:

[ds-DNA(μg/ml)]=((PCR sample value)/(average 100 μg/ml value))*100

Constantly tracking the yields of the PCRs makes it possible to rapidly detect many ways in which PCR can fail or perform poorly. This assay can also be applied after precipitation and resuspension of the PCR products to monitor overall recovery of product. 1 μl of amplified products from one row of wells from each amplified plate by fluorometry was analyzed.

Slides were then coated with poly-L-lysine to have a surface that is both hydrophobic and positively charged. The hydrophobic character of the surface minimizes spreading of the printed spots, and the charge appears to help position the DNA on the surface in a way that makes cross-linking more efficient.

Materials, reagents, and solutions for coating the slides includes: Gold Seal Microscope Slides (#3011, Becton Dickinson, Franklin Lake, N.J.), Ethanol (100%), Poly-L-lysine (#P8920, Sigma, St. Louis, Mo.), 50 Slide Stainless Steel Rack, #900401, and 50 Slide Glass Tank, #900401, (Wheaton Science Products, Millville, N.J.), Sodium Hydroxide, Stir Plate, Stir Bar, Platform Shaker, 30 Slide Rack, #196, plastic, and 30 slide Box, #195, plastic, (Shandon Lipshaw, Pittsburgh, Pa.), Sodium Chloride, Potassium Chloride, Sodium Phosphate Dibasic Heptahydrate, Potassium Phosphate Monobasic, Autoclave, 0.2 mm Filter: Nalgene, Centrifuge: Sorvall Super 20, Slide Box (plastic with no paper or cork liners), (e.g. #60-6306-02, PGC Scientific, Gaithersburg, Md.), 1 L Glass Beaker; 1 L Graduated Cylinder, 1M Sodium Borate (pH 8.0) (Dissolve 61.83 g of Boric acid in 900 ml of DEPC H₂O. Adjust the pH to 8.0 with 1N NaOH. Bring volume up to one liter. Sterilize with a 0.2 micron filter and store at room temperature), Cleaning Solution (H₂O 400 ml, Ethanol 600 ml, NaOH 100 g—Dissolve NaOH in H₂O. Add ethanol and stir until the solution clears. If the solution does not clear, add H₂O until it does), and Poly-L-lysine Solution (poly-L-lysine (0.1% w/v) 35 ml PBS 35 ml H₂O 280 ml 350 ml).

First, the slides are placed into 50 slide racks and the racks are placed in glass tanks with 500 ml of cleaning solution. Gold Seal Slides are highly recommended, as they have been found to have consistently low levels of autofluorescence. It was important to wear powder free gloves when handling the slides to avoid contamination.

The tanks are placed on platform shakers for two hours at 60 rpm. After being shook, the cleaning solution was poured out, and the slides were then washed in H₂O for three minutes. This wash was repeated four times. The slides were then transferred to 30 slide plastic racks and placed into small plastic boxes for coating. The slides were then submerged in 200 ml poly-L-lysine solution per box. The slide boxes were then placed on platform shaker for one hour at 60 rpm. The slides were rinsed three times with H₂O, and submerged in H₂O for one minute, and then centrifuged for two minutes at 400×g and the slide boxes used for coating were dried.

The slides were then placed back into the slide box used for coating and allowed to stand overnight before transferring to a new slide box for storage. This allowed the coating to dry before it was handled. The slides were allowed to age for two weeks on the bench, in a new slide box, before they were printing on. The coating dried slowly, becoming more hydrophobic with time.

Slide boxes used for long term storage should be plastic and free of cork lining. The glue used to affix the cork will leach out over time and give slides stored in these types of boxes a greasy film that has a high degree of autofluorescence. All glassware and racks used for slide cleaning and coating should be cleaned with highly purified H₂O only, and detergent should not be used.

Once the slides were coated, they were printed. The variety of printers and pens for transferring PCR products from titer plates to slides precludes highly detailed descriptions of the process. The following steps provide a general description of the processing.

The print pens were pre-cleaned according to the manufacturer's specification. The printer slide deck was then loaded with poly-L-lysine coated slides from above. The plates containing the purified EST PCR products were thawed and centrifuged briefly, (about two minutes) at 1000 rpm in a horizontal microtiter plate rotor to remove condensation and droplets from the seals before being opening. 5 to 10 μl of the purified EST PCR products were transferred to a plate that served as the source of solution for the printer. Printing with quill-type pens usually requires that the volume of fluid in the print source was sufficiently low, so that when the pen was lowered to the bottom of the well, it was submerged in the solution to a depth of less than a millimeter. This keeps the pen from carrying a large amount of fluid on the outside of the pen shaft and producing variable, large spots on the first few slides printed.

A repetitive test print was run on the first slide. In this operation, the pens were loaded with the DNA solution, and then the pens serially deposited this solution on the first slide in the spotting pattern specified for the print. This test was run to check the size and shape of the specified spotting pattern, as well as its placement on the slide. It also served to verify that the pens were loading and spotting, and that a single loading produced as many spots as were required to deliver material to every slide in the printer. If one or more of the pens was not performing at the desired level, it was re-cleaned or substituted with another pen and tested again. If all pens were performing, the full print was carried out.

At the end of the print, the slides were removed from the printer, labeled with the print identifier and the slide number by writing on the edge of the slide with a diamond scribe and placed in a dust free slide box to age for one week. It was useful to etch a line, which outlined the printed area of the slide, onto the first slide. This served as a guide to locate the area after the slides have been processed, and the salt spots were then washed off.

The slides were placed, printed side face up, in a casserole dish and covered with cling wrap. The slides were then exposed to a 450 mJ dose of ultraviolet irradiation in the Stratalinker. Slides should have been and were aged at ambient temperature in a closed slide box for one week prior to blocking. The slides were then transferred to a 30 slide stainless steel rack and the rack was placed into a small glass tank. 6.0 g succinic anhydride was dissolved in 325 ml 1-methyl-2-pyrrolidinone in a glass beaker by stirring with a stir bar. Nitrile gloves were worn and the work was carried out in a chemical fume hood while handling 1-methyl-2-pyrrolidinone (a teratogen).

25 ml 1M sodium borate buffer (pH 8.0) was added to the beaker. The solution was allowed to mix for a few seconds, then rapidly poured into a glass tank with slides. Succinic anhydride hydrolyzed quite rapidly once the aqueous buffer solution was added. To obtain quantitative passivation of the poly-L-lysine coating, it was critical that the reactive solution be brought in contact with the slides as quickly as possible. The glass tank was placed on a platform shaker in a fume hood for 20 minutes. Small particulates resulting from precipitation of reaction products may be visible in the fluid.

While the slides were incubating on the shaker a boiling H₂O bath was prepared to denature the DNA on the slides. After the slides were incubated for 20 minutes, they were transferred into the boiling H₂O bath. The heating element was immediately turned off after the slides were submerged in the bath. The slides were allowed to stand in the H₂O bath for 2 minutes. The slides were then transferred into a glass tank filled with 100% ethanol and incubated for 4 minutes. The slides were removed and centrifuged at 400 rpm for 3 minutes in a horizontal microtiter plate rotor to dry the slides. The slides were then transferred to a clean, dust free slide box and allowed to stand overnight before being used for collection of gene expression data.

Example 2 Cell Culture and Tumor Samples

The source and other information for the cell lines and tumor samples used herein are described in Table 3 below for both the training set and the test samples.

TABLE 3 Supplement Table: Known Molecular Characteristics of Samples. Histological Molecular Source Sample Label Diagnosis Markers Label Source EWS-C1 EWS-C EWS-FLI1, 10-6 A4573 NCI EWS-C2 EWS-C EWS-FLI1, type I TC71 NCI EWS-C3 EWS-C EWS-FLI1, type I TC108 NCI EWS-C4 EWS-C EWS-FLI1, type I 5838 NCI EWS-C6 EWS-C EWS-FLI1, type I A673 NCI EWS-C7 EWS-C EWS-FLI1, type I ES-CL1 MSKCC EWS-C8 EWS-C EWS-FLI1, type I TC32 NCI EWS-C9 EWS-C EWS-FLI1, type II SK-ES-1 ATCC EWS-C10 EWS-C EWS-FLI1, type II SK-N-MC ATCC EWS-C11 EWS-C EWS-FLI1, type II RDES ATCC EWS-T1 EWS-T EWS-FLI1, type I ES20 MSKCC EWS-T2 EWS-T EWS-FLI1, type II ES13 MSKCC EWS-T3 EWS-T EWS-FLI1, type I ES16 MSKCC EWS-T4 EWS-T EWS-FLI1, type I ES17 MSKCC EWS-T6 EWS-T EWS-FLI1, 7-8 ES22 MSKCC EWS-T7 EWS-T EWS-ERG, 7-9 ES25 MSKCC EWS-T9 EWS-T EWS-FLI1, type I 9602P006 CHTN EWS-T11 EWS-T EWS-FLI1, type I 9703P152 CHTN EWS-T12 EWS-T EWS-FLI1, type I 9704P218 CHTN EWS-T13 EWS-T EWS-FLI1, type I ES23 MSKCC EWS-T14 EWS-T EWS-FLI1, type I 9605P074 CHTN EWS-T15 EWS-T EWS-FLI1, type I 9609P027 CHTN EWS-T19 EWS-T EWS-FLI1, type I SARC75 CHTN RMS-C2 ERMS-C — RD ATCC RMS-C3 ARMS-C ND RH4 NCI RMS-C4 ARMS-C PAX3-FKHR RH3 NCI RMS-C5 ARMS-C PAX3-FKHR RH5 NCI RMS-C6 ARMS-C PAX3-FKHR RH28 NCI RMS-C7 ARMS-C ND RH30 NCI RMS-C8 ERMS-C — CTR ATCC RMS-C9 ARMS-C PAX3-FKHR RH4 NCI RMS-C10 ARMS-C PAX3-FKHR RMS13 NCI RMS-C11 ERMS-C — TE671 ATCC RMS.T1 ARMS-T PAX3-FKHR RMS3 MSKCC RMS.T2 ARMS-T PAX3-FKHR RMS6 MSKCC RMS.T3 ERMS-T — RMS2 MSKCC RMS.T4 ERMS-T no PAX-FKHR RMS5 MSKCC RMS.T5 ARMS-T PAX3-FKHR RMS10 MSKCC RMS.T6 RMS-T ND RT1 CHTN RMS.T7 ERMS-T — RT4 CHTN RMS.T8 RMS-T ND RT5 CHTN RMS.T10 RMS-T ND RT2 CHTN RMS.T11 ERMS-T — RHAB2 CHTN NB-C1 NB-C MYCN amp KCNR NCI NB-C2 NB-C — GICAN NCI NB-C3 NB-C — SK-N-AS ATCC NB-C4 NB-C MYCN amp LAN5 NCI NB-C5 NB-C MYCN amp SK-N-BE2 ATCC NB-C6 NB-C MYCN amp SK-N-DZ ATCC NB-C7 NB-C — GICAN NCI NB-C8 NB-C — NGP NCI NB-C9 NB-C — SH-SY5Y ATCC NB-C10 NB-C MYCN amp SK-N-FI ATCC NB-C11 NB-C Single copy MYCN SK-N-SH ATCC NB-C12 NB-C, MYCN amp CHP-134B NCI BL-C1 BL-C — RAMOS (RAI) ATCC BL-C2 BL-C — ST488 ATCC BL-C3 BL-C — CA46 ATCC BL-C4 BL-C — ST486 ATCC BL-C5 BL-C — RAJI ATCC BL-C6 BL-C — MC116 ATCC BL-C7 BL-C — DAUDI ATCC BL-C8 BL-C — SULTAN ATCC Test1 NB-C MYCN amp IMR32 ATCC Test2 EWS-C ND CHOP1 NCI Test3 Osteosarcoma-C — OsA-CI ATCC Test4 ARMS-T — ARMD1 CHTN Test5 Sarcoma — A204 ATCC Test 6 EWS-T EWS-FLI1, type I 9608P053 CHTN Test7 BL-C — EB1 ATCC Test8 NB-C — SMSSAN NCI Test9 Sk. Muscle — SkM1 CHTN Test10 ERMS-T — ERDM1 CHTN Test11 Prostate Ca.-C — PC3 ATCC Test12 EWS-T — SARC67 CHTN Test13 Sk. Muscle — SkM2 CHTN Test 14 NB-T Single copy MYCN NB3 DZNSG Test 15 BL-C — EB2 ATCC Test 16 NB-T Single copy MYCN NB1 DZNSG Test 17 ARMS-T — ARMD2 CHTN Test 18 BL-C — GA10 ATCC Test 19 EWS-T ND ET3 CHTN Test 20 EWS-T EWS-FLI1, type I 9903P1339 CHTN Test 21 EWS-T EWS-FLI1, type II ES23 MSKCC Test 22 ERMS-T — ERMD2 CHTN Test 23 NB-T Single copy MYCN NB2 DZNSG Test 24 ERMS-T no PAX-FKHR RMS4 MSKCC Test 25 NB-T Single copy MYCN NB4 DZNSG Supplement Table: Known molecular characteristics of samples. Table labels and abbreviations are described in Table 1 in the manuscript. EWS and ARMS samples with noted translocations were verified by RT-PCR. ND: not determined. Amp.: amplification.

All the original histological diagnoses were made at tertiary hospitals, which have reference diagnostic laboratories with extensive experience in the diagnosis of pediatric cancers. Approximately 20% of all samples in each category were randomly selected, blinded and set aside for testing. To augment this test set, we added 4 neuroblastoma tumors and 5 non-SRBCT samples (also blinded to the authors performing the analysis). The EWSs had a spectrum of the expected translocations, and the RMSs were a mixture of both ARMS containing the PAX3-FKHR translocation and embryonal rhabdomyosarcoma (ERMS). The NBs contained both MYCN amplified and single copy samples. The BLs were cell lines derived from BL. Table 3 gives details of these samples as well.

This protocol details the methods used to extract RNA from cells, purify the RNA by a combination of phase extraction and chromatography, and prepare a labeled cDNA copy of the message fraction of the purified RNA. The protocol also describes the process of making fluorescent cDNA representations of the message pools within the isolated total RNA pools. This is accomplished by using the pure total RNA as a substrate for reverse transcription in the presence of nucleotides derivatized with either a Cy3 or a Cy5 fluorescent tag.

The materials, reagents, and solutions needed include: Trizol Reagent (#15596-018, Life Technologies, Rockville, Md.); RNeasy Maxi Kit (#75162, Qiagen, Valencia, Calif.); Chloroform; Ethanol (200 Proof USP Ethyl Alcohol); DPBS (Dulbecco's phosphate buffered saline); 3M sodium acetate (pH 5.2); DATP, dCTP, dGTP, dTTP, 100 mM each, store frozen, −20° C. (#27-2035-02, Pharmacia, Peapack, N.J.); pd(T)12-18 resuspend at 1 mg/ml, and store frozen −20° C. (#27-7858, Amersham Pharmacia Biotech); Anchored oligo primer (anchored;5′-TTT TTT TTT TTT TTT TTT TTV N-3′) (SEQ. ID. NO. 99); resuspend at 2 mg/ml, store frozen −20° C. (e.g. #3597-006, Genosys); CyTM3-dUTP, 1 mM, and CyTM5-dUTP, 1 mM, store −20° C., light sensitive; RNasina Rnase inhibitor, store −20° C. (#N211A, Promega); SUPERSCRIPTTM II Rnase H′ Reverse Transcriptase Kit, store −20° C., (#18064-014, Life Technologies, Rockville, Md.); C0t-1 DNA, 1 mg/ml, store frozen −20° C. (#15279-011, Life Technologies, Rockville, Md.); 0.5M EDTA( pH 8.0); 1 N NaOH; 1M TRIS-HCL; (pH7.5); TE pH 7.4; DEPC water 50×Tris Acetate Buffer; 15 ml round bottom; polypropylene centrifuge tubes; 50 ml conical polypropylene centrifuge tubes; 1.5 ml; Eppendorf tubes; 0.2 ml thin wall PCR tube; MicroCon 100 (Amicon Cat No. 42412); High speed centrifuge for 15 ml tubes; Clinical centrifuge with horizontal rotor for 50 ml conical tubes; Tissue homogenizer (e.g. Polytron PT1200 with Polytron-Aggregate-Dispergier-und-Mischtechnik 147a Ch6014 #027-30-520-0, Brinkmann Instruments Inc., Westbury, N.Y.); RPE Buffer (Add 4 volumes of ethanol per volume of RPE concentrate supplied in Quiagen Kit0; RW1 Buffer (Supplied in Qiagen Kit) 75% EtOH(Ethanol (100%) 375 ml, and DEPC H2O 125 ml for a total of 500 ml); 10× low T dNTP Mix (25 μL dGTP (100 mM), 25 μL dATP (100 mM), 25 μL dCTP (100 mM), 10 μL dTTP (100 mM), and 415 μL DEPC H₂O for a total of 500 μL); 5× First Strand Buffer (Provided with Superscript II); TAE Buffer (50× Tris Acetate Electrophoresis Buffer 20 ml, and DEPC H2O 980 mL for a total of 1000 ml).

If the cells that were used were harvested from tissue culture, the cell pellet was washed twice in DPBS. If the cells that were used were from tissue culture, 1 ml of Trizol was added per 2×10⁷ cells and mixed by shaking. If tissue was being used, 100 mg of frozen tissue was added directly to 4 ml of Trizol, and dissociate by homogenization with a rotating blade tissue homogenizer.

Whatever the source, 2/10 volume of chloroform was added to the cells and shook for 15 seconds, and then allowed to stand for 3 minutes, followed by centrifugation at 12,000×g for 15 minutes at 4° C. The supernatant was taken off and added to a polypropylene tube, while recording the volume of the supernatant.

Then 0.53 volumes of ethanol were slowly added to the supernatant while vortexing, this produced a final ethanol concentration of 35%. The ethanol was added drop by drop and allowed to mix completely with the supernatant before more ethanol is added. If a high local concentration of ethanol is produced, the RNA in that vicinity will precipitate.

The supernatant from an extraction of 2×10⁷ to 1×10⁸ cells was added to an RNeasy maxi column, which is seated in a 50 ml centrifuge tube. The tube was then centrifuged at 2880×g in a clinical centrifuge with a horizontal rotor at room temperature for 5 minutes. The flow-through was then poured back onto the top of the column and centrifuged again. This step is necessary because a significant amount of RNA is not captured by the column matrix in the first pass of the RNA containing solution through the column.

The flow-through was discarded and 15 ml of RW1 buffer was added to the column, followed by centrifugation at 2880×g for 5 minutes. The flow-through was discarded again and then 10 ml of RPE buffer was added, followed again by centrifugation at 2880×g for 5 minutes. Once again, the flow through was discarded and another 10 ml of RPE buffer was added, and the column was centrifuged at 2880×g for 10 minutes.

Next, the column was placed in a fresh 50 ml tube and add 1 ml of DEPC treated water from the kit was added to the column, and the column was allowed to stand for 1 minute. The column was then centrifuged at 2880×g for 5 minutes, and another 1 ml of water was added to the column. The column was allowed to stand for 1 minute, followed by centrifugation at 2880×g for 10 minutes.

Then, 400 μl portions of the column eluate was aliquotted to 1.5 ml Eppendorf tubes, to which 1/10 volume of 3M sodium acetate (pH 5.2) was added, along with 1 ml of ethanol. The tubes were then allowed to stand for 15 minutes, after which they were centrifuged at 12000×g at 4C for 15 minutes. The pellet was then washed two times in 75% EtOH and stored at −80° C.

The RNA was resuspended at approximately 1 mg/ml in DEPC H₂O. It was then concentrated to greater than 7 mg/ml by centrifugation on a MicroCon 100 filter unit, centrifuged at 500×g, checking as necessary to determine the rate of concentration. This step removes many residual, small to medium sized, molecules that inhibit the reverse transcription reaction in the presence of fluorescently derivatized nucleotides. The concentration of RNA in the concentrated sample was then determined by spectrophotometry, and the sample was stored at −80° C.

If an anchored oligo dT primer was used, the primer was annealed to the RNA in the following 17 μl reaction (a 0.2 ml thin wall PCR tube was used so that incubations could be carried out in a PCR cycler):

addition for addition for Component Cy5 labeling Cy3 labeling Total RNA (>7 mg/ml) 150-200 μg 50-80 μg Anchored primer (2 μg/μl) 1 μl 1 μl DEPC H2O to 17 μl to 17 μl

If an oligo dT(12-18) primer was used, the primer was annealed to the RNA in the following 17 μl reaction:

addition for addition for Component Cy5 labeling Cy3 labeling Total RNA (>7 mg/ml) 150-200 μg 50-80 μg dT(12-18) primer (1 μg/μl) 1 μl 1 μl DEPC H2O to 17 μl to 17 μl

The incorporation rate for Cy5-dUTP is less than that of Cy3-dUTP, so more RNA is labeled to achieve more equivalent signal from each species.

It was then heated to 65° C. for 10 minutes and cooled on ice for 2 minutes. Then, 23 μl (8 μl of 5× first strand buffer, 4 μl of 10× low T dNTPs mix, 4 μl of Cy5 or Cy3 dUTP (1 mM), 4 μl of 0.1 M DTT, 1 μl of Rnasin (30 u/μl), and 2 μl of Superscript II (200 u/μl)) of reaction mixture containing either Cy5-dUTP or Cy3-dUTP nucleotides was added, mixed well by pipetting and a brief centrifuge spin was used to concentrate it in the bottom of the tube. Superscript polymerase is very sensitive to denaturation at air/liquid interfaces, so we were careful to suppress foaming in all handling of this reaction.

It was then incubated at 42° C. for 30 min., after which 2 μl Superscript II was added, making sure the enzyme was well mixed in the reaction volume and incubated at 42° C. for 30-60 min. Then, 5 μl of 0.5M EDTA was added, making sure the reaction was stopped with EDTA before adding NaOH (the next step), since nucleic acids precipitate in alkaline magnesium solutions.

Then, 10 μl 1N NaOH was added and it was incubated at 65° C for 60 minutes to hydrolyze residual RNA, after which it was cooled to room temperature. The purity of the sodium hydroxide solution used in this step is crucial. Slight contamination or long storage in a glass vessel can produce a solution that will degrade the Cy5 dye molecule, turning the solution yellow. Some researchers achieve better results by reducing the time of hydrolysis to 30 minutes.

It was then neutralized by adding 25 μl of 1M Tris-HCl (pH 7.5). Then, the labeled cDNA was desalted by adding the neutralized reaction, 400 μl of TE pH 7.5 and 20 μg of human C0t-1 DNA to a MicroCon 100 cartridge. It was then pipetted to mix, and spun for 10 minutes at 500×g. 200 μl TE pH 7.5 was added, and the solution was then concentrated to about 20-30 μl (approximately 8-10 min at 500×g). Alternatively, a smaller pore MicroCon 30 was used to speed the concentration step. In this case, the first wash was centrifuged for approximately 4.5 minutes at 16,000×g and the second (200 μl wash) for about 2.5 minutes at 16,000×g.

It was then recovered by inverting the concentrator over a clean collection tube and spinning for 3 min at 500×g. In some cases, the cy5 labeled cDNA formed a gelatinous blue precipitate that was recovered in the concentrated volume. The presence of this material signaled the presence of contaminants. The more extreme the contamination, the greater the fraction of cDNA which will be captured in this gel. Even if heat solubilized, this material tends to produce uniform, non-specific binding to the DNA targets. When concentrating by centrifugal filtration, the times required to achieve the desired final volume were variable. Overly long spins can remove nearly all the water from the solution being filtered. When fluor-tagged nucleic acids are concentrated onto the filter in this fashion, they are very hard to remove, so it is necessary to approach the desired volume by conservative approximations of the required spin times. If control of volumes proves difficult, the final concentration can be achieved by evaporating liquid in the speed-vac. Vacuum evaporation, if not to dryness, does not degrade the performance of the labeled cDNA.

Next, a 2-3 μl aliquot of the Cy5 labeled cDNA was taken for analysis, leaving 18-28 μl for hybridization. This probe was run on a 2% agarose gel (6 cm wide×8.5 cm long, 2 mm wide teeth) in Tris Acetate Electrophoresis Buffer (TAE). For maximal sensitivity when running samples on a gel for fluor analysis, a loading buffer with minimal dye was used and no ethidium bromide was added to the gel or running buffer.

The gel was then scanned on a Molecular Dynamics Storm fluorescence scanner (setting: red fluorescence, 200 micron resolution, 1000 volts on PMT). Successful labeling produces a dense smear of probe from 400 bp to >1000 bp, with little pile-up of low molecular weight transcripts. Weak labeling and significant levels of low molecular weight material indicates a poor labeling. A fraction of the observed low molecular weight material is unincorporated fluor nucleotide.

Next, the fluorescent cDNA had to be hybridized to the microarray. The volume of hybridization solution required was first determined. The rule of thumb is to use 0.033 μl for each mm 2 of slide surface area covered by the cover slip used to cover the array. An array covered by a 24 mm by 50 mm cover slip required 40 μl of hybridization solution. The volume of the hybridization solution is critical. When too little solution is used, it is difficult to seat the cover slip without introducing air bubbles over some portion of the arrayed ESTs, and the cover slip will not sit at a uniform distance from the slide. If the cover slip is bowed toward the slide in the center, there will be less labeled cDNA in that area and hybridization will be non-uniform. When too much volume is applied, the cover slip will move easily during handling, leading to misplacement relative to the arrayed ESTs, and non-hybridization in some areas of the array.

For a 40 μl hybridization, the Cy3 and Cy5 labeled cDNAs were pooled into a single 0.2 ml thin wall PCR tube and the volume was adjusted to 30 μl by either adding DEPC H₂O, or removing water in a SpeedVac. If a vacuum device was used to remove water, high heat or heat lamps were not used to accelerate evaporation because the fluorescent dyes could be degraded.

For a 40 μl hybridization the following components were combined:

High Sample High Array Blocking Blocking Cy5 + Cy3 probe 30 μl 28 μl  Poly d(A) (8 mg/ml)  1 μl 2 μl Yeast tRNA (4 mg/ml)  1 μl 2 μl Human C0t-1 DNA (10 mg/ml)  1 μl 0 μl 20x SSC  6 μl 6 μl 50x Denhardt's blocking solution  1 μl (optional) 2 μl Total volume 40 ul 40 ul 

Arrays and samples can vary somewhat, making it necessary to vary the composition of the hybridization cocktail. In cases where there is residual hybridization to control repeat DNA samples on the array, more C0t-1 DNA was used, as in the High Sample Blocking formulation. When there is diffuse background or a general haze on all of the array elements, more of the non-specific blocker components was used, as in the High Array Blocking formulation.

The components were mixed well by pipetting, heated at 98° C. for 2 minutes in a PCR cycler, cooled quickly to 25° C. and 0.6 ul of 10% SDS was added. It was then centrifuged for 5 min at 14,000×g. The fluor labeled cDNAs have a tendency to form small, very fluorescent, aggregates which result in bright, punctate background on the array slide. Hard centrifugation will pellet these aggregates, allowing you to avoid introducing them to the array.

The labeled cDNA was applied to a 24 mm×50 mm glass cover slip and then touched with the inverted microarray. Applying the hybridization mix to the array and cover slipping it is an operation which requires some dexterity to get the positioning of the cover slip and the exclusion of air bubbles just right. It was helpful to practice this operation with buffer and plain slides before attempting actual samples. The hybridization solution was added to the cover slip first, since some aggregates of fluor remain in the solution and will bind to the first surface they touch.

The slide was then placed in a microarray hybridization chamber, 5 μl of 3×SSC was added to the reservoir, if the chamber provided one, or at the scribed end of the slide and the chamber was sealed. The chamber was submerged in a 65° C. water bath and the slide was allowed to hybridize for 16-20 hours. There are a wide variety of commercial hybridization chambers. It was worthwhile to prepare a mock hybridization with a blank slide, load it in the chamber and incubate it to test for leaks, or drying of the hybridization fluid, either of which cause severe fluorescent noise on the array.

Next, the unbound fluorescent cDNA was washed off. The hybridization chamber was removed from the water bath, cooled and carefully dried off. The chamber was unsealed and the slide was removed. As there may be negative pressure in the chamber after cooling, it is necessary to remove water from around the seals so that it was not pulled into the chamber and onto the slide when the seals are loosened.

The slide was placed, with the cover slip still affixed, into a Coplin jar filled with 0.5×SSC/0.01% SDS wash buffer. The cover slip was allowed to fall from the slide and then removed from the jar with a forceps. The slide was allowed to wash for 2-5 minutes. The slide was transferred to a fresh Coplin jar filled with 0.06×SSC, and allowed to wash for 2-5 minutes. The sequence of washes may need to be adjusted to allow for more aggressive noise removal, depending on the source of the sample RNA. Useful variations are to add a first wash which is 0.5×SSC/0.1% SDS or to repeat the normal first wash twice.

The slide was then transferred to a slide rack and centrifuged at low rpm (700-1000) for 3 minutes in a clinical centrifuge equipped with a horizontal rotor for microtiter plates. If the slide is simply air dried, it frequently acquires a fluorescent haze. Centrifuging off the liquids results in a lower fluorescent background. As the rate of drying can be quite rapid, it is suggested that the slide be placed in the centrifuge immediately upon removal from the Coplin jar.

Image analysis was performed using DeArray software (Chen, Y., Dougherty, E. R. and Bittner, M. L. Ratio-based decisions and the quantitative analysis of cDNA microarray images, Biomedical Optics 2, 364-374 (1997).

Example 3 Data Analysis

To calibrate ANN models to recognize cancers in each of the four SRBCT categories, gene-expression data from cDNA microarrays as obtained via Examples 1 and 2 above were used. The 63 training samples included both tumor biopsy material (13 EWS and 10 RMS) and cell lines (10 EWS, 10 RMS, 12 NB and 8 Burkitt lymphomas (BL; a subset of BL). For two samples, ST486 (BL-C2 and C4) and GICAN (NB-C2 and C7), we performed two independent microarray experiments to test the reproducibility of the experiments and these were subsequently treated as separate samples.

Genes were filtered based on the intensity of the fluorescence gathered from the cDNA microarray. This type of filtering was designed to remove spots for which image analysis failed. Genes were filtered by requiring that a gene have a red intensity greater than 20 across all experiments. The number of genes that passed this filter was 2308. Each slide was normalized across all experiments. Therefore the expression level was based on a relative (or normalized) red intensity (RRI) for each gene, RRI=mean intensity of that spot/mean intensity of filtered genes. The natural logarithm (ln) of RRI was used as a measure of the expression levels.

Principal component analysis (PCA) further reduced the dimensionality. To allow for a supervised regression model with no over-training (when we have low number of parameters as compared to the number of samples), the dimensionality of the samples was reduced by PCA using centralized In (RRI) values as input. Thus each sample was represented by 88 numbers, which are the results of projection of the gene expressions using PCA eigenvectors. We used the 10 dominant PCA components for subsequent analysis. These 10 dominant components contained 63% of the variance in the data matrix. The remaining PCA components contained variance unrelated to separating the four cancers.

We classified the training samples in the 4 categories using a 3-fold cross validation procedure: the 63 training (labeled) samples were randomly shuffled and split into 3 equally sized groups. Each linear ANN model was then calibrated with the 10 PCA input variables (normalized to centralized z-scores) using 2 of the groups, with the third group reserved for testing predictions (validation). This procedure was repeated 3 times, each time with a different group used for validation. The random shuffling was redone 1250 times and for each shuffling we analyzed 3 ANN models. Thus, in total, each sample belonged to a validation set 1250 times, and 3750 ANN models were calibrated. The three-fold cross-validation procedure produced at total of 3750 ANN models, and the training and validation was successful, see FIG. 5.

In addition, there was no sign of ‘over-training’ of the models, as would be shown by a rise in the summed square error for the validation set with increasing training iterations or ‘epochs’, see FIG. 4.

For each diagnostic category (EWS, RMS, NB or BL), each ANN model gave an output between 0 (not this category) and 1 (this category). The 1250 outputs for each validation sample were used as a committee as follows. We calculated the average of all the predicted outputs (a committee vote) and then a sample was classified as a particular cancer if it received the highest committee vote for that cancer. In clinical settings, it is important to be able to reject a diagnostic classification including samples not belonging to any of the four diagnoses. Therefore, to be able to reject classification we did as follows. A squared Euclidean distance was computed for each cancer type, between the committee vote for a sample and the ‘ideal’ output for that cancer type; normalized such that it is unity between cancer types as described above. Using the 1250 ANN models for each validation sample we constructed for each cancer type an empirical probability distribution for the distances. Using these distributions, samples are only diagnosed as a specific cancer if they lie within the 95th percentile. All 3750 models were used to classify the additional 25 test samples.

Using these ANN models, all of the 63 training samples were correctly assigned/classified to their respective categories, having received the highest committee vote (average output) for that category.

Diagnostic results for the 63 training samples can be seen in Table 4 below.

TABLE 4 Training sample characteristics

Source label refers to the original name of the sample as labeled by the source. Histological diagnosis is defined as cancer type suffixed with -T for a tumor sample and -C for a cell line. Highlighted in gray is the ANN classification of the samples. NCI: National Cancer Institute, National Institutes of Health, ATCC: American Type Culture Collection, MSKCC: Memorial Sloan-Kettering Cancer Center, CHTN: Cooperative Human Tissue Network.

Example 4 Optimization of Genes Utilized for Classification

The contribution of each gene to the classification by the ANN models was determined by measuring the sensitivity of the classification to a change in the expression level of each gene, using the 3750 previously calibrated models.

The sensitivity to the different genes was determined by the absolute value of the partial derivative of the output with respect to the gene expressions, averaged over samples and ANN models. A large sensitivity implied that changing the expression influences the output significantly.

In this way the genes were ranked according to their significance for the classification. The top 200 ranked genes are seen below in Table 5. The weight of each gene is the sensitivity measurement as calculated by Equation (2), page 19 above

TABLE 5 Unique Unigene Rank Image_Id Name of Gene number Weight SEQ. ID. NO. 1 296448 “insulin-like growth factor 2 Hs.251664 1.00 +− 0.03 SEQ. ID. NO. 72 (somatomedin A)” 2 207274 “insulin-like growth factor 2 Hs.251664 0.97 +− 0.03 SEQ. ID. NO. 73 (somatomedin A)” 3 295985 “Homo sapiens cDNA FLJ20653 fis, Hs.180059 0.87 +− 0.02 SEQ. ID. NO. 26 clone KAT01739” 4 41591 “meningioma (disrupted in balanced Hs.268515 0.86 +− 0.02 SEQ. ID. NO. 60 translocation) 1” 5 365826 “growth arrest-specific 1” Hs.65029 0.86 +− 0.02 SEQ. ID. NO. 59 6 714453 “interleukin 4 receptor” Hs.75545 0.85 +− 0.02 SEQ. ID. NO. 83 7 812965 “v-myc avian myelocytomatosis viral Hs.79070 0.81 +− 0.02 SEQ. ID. NO. 82 oncogene homolog” 8 486787 “calponin 3, acidic” Hs.194662 0.81 +− 0.02 SEQ. ID. NO. 43 9 244618 “ESTs” Hs.15463 0.80 +− 0.02 SEQ. ID. NO. 77 10 417226 “v-myc avian myelocytomatosis viral Hs.79070 0.80 +− 0.02 SEQ. ID. NO. 81 oncogene homolog” 11 840942 “major histocompatibility complex, class Hs.814 0.79 +− 0.02 SEQ. ID. NO. 87 II, DP beta 1” 12 770394 “Fc fragment of IgG, receptor, transporter, Hs.160741 0.78 +− 0.02 SEQ. ID. NO. 20 alpha” 13 812105 “ALL1-fused gene from chromosome 1q” Hs.75823 0.76 +− 0.02 SEQ. ID. NO. 32 14 357031 “tumor necrosis factor, alpha-induced Hs.29352 0.75 +− 0.02 SEQ. ID. NO. 18 protein 6” 15 629896 “microtubule-associated protein 1B” Hs.103042 0.74 +− 0.02 SEQ. ID. NO. 37 16 308163 “ESTs” Hs.84520 0.73 +− 0.02 SEQ. ID. NO. 57 17 43733 “glycogenin 2” Hs.58589 0.72 +− 0.02 SEQ. ID. NO. 21 18 489631 “chondroitin sulfate proteoglycan 2 Hs.81800 0.71 +− 0.02 SEQ. ID. NO. 100 (versican)” 19 866702 “protein tyrosine phosphatase, non- Hs.211595 0.71 +− 0.02 SEQ. ID. NO. 16 receptor type 13 (APO-1/CD95 (Fas)- associated phosphatase)” 20 377461 “caveolin 1, caveolae protein, 22 kD” Hs.281621 0.70 +− 0.02 SEQ. ID. NO. 19 21 324494 “heat shock 27 kD protein 2” Hs.78846 0.69 +− 0.02 SEQ. ID. NO. 62 22 80109 “major histocompatibility complex, class Hs.198253 0.69 +− 0.02 SEQ. ID. NO. 88 II, DQ alpha 1” 23 39093 “methionine aminopeptidase; eIF-2- Hs.78935 0.69 +− 0.01 SEQ. ID. NO. 63 associated p67” 24 82225 “secreted frizzled-related protein 1” Hs.7306 0.67 +− 0.01 SEQ. ID. NO. 42 25 308231 “Homo sapiens cDNA FLJ20153 fis, Hs.109805 0.67 +− 0.02 SEQ. ID. NO. 39 clone COL08656, highly similar to AJ001381 Homo sapiens incomplete cDNA for a mutated allele” 26 211758 “ribosomal protein S23” Hs.3463 0.67 +− 0.01 SEQ. ID. NO. 101 27 1E+06 “troponin T1, skeletal, slow” Hs.73980 0.66 +− 0.02 SEQ. ID. NO. 70 28 878280 “collapsin response mediator protein 1” Hs.155392 0.65 +− 0.02 SEQ. ID. NO. 33 29 383188 “recoverin” Hs.80539 0.64 +− 0.01 SEQ. ID. NO. 38 30 795877 “serum-inducible kinase” Hs.3838 0.64 +− 0.01 SEQ. ID. NO. 102 31 784593 “ESTs” Hs.6838 0.63 +− 0.01 SEQ. ID. NO. 41 32 135688 “GATA-binding protein 2” Hs.760 0.62 +− 0.01 SEQ. ID. NO. 44 33 325182 “cadherin 2, N-cadherin (neuronal)” Hs.161 0.62 +− 0.01 SEQ. ID. NO. 31 34 461425 “myosin, light polypeptide 4, alkali; atrial, Hs.154156 0.61 +− 0.01 SEQ. ID. NO. 75 embryonic” 35 1E+06 “transducin-like enhancer of split 2, Hs.173063 0.61 +− 0.02 SEQ. ID. NO. 15 homolog of Drosophila E(sp1)” 36 298062 “troponin T2, cardiac” Hs.89749 0.61 +− 0.02 SEQ. ID. NO. 74 37 841641 “cyclin D1 (PRAD1: parathyroid Hs.82932 0.61 +− 0.01 SEQ. ID. NO. 5 adenomatosis 1)” 38 745343 “regenerating islet-derived 1 alpha Hs.1032 0.60 +− 0.01 SEQ. ID. NO. 85 (pancreatic stone protein, pancreatic thread protein)” 39 755599 “interferon induced transmembrane Hs.146360 0.59 +− 0.02 SEQ. ID. NO. 25 protein 1 (9-27)” 40 809901 “collagen, type XV, alpha 1” Hs.83164 0.59 +− 0.01 SEQ. ID. NO. 67 41 859359 “quinone oxidoreductase homolog” Hs.50649 0.59 +− 0.01 SEQ. ID. NO. 50 42 784224 “fibroblast growth factor receptor 4” Hs.165950 0.59 +− 0.02 SEQ. ID. NO. 71 43 42558 “glycine amidinotransferase (L- Hs.75335 0.58 +− 0.01 SEQ. ID. NO. 79 arginine:glycine amidinotransferase)” 44 183337 “major histocompatibility complex, class Hs.77522 0.58 +− 0.01 SEQ. ID. NO. 89 II, DM alpha” 45 289645 “amyloid beta (A4) precursor-like protein Hs.74565 0.58 +− 0.01 SEQ. ID. NO. 4 1” 46 377048 “Homo sapiens cDNA FLJ20153 fis, Hs.109805 0.57 +− 0.01 SEQ. ID. NO. 40 clone COL08656, highly similar to AJ001381 Homo sapiens incomplete cDNA for a mutated allele” 47 122159 “collagen, type III, alpha 1 (Ehlers-Danlos Hs.119571 0.57 +− 0.01 SEQ. ID. NO. 66 syndrome type IV, autosomal dominant)” 48 245330 “insulin-like growth factor 2 Hs.251664 0.57 +− 0.01 SEQ. ID. NO. 78 (somatomedin A)” 49 814260 “follicular lymphoma variant translocation Hs.74050 0.57 +− 0.01 SEQ. ID. NO. 17 1” 50 824602 “interferon, gamma-inducible protein 16” Hs.155530 0.57 +− 0.01 SEQ. ID. NO. 84 51 44563 “growth associated protein 43” Hs.79000 0.56 +− 0.01 SEQ. ID. NO. 35 52 767495 “GLI-Kruppel family member GLI3 Hs.72916 0.56 +− 0.01 SEQ. ID. NO. 103 (Greig cephalopolysyndactyly syndrome)” 53 769716 “neurofibromin 2 (bilateral acoustic Hs.902 0.55 +− 0.01 SEQ. ID. NO. 104 neuroma)” 54 486110 “profilin 2” Hs.91747 0.55 +− 0.01 SEQ. ID. NO. 45 55 1E+06 “pim-2 oncogene” Hs.80205 0.55 +− 0.01 SEQ. ID. NO. 92 56 756556 “complement component 1 inhibitor Hs.151242 0.54 +− 0.01 SEQ. ID. NO. 65 (angioedema, hereditary)” 57 377731 “glutathione S-transferase M5” Hs.75652 0.54 +− 0.01 SEQ. ID. NO. 23 58 52076 “olfactomedin related ER localized Hs.74376 0.54 +− 0.02 SEQ. ID. NO. 13 protein” 59 810057 “cold shock domain protein A” Hs.1139 0.54 +− 0.01 SEQ. ID. NO. 105 60 233721 “insulin-like growth factor binding protein Hs.162 0.54 +− 0.01 SEQ. ID. NO. 28 2 (36 kD)” 61 293500 “ESTs” Hs.49714 0.54 +− 0.01 SEQ. ID. NO. 80 62 75254 “cysteine and glycine-rich protein 2 (LIM Hs.10526 0.54 +− 0.01 SEQ. ID. NO. 106 domain only, smooth muscle)” 63 377468 “sprouty (Drosophila) homolog 1 Hs.88044 0.53 +− 0.01 SEQ. ID. NO. 107 (antagonist of FGF signaling)” 64 809910 “interferon induced transmembrane Hs.182241 0.53 +− 0.01 SEQ. ID. NO. 55 protein 3 (1-8U)” 65 395708 “dihydropyrimidinase-like 4” Hs.100058 0.53 +− 0.01 SEQ. ID. NO. 30 66 416959 “nuclear factor I/B” Hs.33287 0.53 +− 0.01 SEQ. ID. NO. 29 67 1E+06 “antigen identified by monoclonal Hs.177543 0.52 +− 0.01 SEQ. ID. NO. 22 antibodies 12E7, F21 and O13” 68 609663 “protein kinase, cAMP-dependent, Hs.77439 0.51 +− 0.01 SEQ. ID. NO. 95 regulatory, type II, beta” 69 212640 “Rho GTPase activating protein 4” Hs.3109 0.51 +− 0.01 SEQ. ID. NO. 108 70 130057 “ESTs” Hs.23057 0.51 +− 0.01 SEQ. ID. NO. 109 71 563673 “antiquitin 1” Hs.74294 0.51 +− 0.01 SEQ. ID. NO. 10 72 770059 “heparan sulfate proteoglycan 2 Hs.211573 0.51 +− 0.01 SEQ. ID. NO. 110 (perlecan)” 73 782503 “Homo sapiens clone 23716 mRNA Hs.12214 0.50 +− 0.01 SEQ. ID. NO. 7 sequence” 74 292522 “ESTs” Hs.38022 0.50 +− 0.01 SEQ. ID. NO. 36 75 365515 “fibroblast growth factor 7 (keratinocyte Hs.164568 0.50 +− 0.01 SEQ. ID. NO. 111 growth factor)” 76 1E+06 “cysteine-rich protein 1 (intestinal)” Hs.17409 0.50 +− 0.01 SEQ. ID. NO. 112 77 767183 “hematopoietic cell-specific Lyn substrate Hs.14601 0.50 +− 0.01 SEQ. ID. NO. 91 1” 78 811000 “lectin, galactoside-binding, soluble, 3 Hs.79339 0.50 +− 0.01 SEQ. ID. NO. 6 binding protein (galectin 6 binding protein)” 79 308497 “KIAA0467 protein” Hs.11147 0.49 +− 0.01 SEQ. ID. NO. 24 80 80338 “selenium binding protein 1” Hs.7833 0.49 +− 0.01 SEQ. ID. NO. 14 81 200814 “membrane metallo-endopeptidase Hs.1298 0.49 +− 0.01 SEQ. ID. NO. 94 (neutral endopeptidase, enkephalinase, CALLA, CD10)” 82 898219 “mesoderm specific transcript (mouse) Hs.79284 0.49 +− 0.01 SEQ. ID. NO. 113 homolog” 83 796258 “sarcoglycan, alpha (50 kD dystrophin- Hs.99931 0.49 +− 0.01 SEQ. ID. NO. 76 associated glycoprotein)” 84 377671 “integrin, alpha 7” Hs.74369 0.48 +− 0.01 SEQ. ID. NO. 68 85 839736 “crystallin, alpha B” Hs.1940 0.48 +− 0.01 SEQ. ID. NO. 61 86 208718 “annexin A1” Hs.78225 0.48 +− 0.01 SEQ. ID. NO. 2 87 32299 “inositol(myo)-1(or 4)-monophosphatase Hs.5753 0.48 +− 0.01 SEQ. ID. NO. 114 2” 88 246377 “EST” Hs.102670 0.48 +− 0.01 SEQ. ID. NO. 51 89 413633 “EST” — 0.48 +− 0.01 SEQ. ID. NO. 115 90 140806 “peptidylglycine alpha-amidating Hs.83920 0.47 +− 0.01 SEQ. ID. NO. 116 monooxygenase” 91 294496 “ESTs” Hs.23037 0.47 +− 0.01 SEQ. ID. NO. 117 92 755750 “non-metastatic cells 2, protein (NM23B) Hs.275163 0.47 +− 0.01 SEQ. ID. NO. 49 expressed in” 93 811108 “thyroid hormone receptor interactor 6” Hs.119498 0.47 +− 0.01 SEQ. ID. NO. 118 94 246035 “ESTs” Hs.78026 0.47 +− 0.01 SEQ. ID. NO. 119 95 796904 “pleomorphic adenoma gene-like 1” Hs.75825 0.47 +− 0.01 SEQ. ID. NO. 120 96 788107 “bridging integrator 1” Hs.193163 0.47 +− 0.01 SEQ. ID. NO. 52 97 714106 “plasminogen activator, urokinase” Hs.77274 0.47 +− 0.01 SEQ. ID. NO. 121 98 842918 “FERM, RhoGEF (ARHGEF) and Hs.183738 0.47 +− 0.01 SEQ. ID. NO. 122 pleckstrin domain protein 1 (chondrocyte- derived)” 99 788472 “nucleobindin 1” Hs.172609 0.47 +− 0.01 SEQ. ID. NO. 123 100 52096 “platelet-derived growth factor receptor, Hs.74615 0.46 +− 0.01 SEQ. ID. NO. 124 alpha polypeptide” 101 823886 “Smooth muscle myosin heavy chain Hs.2094 0.46 +− 0.01 SEQ. ID. NO. 125 isoform SMemb [human, umbilical cord, fetal aorta, mRNA Partial, 971 nt]” 102 782193 “thioredoxin” Hs.76136 0.46 +− 0.01 SEQ. ID. NO. 126 103 214990 “gelsolin (amyloidosis, Finnish type)” Hs.80562 0.46 +− 0.01 SEQ. ID. NO. 127 104 144932 “deleted in oral cancer (mouse, homolog) Hs.3436 0.46 +− 0.01 SEQ. ID. NO. 128 1” 105 782811 “high-mobility group (nonhistone Hs.139800 0.46 +− 0.01 SEQ. ID. NO. 129 chromosomal) protein isoforms I and Y” 106 813698 “sprouty (Drosophila) homolog 2” Hs.18676 0.45 +− 0.01 SEQ. ID. NO. 130 107 212542 “Homo sapiens mRNA; cDNA Hs.21851 0.45 +− 0.01 SEQ. ID. NO. 53 DKFZp586J2118 (from clone DKFZp586J2118)” 108 204545 “ESTs” Hs.8966 0.45 +− 0.01 SEQ. ID. NO. 58 109 341588 “CGI-119 protein” Hs.25615 0.45 +− 0.01 SEQ. ID. NO. 131 110 297392 “metallothionein 1L” Hs.94360 0.45 +− 0.01 SEQ. ID. NO. 93 111 813841 “plasminogen activator, tissue” Hs.274404 0.45 +− 0.01 SEQ. ID. NO. 132 112 491692 “collagen, type IV, alpha 1” Hs.119129 0.44 +− 0.01 SEQ. ID. NO. 133 113 142134 “hypothetical protein FLJ20185” Hs.272972 0.44 +− 0.01 SEQ. ID. NO. 134 114 214572 “ESTs” Hs.280460 0.44 +− 0.01 SEQ. ID. NO. 135 115 878182 “alpha-2-macroglobulin” Hs.74561 0.44 +− 0.01 SEQ. ID. NO. 136 116 360047 “SWI/SNF related, matrix associated, Hs.77069 0.44 +− 0.01 SEQ. ID. NO. 137 actin dependent regulator of chromatin, subfamily d, member 3” 117 878652 “procollagen C-endopeptidase enhancer” Hs.202097 0.44 +− 0.01 SEQ. ID. NO. 138 118 450152 “Meis (mouse) homolog 3” Hs.117313 0.44 +− 0.01 SEQ. ID. NO. 139 119 45542 “Human insulin-like growth factor binding Hs.103391 0.44 +− 0.01 SEQ. ID. NO. 64 protein 5 (IGFBP5) mRNA” 120 742132 “interferon-stimulated protein, 15 kDa” Hs.833 0.44 +− 0.01 SEQ. ID. NO. 140 121 82903 “TAP binding protein (tapasin)” Hs.179600 0.44 +− 0.01 SEQ. ID. NO. 141 122 773215 “runt-related transcription factor 1 (acute Hs.129914 0.44 +− 0.01 SEQ. ID. NO. 142 myeloid leukemia 1; aml1 oncogene)” 123 789253 “presenilin 2 (Alzheimer disease 4)” Hs.25363 0.44 +− 0.01 SEQ. ID. NO. 143 124 814526 “seb4D” Hs.236361 0.44 +− 0.01 SEQ. ID. NO. 96 125 435953 “inositol 1,4,5-triphosphate receptor, type Hs.77515 0.44 +− 0.01 SEQ. ID. NO. 144 3” 126 245860 “Homo sapiens mRNA; cDNA Hs.181104 0.44 +− 0.01 SEQ. ID. NO. 145 DKFZp564H1916 (from clone DKFZp564H1916)” 127 159455 “similar to vaccinia virus HindIII K4L Hs.74573 0.44 +− 0.01 SEQ. ID. NO. 146 ORF” 128 220096 “—” — 0.44 +− 0.01 SEQ. ID. NO. 147 129 45291 “dentatorubral-pallidoluysian atrophy Hs.169488 0.43 +− 0.01 SEQ. ID. NO. 54 (atrophin-1)” 130 241412 “E74-like factor 1 (ets domain Hs.154365 0.43 +− 0.01 SEQ. ID. NO. 90 transcription factor)” 131 1E+06 “matrix metalloproteinase 2 (gelatinase A, Hs.111301 0.43 +− 0.01 SEQ. ID. NO. 148 72 kD gelatinase, 72 kD type IV collagenase)” 132 250654 “secreted protein, acidic, cysteine-rich Hs.111779 0.43 +− 0.01 SEQ. ID. NO. 149 (osteonectin)” 133 343867 “allograft inflammatory factor 1” Hs.76364 0.43 +− 0.01 SEQ. ID. NO. 150 134 234237 “Pirin” Hs.279663 0.42 +− 0.01 SEQ. ID. NO. 151 135 713922 “glutathione S-transferase M1” Hs.278633 0.42 +− 0.01 SEQ. ID. NO. 152 136 823928 “glutathione S-transferase theta 2” Hs.1581 0.42 +− 0.01 SEQ. ID. NO. 153 137 810504 “proteolipid protein 2 (colonic epithelium- Hs.77422 0.42 +− 0.01 SEQ. ID. NO. 154 enriched)” 138 788511 “ribosomal protein S6 kinase, 90 kD, Hs.149957 0.41 +− 0.01 SEQ. ID. NO. 155 polypeptide 1” 139 471266 “DiGeorge syndrome critical region gene Hs.153910 0.41 +− 0.01 SEQ. ID. NO. 156 6” 140 299737 “Homo sapiens clone 24411 mRNA Hs.20952 0.41 +− 0.01 SEQ. ID. NO. 157 sequence” 141 740554 “Homo sapiens mRNA; cDNA Hs.263671 0.41 +− 0.01 SEQ. ID. NO. 158 DKFZp434I0812 (from clone DKFZp434I0812); partial cds” 142 754600 “nuclear factor I/X (CCAAT-binding Hs.35841 0.41 +− 0.01 SEQ. ID. NO. 159 transcription factor)” 143 151261 “ESTs” Hs.237971 0.41 +− 0.01 SEQ. ID. NO. 160 144 815239 “Rho guanine nucleotide exchange factor Hs.252280 0.41 +− 0.01 SEQ. ID. NO. 161 (GEF) 1” 145 624360 “proteasome (prosome, macropain) Hs.180062 0.41 +− 0.01 SEQ. ID. NO. 162 subunit, beta type, 8 (large multifunctional protease 7)” 146 213136 “BTG family, member 2” Hs.75462 0.41 +− 0.01 SEQ. ID. NO. 163 147 21652 “catenin (cadherin-associated protein), Hs.178452 0.41 +− 0.01 SEQ. ID. NO. 56 alpha 1 (102 kD)” 148 813266 “four and a half LIM domains 1” Hs.239069 0.41 +− 0.01 SEQ. ID. NO. 47 149 236282 “Wiskott-Aldrich syndrome (ecezema- Hs.2157 0.41 +− 0.01 SEQ. ID. NO. 164 thrombocytopenia)” 150 755228 “dynamin 1” Hs.166161 0.41 +− 0.01 SEQ. ID. NO. 165 151 161993 “CCAAT/enhancer binding protein Hs.99029 0.41 +− 0.01 SEQ. ID. NO. 166 (C/EBP), beta” 152 358433 “retinoid X receptor, gamma” Hs.26550 0.41 +− 0.01 SEQ. ID. NO. 167 153 841620 “dihydropyrimidinase-like 2” Hs.173381 0.41 +− 0.01 SEQ. ID. NO. 8 154 293859 “Putative prostate cancer tumor Hs.71119 0.41 +− 0.01 SEQ. ID. NO. 168 suppressor” 155 190887 “myeloid differentiation primary response Hs.82116 0.41 +− 0.01 SEQ. ID. NO. 169 gene (88)” 156 362483 “spectrin, beta, non-erythrocytic 1” Hs.107164 0.41 +− 0.01 SEQ. ID. NO. 170 157 139376 “hypothetical protein” Hs.91973 0.40 +− 0.01 SEQ. ID. NO. 171 158 786084 “chromobox homolog 1 (Drosophila HP1 Hs.77254 0.40 +− 0.01 SEQ. ID. NO. 172 beta)” 159 193182 “transforming, acidic coiled-coil Hs.173159 0.40 +− 0.01 SEQ. ID. NO. 173 containing protein 1” 160 768246 “glucose-6-phosphate dehydrogenase” Hs.80206 0.40 +− 0.01 SEQ. ID. NO. 174 161 774502 “protein tyrosine phosphatase, non- Hs.62 0.40 +− 0.01 SEQ. ID. NO. 175 receptor type 12” 162 868304 “actin, alpha 2, smooth muscle, aorta” Hs.195851 0.40 +− 0.01 SEQ. ID. NO. 86 163 379708 “chromodomain helicase DNA binding Hs.25601 0.40 +− 0.01 SEQ. ID. NO. 176 protein 3” 164 504791 “glutathione S-transferase A4” Hs.169907 0.40 +− 0.01 SEQ. ID. NO. 11 165 755506 “annexin A4” Hs.77840 0.40 +− 0.01 SEQ. ID. NO. 177 166 1E+06 “homeo box B7” Hs.819 0.40 +− 0.01 SEQ. ID. NO. 178 167 824704 “mannose phosphate isomerase” Hs.75694 0.40 +− 0.01 SEQ. ID. NO. 179 168 770014 “T cell receptor alpha locus” Hs.74647 0.40 +− 0.01 SEQ. ID. NO. 180 169 22040 “matrix metalloproteinase 9 (gelatinase B, Hs.151738 0.40 +− 0.01 SEQ. ID. NO. 181 92 kD gelatinase, 92 kD type IV collagenase)” 170 66714 “peanut (Drosophila)-like 2” Hs.155524 0.40 +− 0.01 SEQ. ID. NO. 182 171 172783 “hypothetical protein FLJ10390” Hs.133475 0.40 +− 0.01 SEQ. ID. NO. 183 172 273435 “v-yes-1 Yamaguchi sarcoma viral Hs.194148 0.40 +− 0.01 SEQ. ID. NO. 184 oncogene homolog 1” 173 323371 “amyloid beta (A4) precursor protein Hs.177486 0.39 +− 0.01 SEQ. ID. NO. 27 (protease nexin-II, Alzheimer disease)” 174 344134 “immunoglobulin lambda-like polypeptide Hs.170116 0.39 +− 0.01 SEQ. ID. NO. 185 3” 175 291756 “tubulin, beta, 5” Hs.108014 0.39 +− 0.01 SEQ. ID. NO. 1 176 47475 “p53 inducible protein” Hs.258503 0.39 +− 0.01 SEQ. ID. NO. 186 177 760299 “Dickkopf gene 3” Hs.4909 0.39 +− 0.01 SEQ. ID. NO. 187 178 24415 “tumor protein p53 (Li-Fraumeni Hs.1846 0.39 +− 0.01 SEQ. ID. NO. 188 syndrome)” 179 727251 “CD9 antigen (p24)” Hs.1244 0.39 +− 0.01 SEQ. ID. NO. 189 180 770868 “NGFI-A binding protein 2 (ERG1 Hs.159223 0.39 +− 0.01 SEQ. ID. NO. 190 binding protein 2)” 181 364934 “death-associated protein kinase 1” Hs.153924 0.39 +− 0.01 SEQ. ID. NO. 12 182 1E+06 “creatine kinase, brain” Hs.173724 0.39 +− 0.01 SEQ. ID. NO. 191 183 769959 “collagen, type IV, alpha 2” Hs.75617 0.39 +− 0.01 SEQ. ID. NO. 69 184 144797 “a disintegrin-like and metalloprotease Hs.8230 0.39 +− 0.01 SEQ. ID. NO. 192 (reprolysin type) with thrombospondin type 1 motif, 1” 185 108351 “Homo sapiens cDNA FLJ11302 fis, Hs.13781 0.38 +− 0.01 SEQ. ID. NO. 193 clone PLACE1009971” 186 51448 “activating transcription factor 3” Hs.460 0.38 +− 0.01 SEQ. ID. NO. 194 187 301122 “extracellular matrix protein 1” Hs.81071 0.38 +− 0.01 SEQ. ID. NO. 195 188 814798 “aldehyde dehydrogenase 6” Hs.75746 0.38 +− 0.01 SEQ. ID. NO. 196 189 788695 “troponin T3, skeletal, fast” Hs.73454 0.38 +− 0.01 SEQ. ID. NO. 197 190 769028 “mesenchyme homeo box 1” Hs.438 0.38 +− 0.01 SEQ. ID. NO. 198 191 811028 “cathepsin D (lysosomal aspartyl Hs.79572 0.38 +− 0.01 SEQ. ID. NO. 199 protease)” 192 196992 “aldo-keto reductase family 1, member C1 Hs.275374 0.38 +− 0.01 SEQ. ID. NO. 200 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)” 193 586854 “CGI-119 protein” Hs.25615 0.38 +− 0.01 SEQ. ID. NO. 201 194 1E+06 “ATPase, Na+/K+ transporting, alpha 1 Hs.190703 0.38 +− 0.01 SEQ. ID. NO. 202 polypeptide” 195 752652 “transcription factor 7-like 2 (T-cell Hs.154485 0.38 +− 0.01 SEQ. ID. NO. 203 specific, HMG-box)” 196 813168 “ESTs” Hs.59896 0.38 +− 0.01 SEQ. ID. NO. 204 197 143306 “lymphocyte-specific protein 1” Hs.56729 0.38 +− 0.01 SEQ. ID. NO. 205 198 810551 “low density lipoprotein-related protein 1 Hs.89137 0.37 +− 0.01 SEQ. ID. NO. 206 (alpha-2-macroglobulin receptor)” 199 882506 “lysyl oxidase-like 2” Hs.83354 0.37 +− 0.01 SEQ. ID. NO. 207 200 141768 “v-erb-b2 avian erythroblastic leukemia Hs.173664 0.37 +− 0.01 SEQ. ID. NO. 208 viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog)”

The ANN analysis utilized in this example has lead to the identification of genes specific for each of the four cancers (EWS, RMS, NB and BL), with implications for biology and therapy, a strength of this method is its lack of requirement for genes to be exclusively associated with a single cancer type. The top 96 discriminating genes included not only those that had high (61) or low levels (12 BLs and 1 EWS) of expression in one particular cancer, but also genes that were differentially expressed in two diagnostic categories as compared to the remaining two. The genes that are not exclusively expressed in two cancer types can be used for diagnosis (to separate these two from the other cancers) and are potential targets for these both these cancers.

As expected, our method identified genes related to tumor histogenesis, but includes genes that may not normally be expressed in the corresponding mature tissue. Of the 16 genes highly expressed only in EWS, two (MIC2 (SEQ. ID. NO. 22) and GYG2 (SEQ. ID. NO. 21)) have been previously described. Of the 14 genes that have not previously been reported to be highly expressed in EWS, four (TUBB5 (SEQ. ID. NO. 1), ANXA1 (SEQ. ID. NO. 2), NOE1 (SEQ. ID. NO. 13) and GSTM5 (SEQ. ID. NO. 23)) were neural specific genes lending more credence to the proposed neural histogenesis of EWS. Twenty genes were highly expressed only in RMS, including 8 specific for muscle tissue and 5 (FGFR4 (SEQ. ID. NO. 71), IGF2 (SEQ. ID. NO. 72), MYL4 (SEQ. ID. NO. 75), ITGA7 (SEQ. ID. NO. 68), and IGFBP5 (SEQ. ID. NO. 64)) related to myogenesis. Among the latter, IGF2 (SEQ. ID. NO. 72), MYL4 (SEQ. ID. NO. 75) and IGFBP5 (SEQ. ID. NO. 64) expression has been reported in RMS, and only ITGA7 (SEQ. ID. NO. 68) and IGFBP5 (SEQ. ID. NO. 64) were found to be expressed in our two normal muscle samples, making the other genes good targets for therapy. Of the genes specifically expressed in a cancer type, 41 have not been previously reported, including 7 ESTs with no current known function (starred * in FIG. 8). All of these warrant further study and may provide new insights into the biology and importantly new targets for the treatment of these cancers. All or a combination of these genes can be used for designing drugs (small molecule screening), or be used in designing vaccines for cancer therapy.

An ANN method of the invention can also be used to rank genes that are important for each of the four SRBCTs: neuroblastoma (NB), rhabdomyosarcoma (RMS), Burkitt's (BL) and the Ewing family of tumors (EWS). Tables 6 through 9 show weighted gene lists (i.e. the most important genes in order of importance) for NB, RMS, BL, and EWS respectively. The genes in each of these tables are more highly ranked and are highly expressed in each of the individual cancers.

TABLE 6 Ranked genes for Neuroblastoma (NB) Rank Clone Id GeneDescription Unigene Weight SEQ. ID. NO. 2 812105 “ALL1-fused gene from chromosome 1q” Hs.75823 0.96 +− 0.03 SEQ. ID. NO. 32 6 325182 “cadherin 2, N-cadherin (neuronal)” Hs.161 0.84 +− 0.03 SEQ. ID. NO. 31 8 629896 “microtubule-associated protein 1B” Hs.103042 0.82 +− 0.03 SEQ. ID. NO. 37 10 878280 “collapsin response mediator protein 1” Hs.155392 0.80 +− 0.03 SEQ. ID. NO. 33 11 308231 “Homo sapiens cDNA FLJ20153 fis, clone Hs.109805 0.78 +− 0.03 SEQ. ID. NO. 39 COL08656, highly similar to AJ001381 Homo sapiens incomplete cDNA for a mutated allele” 13 295985 “Homo sapiens cDNA FLJ20653 fis, clone Hs.180059 0.75 +− 0.03 SEQ. ID. NO. 26 KAT01739” 14 44563 “growth associated protein 43” Hs.79000 0.75 +− 0.02 SEQ. ID. NO. 35 19 135688 “GATA-binding protein 2” Hs.760 0.68 +− 0.02 SEQ. ID. NO. 44 21 383188 “recoverin” Hs.80539 0.64 +− 0.02 SEQ. ID. NO. 38 23 395708 “dihydropyrimidinase-like 4” Hs.100058 0.63 +− 0.02 SEQ. ID. NO. 30 25 82225 “secreted frizzled-related protein 1” Hs.7306 0.62 +− 0.02 SEQ. ID. NO. 42 26 486787 “calponin 3, acidic” Hs.194662 0.62 +− 0.02 SEQ. ID. NO. 43 28 377048 “Homo sapiens cDNA FLJ20153 fis, clone Hs.109805 0.62 +− 0.02 SEQ. ID. NO. 40 COL08656, highly similar to AJ001381 Homo sapiens incomplete cDNA for a mutated allele” 30 486110 “profilin 2” Hs.91747 0.59 +− 0.02 SEQ. ID. NO. 45 32 768246 “glucose-6-phosphate dehydrogenase” Hs.80206 0.58 +− 0.02 SEQ. ID. NO. 174 34 786084 “chromobox homolog 1 (Drosophila HP1 Hs.77254 0.57 +− 0.02 SEQ. ID. NO. 172 beta)” 36 211758 “ribosomal protein S23” Hs.3463 0.57 +− 0.02 SEQ. ID. NO. 101 40 755228 “dynamin 1” Hs.166161 0.55 +− 0.02 SEQ. ID. NO. 165 42 220096 “—” — 0.55 +− 0.02 SEQ. ID. NO. 147 43 823886 “Smooth muscle myosin heavy chain Hs.2094 0.55 +− 0.02 SEQ. ID. NO. 125 isoform SMemb [human, umbilical cord, fetal aorta, mRNA Partial, 971 nt]” 44 788472 “nucleobindin 1” Hs.172609 0.54 +− 0.02 SEQ. ID. NO. 123 45 878652 “procollagen C-endopeptidase enhancer” Hs.202097 0.54 +− 0.02 SEQ. ID. NO. 138 46 234237 “Pirin” Hs.279663 0.54 +− 0.02 SEQ. ID. NO. 151 50 450152 “Meis (mouse) homolog 3” Hs.117313 0.51 +− 0.02 SEQ. ID. NO. 139 51 743229 “neurofilament 3 (150 kD medium)” Hs.71346 0.51 +− 0.02 SEQ. ID. NO. 209 56 134748 “glycine cleavage system protein H Hs.77631 0.49 +− 0.02 SEQ. ID. NO. 210 (aminomethyl carrier)” 60 486175 “solute carrier family 16 (monocarboxylic Hs.75231 0.48 +− 0.02 SEQ. ID. NO. 211 acid transporters), member 1” 61 376516 “cell division cycle 4-like” Hs.62354 0.48 +− 0.02 SEQ. ID. NO. 212 63 292522 “ESTs” Hs.38022 0.48 +− 0.02 SEQ. ID. NO. 36 66 843098 “brain acid-soluble protein 1” Hs.79516 0.48 +− 0.02 SEQ. ID. NO. 213 68 448386 “pre-B-cell leukemia transcription factor 3” Hs.171680 0.47 +− 0.02 SEQ. ID. NO. 214 70 756401 “Ras homolog enriched in brain 2” Hs.279903 0.47 +− 0.02 SEQ. ID. NO. 215 74 842918 “FERM, RhoGEF (ARHGEF) and Hs.183738 0.46 +− 0.02 SEQ. ID. NO. 122 pleckstrin domain protein 1 (chondrocyte- derived)” 76 784593 “ESTs” Hs.6838 0.46 +− 0.02 SEQ. ID. NO. 41 84 364510 “special AT-rich sequence binding protein Hs.74592 0.44 +− 0.01 SEQ. ID. NO. 216 1 (binds to nuclear matrix/scaffold- associating DNA's)” 88 810864 “CGI-48 protein” Hs.6153 0.43 +− 0.01 SEQ. ID. NO. 217 90 66977 “androgen induced protein” Hs.107528 0.43 +− 0.01 SEQ. ID. NO. 218 92 151261 “ESTs” Hs.237971 0.43 +− 0.01 SEQ. ID. NO. 160 95 289645 “amyloid beta (A4) precursor-like protein Hs.74565 0.43 +− 0.01 SEQ. ID. NO. 4 1” 96 416959 “nuclear factor I/B” Hs.33287 0.43 +− 0.01 SEQ. ID. NO. 29 98 47110 “heterogeneous nuclear ribonucleoprotein Hs.79625 0.43 +− 0.01 SEQ. ID. NO. 219 D” 101 244637 “chromosome 15 open reading frame 3” Hs.75847 0.42 +− 0.01 SEQ. ID. NO. 220 102 949934 “heterogeneous nuclear ribonucleoprotein Hs.77492 0.42 +− 0.01 SEQ. ID. NO. 221 A0” 103 544664 “matrin 3” Hs.78825 0.42 +− 0.01 SEQ. ID. NO. 222 108 782811 “high-mobility group (nonhistone Hs.139800 0.42 +− 0.01 SEQ. ID. NO. 129 chromosomal) protein isoforms I and Y” 109 812967 “tetraspan 5” Hs.20709 0.41 +− 0.01 SEQ. ID. NO. 223 114 75254 “cysteine and glycine-rich protein 2 (LIM Hs.10526 0.41 +− 0.01 SEQ. ID. NO. 106 domain only, smooth muscle)” 115 235102 “ESTs, Moderately similar to LAK-1 Hs.39488 0.41 +− 0.01 SEQ. ID. NO. 224 [H. sapiens]” 118 81518 “apelin; peptide ligand for APJ receptor” Hs.181060 0.41 +− 0.01 SEQ. ID. NO. 225 119 344243 “uridine monophosphate kinase” Hs.75939 0.41 +− 0.01 SEQ. ID. NO. 226 120 789376 “thioredoxin reductase 1” Hs.13046 0.41 +− 0.01 SEQ. ID. NO. 227 122 811956 “RAN, member RAS oncogene family” Hs.10842 0.40 +− 0.01 SEQ. ID. NO. 228 124 811095 “Homo sapiens mRNA for KIAA1291 Hs.9805 0.40 +− 0.01 SEQ. ID. NO. 229 protein, partial cds” 125 823598 “proteasome (prosome, macropain) 26S Hs.4295 0.40 +− 0.01 SEQ. ID. NO. 230 subunit, non-ATPase, 12” 130 896949 “3-hydroxy-3-methylglutaryl-Coenzyme A Hs.11899 0.40 +− 0.01 SEQ. ID. NO. 231 reductase” 132 140806 “peptidylglycine alpha-amidating Hs.83920 0.40 +− 0.01 SEQ. ID. NO. 116 monooxygenase” 133 760299 “Dickkopf gene 3” Hs.4909 0.40 +− 0.01 SEQ. ID. NO. 187 135 22260 “cytochrome c-1” Hs.697 0.40 +− 0.01 SEQ. ID. NO. 232 137 294496 “ESTs” Hs.23037 0.39 +− 0.01 SEQ. ID. NO. 117 138 813266 “four and a half LIM domains 1” Hs.239069 0.39 +− 0.01 SEQ. ID. NO. 47 139 234150 “myotubularin related protein 4” Hs.141727 0.39 +− 0.01 SEQ. ID. NO. 233 140 246194 “ESTs” Hs.125522 0.39 +− 0.01 SEQ. ID. NO. 234 142 207358 “solute carrier family 2 (facilitated glucose Hs.169902 0.39 +− 0.01 SEQ. ID. NO. 235 transporter), member 1” 148 1456118 “proteasome (prosome, macropain) Hs.9280 0.38 +− 0.01 SEQ. ID. NO. 236 subunit, beta type, 9 (large multifunctional protease 2)” 149 753215 “guanine nucleotide binding protein (G Hs.203862 0.38 +− 0.01 SEQ. ID. NO. 237 protein), alpha inhibiting activity polypeptide 1” 151 51041 “ESTs” Hs.280770 0.38 +− 0.01 SEQ. ID. NO. 238 153 813499 “Sjogren's syndrome/scleroderma Hs.25723 0.37 +− 0.01 SEQ. ID. NO. 239 autoantigen 1” 154 1142132 “RaP2 interacting protein 8” Hs.6755 0.37 +− 0.01 SEQ. ID. NO. 240 155 789182 “proliferating cell nuclear antigen” Hs.78996 0.37 +− 0.01 SEQ. ID. NO. 241 161 726236 “paired mesoderm homeo box 1” Hs.155606 0.37 +− 0.01 SEQ. ID. NO. 242 164 866694 “butyrate-induced transcript 1” Hs.260622 0.37 +− 0.01 SEQ. ID. NO. 243 165 853368 “thymidylate synthetase” Hs.82962 0.37 +− 0.01 SEQ. ID. NO. 244 167 85259 “heme oxygenase (decycling) 1” Hs.202833 0.36 +− 0.01 SEQ. ID. NO. 245 168 83279 “translocase of inner mitochondrial Hs.11866 0.36 +− 0.01 SEQ. ID. NO. 246 membrane 23 (yeast) homolog” 169 137535 “transcriptional intermediary factor 1” Hs.183858 0.36 +− 0.01 SEQ. ID. NO. 247 170 770391 “polymerase (RNA) II (DNA directed) Hs.79402 0.36 +− 0.01 SEQ. ID. NO. 248 polypeptide C (33 kD)” 174 824591 “heterogeneous nuclear ribonucleoprotein Hs.808 0.36 +− 0.01 SEQ. ID. NO. 249 F” 177 783697 “BCL2/adenovirus E1B 19 kD-interacting Hs.79428 0.36 +− 0.01 SEQ. ID. NO. 250 protein 3” 178 144932 “deleted in oral cancer (mouse, homolog) Hs.3436 0.36 +− 0.01 SEQ. ID. NO. 128 1” 179 795543 “thioredoxin peroxidase (antioxidant Hs.83383 0.36 +− 0.01 SEQ. ID. NO. 251 enzyme)” 181 292996 “tyrosine 3-monooxygenase/tryptophan 5- Hs.75544 0.36 +− 0.01 SEQ. ID. NO. 252 monooxygenase activation protein, eta polypeptide” 182 345833 “heterogeneous nuclear ribonucleoprotein Hs.81361 0.36 +− 0.01 SEQ. ID. NO. 253 A/B” 184 810510 “ESTs” Hs.14317 0.35 +− 0.01 SEQ. ID. NO. 254 185 882510 “karyopherin alpha 2 (RAG cohort 1, Hs.159557 0.35 +− 0.01 SEQ. ID. NO. 255 importin alpha 1)” 186 144905 “PRO1912 protein” Hs.29494 0.35 +− 0.01 SEQ. ID. NO. 256 188 878833 “ubiquitin carboxyl-terminal esterase L1 Hs.76118 0.35 +− 0.01 SEQ. ID. NO. 257 (ubiquitin thiolesterase)” 189 139835 “UDP-glucose dehydrogenase” Hs.28309 0.35 +− 0.01 SEQ. ID. NO. 258 190 207082 “glucosamine-6-phosphate deaminase” Hs.278500 0.35 +− 0.01 SEQ. ID. NO. 259 193 884718 “Hairpin binding protein, histone” Hs.75257 0.35 +− 0.01 SEQ. ID. NO. 260 195 71672 “electron-transfer-flavoprotein, alpha Hs.169919 0.34 +− 0.01 SEQ. ID. NO. 261 polypeptide (glutaric aciduria II)” 197 789204 “translocation protein 1” Hs.8146 0.34 +− 0.01 SEQ. ID. NO. 262 198 757404 “von Hippel-Lindau binding protein 1” Hs.198307 0.34 +− 0.01 SEQ. ID. NO. 263 200 784257 “kinesin family member 3C” Hs.21611 0.34 +− 0.01 SEQ. ID. NO. 34

TABLE 7 Ranked Genes for Rhabdomyosarcoma (RMS) Rank Clone Id GeneDescription Unigene Weight SEQ. ID. NO. 1 296448 “insulin-like growth factor 2 Hs.251664 0.95 +− 0.05 SEQ. ID. NO. 72 (somatomedin A)” 2 207274 “insulin-like growth factor 2 Hs.251664 0.90 +− 0.04 SEQ. ID. NO. 73 (somatomedin A)” 3 244618 “ESTs” Hs.15463 0.70 +− 0.03 SEQ. ID. NO. 77 4 489631 “chondroitin sulfate proteaglycan 2 Hs.81800 0.54 +− 0.03 SEQ. ID. NO. 99 (versican)” 5 298062 “troponin T2, cardiac” Hs.89749 0.53 +− 0.03 SEQ. ID. NO. 74 6 784224 “fibroblast growth factor receptor 4” Hs.165950 0.53 +− 0.03 SEQ. ID. NO. 71 7 1409509 “troponin T1, skeletal, slow” Hs.73980 0.52 +− 0.02 SEQ. ID. NO. 70 8 461425 “myosin, light polypeptide 4, alkali; Hs.154156 0.50 +− 0.02 SEQ. ID. NO. 75 atrial, embryonic” 9 245330 “insulin-like growth factor 2 Hs.251664 0.47 +− 0.02 SEQ. ID. NO. 78 (somatomedin A)” 10 796258 “sarcoglycan, alpha (50 kD Hs.99931 0.46 +− 0.02 SEQ. ID. NO. 76 dystrophin-associated glycoprotein)” 11 293500 “ESTs” Hs.49714 0.45 +− 0.02 SEQ. ID. NO. 80 12 122159 “collagen, type III, alpha 1 (Ehlers- Hs.119571 0.45 +− 0.02 SEQ. ID. NO. 66 Danlos syndrome type IV, autosomal dominant)” 13 324494 “heat shock 27 kD protein 2” Hs.78846 0.44 +− 0.02 SEQ. ID. NO. 62 14 898219 “mesoderm specific transcript Hs.79284 0.44 +− 0.02 SEQ. ID. NO. 113 (mouse) homolog” 15 714453 “interleukin 4 receptor” Hs.75545 0.44 +− 0.02 SEQ. ID. NO. 83 16 42558 “glycine amidinotransferase (L- Hs.75335 0.44 +− 0.02 SEQ. ID. NO. 79 arginine:glycine amidinotransferase)” 17 377468 “sprouty (Drosophila) homolog 1 Hs.88044 0.43 +− 0.02 SEQ. ID. NO. 107 (antagonist of FGF signaling)” 18 769716 “neurofibromin 2 (bilateral acoustic Hs.902 0.42 +− 0.02 SEQ. ID. NO. 104 neuroma)” 19 809901 “collagen, type XV, alpha 1” Hs.83164 0.42 +− 0.02 SEQ. ID. NO. 67 20 813841 “plasminogen activator, tissue” Hs.274404 0.41 +− 0.02 SEQ. ID. NO. 132 21 795877 “serum-inducible kinase” Hs.3838 0.41 +− 0.02 SEQ. ID. NO. 102 22 214572 “ESTs” Hs.280460 0.40 +− 0.02 SEQ. ID. NO. 135 23 130057 “ESTs” Hs.23057 0.39 +− 0.02 SEQ. ID. NO. 109 24 767495 “GLI-Kruppel family member GLI3 Hs.72916 0.39 +− 0.02 SEQ. ID. NO. 103 (Greig cephalopolysyndactyly syndrome)” 25 246035 “ESTs” Hs.78026 0.39 +− 0.02 SEQ. ID. NO. 119 26 41591 “meningioma (disrupted in balanced Hs.268515 0.38 +− 0.02 SEQ. ID. NO. 60 translocation) 1” 27 714106 “plasminogen activator, urokinase” Hs.77274 0.38 +− 0.02 SEQ. ID. NO. 121 28 770059 “heparan sulfate proteoglycan 2 Hs.211573 0.38 +− 0.02 SEQ. ID. NO. 110 (perlecan)” 29 814798 “aldehyde dehydrogenase 6” Hs.75746 0.37 +− 0.02 SEQ. ID. NO. 196 30 365515 “fibroblast growth factor 7 Hs.164568 0.37 +− 0.02 SEQ. ID. NO. 111 (keratinocyte growth factor)” 31 788107 “bridging integrator 1” Hs.193163 0.36 +− 0.02 SEQ. ID. NO. 52 32 250654 “secreted protein, acidic, cysteine- Hs.111779 0.36 +− 0.02 SEQ. ID. NO. 149 rich (osteonectin)” 33 295985 “Homo sapiens cDNA FLJ20653 fis, Hs.180059 0.36 +− 0.02 SEQ. ID. NO. 26 clone KAT01739” 34 789253 “presenilin 2 (Alzheimer disease 4)” Hs.25363 0.36 +− 0.02 SEQ. ID. NO. 143 35 299737 “Homo sapiens clone 24411 mRNA Hs.20952 0.35 +− 0.02 SEQ. ID. NO. 157 sequence” 36 859359 “quinone oxidoreductase homolog” Hs.50649 0.35 +− 0.02 SEQ. ID. NO. 50 37 66714 “peanut (Drosophila)-like 2” Hs.155524 0.34 +− 0.02 SEQ. ID. NO. 182 39 755750 “non-metastatic cells 2, protein Hs.275163 0.34 +− 0.02 SEQ. ID. NO. 49 (NM23B) expressed in” 40 727251 “CD9 antigen (p24)” Hs.1244 0.33 +− 0.02 SEQ. ID. NO. 189 41 25725 “farnesyl-diphosphate Hs.48876 0.33 +− 0.02 SEQ. ID. NO. 264 farnesyltransferase 1” 42 143306 “lymphocyte-specific protein 1” Hs.56729 0.33 +− 0.02 SEQ. ID. NO. 205 45 491692 “collagen, type IV, alpha 1” Hs.119129 0.32 +− 0.02 SEQ. ID. NO. 133 46 142134 “hypothetical protein FLJ20185” Hs.272972 0.32 +− 0.02 SEQ. ID. NO. 134 47 813823 “lumican” Hs.79914 0.32 +− 0.02 SEQ. ID. NO. 265 48 788695 “troponin T3, skeletal, fast” Hs.73454 0.32 +− 0.02 SEQ. ID. NO. 197 49 308163 “ESTs” Hs.84520 0.32 +− 0.02 SEQ. ID. NO. 57 50 377671 “integrin, alpha 7” Hs.74369 0.31 +− 0.02 SEQ. ID. NO. 68 51 281901 “ESTs” Hs.74280 0.31 +− 0.02 SEQ. ID. NO. 266 52 796904 “pleomorphic adenoma gene-like 1” Hs.75825 0.31 +− 0.01 SEQ. ID. NO. 120 53 773215 “runt-related transcription factor 1 Hs.129914 0.30 +− 0.01 SEQ. ID. NO. 142 (acute myeloid leukemia 1; aml1 oncogene)” 55 486787 “calponin 3, acidic” Hs.194662 0.30 +− 0.01 SEQ. ID. NO. 43 56 341588 “CGI-119 protein” Hs.25615 0.29 +− 0.01 SEQ. ID. NO. 131 57 839552 “nuclear receptor coactivator 1” Hs.74002 0.29 +− 0.01 SEQ. ID. NO. 267 58 365826 “growth arrest-specific 1” Hs.65029 0.29 +− 0.01 SEQ. ID. NO. 59 59 111884 “ESTs, Weakly similar to hTcf-4 Hs.102367 0.29 +− 0.01 SEQ. ID. NO. 268 [H. sapiens]” 60 797048 “bone morphogenetic protein 4” Hs.68879 0.28 +− 0.01 SEQ. ID. NO. 269 61 769959 “collagen, type IV, alpha 2” Hs.75617 0.28 +− 0.01 SEQ. ID. NO. 69 62 204545 “ESTs” Hs.8966 0.28 +− 0.01 SEQ. ID. NO. 58 63 771323 “procollagen-lysine, 2-oxoglutarate 5- Hs.75093 0.27 +− 0.01 SEQ. ID. NO. 270 dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI)” 65 897865 “midline 1 (Opitz/BBB syndrome)” Hs.27695 0.27 +− 0.01 SEQ. ID. NO. 271 66 298417 “trefoil factor 3 (intestinal)” Hs.82961 0.27 +− 0.01 SEQ. ID. NO. 272 67 79022 “FBJ murine osteosarcoma viral Hs.75678 0.27 +− 0.01 SEQ. ID. NO. 273 oncogene homolog B” 68 290378 “podocalyxin-like” Hs.16426 0.27 +− 0.01 SEQ. ID. NO. 274 69 784593 “ESTs” Hs.6838 0.27 +− 0.01 SEQ. ID. NO. 41 70 32493 “integrin, alpha 6” Hs.227730 0.27 +− 0.01 SEQ. ID. NO. 275 71 45542 “Human insulin-like growth factor Hs.103391 0.26 +− 0.01 SEQ. ID. NO. 64 binding protein 5 (IGFBP5) mRNA” 72 208001 “CD59 antigen p18-20 (antigen Hs.119663 0.26 +− 0.01 SEQ. ID. NO. 276 identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344)” 73 413633 “EST” — 0.26 +− 0.01 SEQ. ID. NO. 115 74 284882 “collagen, type II, alpha 1 (primary Hs.81343 0.26 +− 0.01 SEQ. ID. NO. 277 osteoarthritis, spondyloepiphyseal dysplasia, congenital)” 75 273435 “v-yes-1 Yamaguchi sarcoma viral Hs.194148 0.26 +− 0.01 SEQ. ID. NO. 184 oncogene homolog 1” 76 839991 “collagen, type I, alpha 2” Hs.179573 0.26 +− 0.01 SEQ. ID. NO. 278 78 323371 “amyloid beta (A4) precursor protein Hs.177486 0.26 +− 0.01 SEQ. ID. NO. 27 (protease nexin-II, Alzheimer disease)” 79 362483 “spectrin, beta, non-erythrocylic 1” Hs.107164 0.26 +− 0.01 SEQ. ID. NO. 170 80 839736 “crystallin, alpha B” Hs.1940 0.25 +− 0.01 SEQ. ID. NO. 61 81 380620 “presenilin 2 (Alzheimer disease 4)” Hs.25363 0.25 +− 0.01 SEQ. ID. NO. 279 82 343867 “allograft inflammatory factor 1” Hs.76364 0.25 +− 0.01 SEQ. ID. NO. 150 83 882506 “lysyl oxidase-like 2” Hs.83354 0.25 +− 0.01 SEQ. ID. NO. 207 84 214990 “gelsolin (amyloidosis, Finnish type)” Hs.80562 0.25 +− 0.01 SEQ. ID. NO. 127 85 878182 “alpha-2-macroglobulin” Hs.74561 0.25 +− 0.01 SEQ. ID. NO. 136 86 301122 “extracellular matrix protein 1” Hs.81071 0.25 +− 0.01 SEQ. ID. NO. 195 87 198982 “DNA (cytosine-5-)- Hs.97681 0.25 +− 0.01 SEQ. ID. NO. 280 methyltransferase 2” 88 138672 “ESTs” Hs.28412 0.25 +− 0.01 SEQ. ID. NO. 281 89 246377 “EST” Hs.102670 0.24 +− 0.01 SEQ. ID. NO. 51 90 50941 “cadherin 13, H-cadherin (heart)” Hs.63984 0.24 +− 0.01 SEQ. ID. NO. 282 91 812196 “UDP-glucose ceramide Hs.152601 0.24 +− 0.01 SEQ. ID. NO. 283 glucosyltransferase” 92 120881 “proteasome (prosome, macropain) Hs.251531 0.24 +− 0.01 SEQ. ID. NO. 284 subunit, alpha type, 4” 93 813698 “sprouty (Drosophila) homolog 2” Hs.18676 0.24 +− 0.01 SEQ. ID. NO. 130 94 810612 “S100 calcium-binding protein A11 Hs.256290 0.24 +− 0.01 SEQ. ID. NO. 285 (calgizzarin)” 97 767851 “fibrillin 1 (Marfan syndrome)” Hs.750 0.23 +− 0.01 SEQ. ID. NO. 286 99 211758 “ribosomal protein S23” Hs.3463 0.23 +− 0.01 SEQ. ID. NO. 101 100 506369 “nidogen (enactin)” Hs.62041 0.23 +− 0.01 SEQ. ID. NO. 287 101 75254 “cysteine and glycine-rich protein 2 Hs.10526 0.23 +− 0.01 SEQ. ID. NO. 106 (LIM domain only, smooth muscle)” 103 823851 “AE-binding protein 1” Hs.118397 0.23 +− 0.01 SEQ. ID. NO. 288 104 52096 “platelet-derived growth factor Hs.74615 0.23 +− 0.01 SEQ. ID. NO. 124 receptor, alpha polypeptide” 106 760224 “X-ray repair complementing Hs.98493 0.23 +− 0.01 SEQ. ID. NO. 289 defective repair in Chinese hamster cells 1” 107 725473 “DNA segment on chromosome 12 Hs.74085 0.23 +− 0.01 SEQ. ID. NO. 290 (unique) 2489 expressed sequence” 111 148028 “epidermal growth factor receptor Hs.2132 0.23 +− 0.01 SEQ. ID. NO. 291 pathway substrate 8” 113 769028 “mesenchyme homeo box 1” Hs.438 0.23 +− 0.01 SEQ. ID. NO. 198 115 39093 “methionine aminopeptidase; eIF-2- Hs.78935 0.22 +− 0.01 SEQ. ID. NO. 63 associated p67” 116 854899 “dual specificity phosphatase 6” Hs.180383 0.22 +− 0.01 SEQ. ID. NO. 48 118 547247 “stanniocalcin” Hs.25590 0.22 +− 0.01 SEQ. ID. NO. 292 119 26418 “endothelial differentiation, Hs.154210 0.22 +− 0.01 SEQ. ID. NO. 293 sphingolipid G-protein-coupled receptor, 1” 120 811848 “transforming growth factor beta 1 Hs.25511 0.22 +− 0.01 SEQ. ID. NO. 294 induced transcript 1” 123 178463 “transcription factor 8 (represses Hs.232068 0.22 +− 0.01 SEQ. ID. NO. 295 interleukin 2 expression)” 124 810859 “natural killer cell transcript 4” Hs.943 0.22 +− 0.01 SEQ. ID. NO. 296 125 40643 “platelet-derived growth factor Hs.76144 0.22 +− 0.01 SEQ. ID. NO. 297 receptor, beta polypeptide” 126 782193 “thioredoxin” Hs.76136 0.22 +− 0.01 SEQ. ID. NO. 126 127 1412412 “elastase 1, pancreatic” Hs.21 0.22 +− 0.01 SEQ. ID. NO. 298 128 470128 “myosin IC” Hs.82251 0.22 +− 0.01 SEQ. ID. NO. 299 129 68950 “cyclin E1” Hs.9700 0.22 +− 0.01 SEQ. ID. NO. 300 130 66552 “ESTs” Hs.119021 0.22 +− 0.01 SEQ. ID. NO. 301 131 233721 “insulin-like growth factor binding Hs.162 0.22 +− 0.01 SEQ. ID. NO. 28 protein 2 (36 kD)” 133 814444 “cofactor required for Sp1 Hs.279902 0.21 +− 0.01 SEQ. ID. NO. 302 transcriptional activation, subunit 9 (33 kD)” 134 160723 “laminin, gamma 1 (formerly Hs.214982 0.21 +− 0.01 SEQ. ID. NO. 303 LAMB2)” 135 752652 “transcription factor 7-like 2 (T-cell Hs.154485 0.21 +− 0.01 SEQ. ID. NO. 203 specific, HMG-box)” 136 180902 “CGI-43 protein” Hs.111515 0.21 +− 0.01 SEQ. ID. NO. 304 137 154472 “fibroblast growth factor receptor 1 Hs.748 0.21 +− 0.01 SEQ. ID. NO. 305 (fms-related tyrosine kinase 2, Pfeiffer syndrome)” 139 82225 “secreted frizzled-related protein 1” Hs.7306 0.21 +− 0.01 SEQ. ID. NO. 42 140 898092 “connective tissue growth factor” Hs.75511 0.21 +− 0.01 SEQ. ID. NO. 306 142 773568 “POU domain, class 4, transcription Hs.211588 0.21 +− 0.01 SEQ. ID. NO. 307 factor 1” 143 144797 “a disintegrin-like and Hs.8230 0.21 +− 0.01 SEQ. ID. NO. 308 metalloprotease (reprolysin type) with thrombospondin type 1 motif, 1” 145 139818 “KIAA0669 gene product” Hs.52526 0.21 +− 0.01 SEQ. ID. NO. 309 146 358433 “retinoid X receptor, gamma” Hs.26550 0.21 +− 0.01 SEQ. ID. NO. 167 147 141192 “Leman coiled-coil protein” Hs.92186 0.21 +− 0.01 SEQ. ID. NO. 310 148 813707 “regulator of G-protein signalling 16” Hs.183601 0.21 +− 0.01 SEQ. ID. NO. 311 149 781014 “suppression of tumorigenicity 5” Hs.79265 0.21 +− 0.01 SEQ. ID. NO. 312 150 857640 “Human alpha-2 collagen type VI Hs.281620 0.21 +− 0.01 SEQ. ID. NO. 313 mRNA, 3′ end” 151 811028 “cathepsin D (lysosomal aspartyl Hs.79572 0.21 +− 0.01 SEQ. ID. NO. 199 protease)” 153 196992 “aldo-keto reductase family 1, Hs.275374 0.20 +− 0.01 SEQ. ID. NO. 200 member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)- hydroxysteroid dehydrogenase)” 154 781019 “paraoxonase 2” Hs.169857 0.20 +− 0.01 SEQ. ID. NO. 314 155 491559 “fatty acid binding protein 3, muscle Hs.49881 0.20 +− 0.01 SEQ. ID. NO. 315 and heart (mammary-derived growth inhibitor)” 156 358531 “v-jun avian sarcoma virus 17 Hs.78465 0.20 +− 0.01 SEQ. ID. NO. 316 oncogene homolog” 157 127099 “Homo sapiens cDNA FLJ20754 fis, Hs.72249 0.20 +− 0.01 SEQ. ID. NO. 317 clone HEP02246” 158 263716 “collagen, type VI, alpha 1” Hs.108885 0.20 +− 0.01 SEQ. ID. NO. 318 162 787861 “dual-specificity tyrosine-(Y)- Hs.173135 0.20 +− 0.01 SEQ. ID. NO. 319 phosphorylation regulated kinase 2” 163 246722 “trinucleotide repeat containing 3” Hs.21858 0.20 +− 0.01 SEQ. ID. NO. 320 164 151449 “protein tyrosine phosphatase, non- Hs.155693 0.20 +− 0.01 SEQ. ID. NO. 321 receptor type 21” 165 81475 “—” — 0.20 +− 0.01 SEQ. ID. NO. 322 166 810512 “thrombospondin 1” Hs.87409 0.20 +− 0.01 SEQ. ID. NO. 323 168 233071 “transmembrane protein 2” Hs.160417 0.19 +− 0.01 SEQ. ID. NO. 324 170 809910 “interferon induced transmembrane Hs.182241 0.19 +− 0.01 SEQ. ID. NO. 55 protein 3 (1-8U)” 171 233688 “a disintegrin and metalloproteinase Hs.8850 0.19 +− 0.01 SEQ. ID. NO. 325 domain 12 (meltrin alpha)” 172 128054 “H2A histone family, member X” Hs.147097 0.19 +− 0.01 SEQ. ID. NO. 326 173 143523 “collagen, type V, alpha 1” Hs.146428 0.19 +− 0.01 SEQ. ID. NO. 327 174 809719 “protein tyrosine phosphatase, Hs.170121 0.19 +− 0.01 SEQ. ID. NO. 328 receptor type, c polypeptide” 175 45291 “dentatorubral-pallidoluysian atrophy Hs.169488 0.19 +− 0.01 SEQ. ID. NO. 54 (atrophin-1)” 176 758266 “thrombospondin 4” Hs.75774 0.19 +− 0.01 SEQ. ID. NO. 329 178 247818 “ESTs” Hs.239666 0.19 +− 0.01 SEQ. ID. NO. 330 179 130824 “S-phase kinase-associated protein 2 Hs.23348 0.19 +− 0.01 SEQ. ID. NO. 331 (p45)” 180 341328 “tropomyosin 1 (alpha)” Hs.77899 0.19 +− 0.01 SEQ. ID. NO. 332 181 123916 “dystrophia myotonica-containing Hs.275924 0.19 +− 0.01 SEQ. ID. NO. 333 WD repeat motif” 183 682555 “insulin-like growth factor 1 receptor” Hs.239176 0.19 +− 0.01 SEQ. ID. NO. 334 184 868380 “Fc fragment of IgG, low affinity IIa, Hs.78864 0.19 +− 0.01 SEQ. ID. NO. 335 receptor for (CD32)” 187 869187 “Homo sapiens clone 23698 mRNA Hs.8136 0.19 +− 0.01 SEQ. ID. NO. 336 sequence” 190 207920 “solute carrier family 17 (sodium Hs.19710 0.19 +− 0.01 SEQ. ID. NO. 337 phosphate), member 2” 192 469345 “kinase insert domain receptor (a type Hs.12337 0.18 +− 0.01 SEQ. ID. NO. 338 III receptor tyrosine kinase)” 193 754406 “integrin, alpha M (complement Hs.172631 0.18 +− 0.01 SEQ. ID. NO. 339 component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide)” 196 43563 “cytochrome P450, subfamily Hs.82568 0.18 +− 0.01 SEQ. ID. NO. 340 XXVIIA (steroid 27-hydroxylase, cerebrotendinous xanthomatosis), polypeptide 1” 198 753775 “guanosine monophosphate Hs.1435 0.18 +− 0.01 SEQ. ID. NO. 341 reductase”

TABLE 8 Ranked genes for Burkitt's (BL) Rank Clone Id GeneDescription Unigene Weight SEQ. ID. NO. 2 80109 “major histocompatibility complex, Hs.198253 0.58 +− 0.02 SEQ. ID. NO. 88 class II, DQ alpha 1” 3 840942 “major histocompatibility complex, Hs.814 0.56 +− 0.02 SEQ. ID. NO. 87 class II, DP beta 1” 7 183337 “major histocompatibility complex, Hs.77522 0.52 +− 0.02 SEQ. ID. NO. 89 class II, DM alpha” 17 609663 “protein kinase, cAMP-dependent, Hs.77439 0.45 +− 0.02 SEQ. ID. NO. 95 regulatory, type II, beta” 23 767183 “hematopoietic cell-specific Lyn Hs.14601 0.43 +− 0.02 SEQ. ID. NO. 91 substrate 1” 27 297392 “metallothionein 1L” Hs.94360 0.42 +− 0.02 SEQ. ID. NO. 93 30 200814 “membrane metallo-endopeptidase Hs.1298 0.41 +− 0.02 SEQ. ID. NO. 94 (neutral endopeptidase, enkephalinase, CALLA, CD10)” 33 241412 “E74-like factor 1 (ets domain Hs.154365 0.41 +− 0.02 SEQ. ID. NO. 90 transcription factor)” 35 1469292 “pim-2 oncogene” Hs.80205 0.39 +− 0.02 SEQ. ID. NO. 92 45 417226 “v-myc avian myelocytomatosis Hs.79070 0.38 +− 0.01 SEQ. ID. NO. 81 viral oncogene homolog” 57 47475 “p53 inducible protein” Hs.258503 0.36 +− 0.01 186 61 236282 “Wiskott-Aldrich syndrome Hs.2157 0.35 +− 0.01 SEQ. ID. NO. 164 (ecezema-thrombocytopenia)” 63 868304 “actin, alpha 2, smooth muscle, Hs.195851 0.34 +− 0.01 SEQ. ID. NO. 86 aorta” 65 740604 “interferon stimulated gene (20 kD)” Hs.183487 0.34 +− 0.01 SEQ. ID. NO. 342 82 824602 “interferon, gamma-inducible Hs.155530 0.31 +− 0.01 SEQ. ID. NO. 84 protein 16” 83 624360 “proteasome (prosome, macropain) Hs.180062 0.31 +− 0.01 SEQ. ID. NO. 162 subunit, beta type, 8 (large multifunctional protease 7)” 84 344134 “immunoglobulin lambda-like Hs.170116 0.31 +− 0.01 SEQ. ID. NO. 185 polypeptide 3” 85 193913 “v-yes-1 Yamaguchi sarcoma viral Hs.80887 0.31 +− 0.01 SEQ. ID. NO. 343 related oncogene homolog” 88 814526 “seb4D” Hs.236361 0.31 +− 0.01 SEQ. ID. NO. 96 101 236034 “uncoupling protein 2 Hs.80658 0.30 +− 0.01 SEQ. ID. NO. 344 (mitochondrial, proton carrier)” 106 745343 “regenerating islet-derived 1 alpha Hs.1032 0.30 +− 0.01 SEQ. ID. NO. 85 (pancreatic stone protein, pancreatic thread protein)” 114 788511 “ribosomal protein S6 kinase, 90 kD, Hs.149957 0.29 +− 0.01 SEQ. ID. NO. 155 polypeptide 1” 118 283315 “phosphoglycerate mutase 2 Hs.46039 0.29 +− 0.01 SEQ. ID. NO. 345 (muscle)” 135 502333 “nuclear receptor coactivator 3” Hs.225977 0.27 +− 0.01 SEQ. ID. NO. 316 136 262920 “endothelial differentiation-related Hs.174050 0.27 +− 0.01 SEQ. ID. NO. 347 factor 1” 140 897177 “phosphoglycerate mutase 1 (brain)” Hs.181013 0.27 +− 0.01 SEQ. ID. NO. 348 146 700792 “cyclin-dependent kinase inhibitor 3 Hs.84113 0.27 +− 0.01 SEQ. ID. NO. 349 (CDK2-associated dual specificity phosphatase)” 147 626502 “actin related protein 2/3 complex, Hs.11538 0.27 +− 0.01 SEQ. ID. NO. 350 subunit 1B (41 kD)” 149 769657 “protein phosphatase 1, regulatory Hs.267819 0.27 +− 0.01 SEQ. ID. NO. 351 (inhibitor) subunit 2” 152 435953 “inositol 1,4,5-triphosphate receptor, Hs.77515 0.26 +− 0.01 SEQ. ID. NO. 144 type 3” 155 812965 “v-myc avian myelocytomatosis Hs.79070 0.26 +− 0.01 SEQ. ID. NO. 82 viral oncogene homolog” 159 714453 “interleukin 4 receptor” Hs.75545 0.26 +− 0.01 SEQ. ID. NO. 83 163 145112 “intercellular adhesion molecule 1 Hs.168383 0.25 +− 0.01 SEQ. ID. NO. 352 (CD54), human rhinovirus receptor” 164 80649 “Rho-associated, coiled-coil Hs.17820 0.25 +− 0.01 SEQ. ID. NO. 353 containing protein kinase 1” 172 240208 “DKFZP434O125 protein” Hs.102669 0.25 +− 0.01 SEQ. ID. NO. 354 174 298155 “acyl-Coenzyme A dehydrogenase, Hs.79158 0.25 +− 0.01 SEQ. ID. NO. 355 C-4 to C-12 straight chain” 176 530185 “CD83 antigen (activated B Hs.79197 0.25 +− 0.01 SEQ. ID. NO. 356 lymphocytes, immunoglobulin superfamily)” 185 755145 “villin 2 (ezrin)” Hs.155191 0.24 +− 0.01 SEQ. ID. NO. 357 192 68977 “proteasome (prosome, macropain) Hs.9661 0.24 +− 0.01 SEQ. ID. NO. 358 subunit, beta type, 10”

TABLE 9 Ranked genes for Ewing family of tumors (EWS) Rank Clone Id GeneDescription Unigene Weight SEQ. ID. NO. 2 866702 “protein tyrosine phosphatase, non-receptor type Hs.211595 0.47 +− 0.03 SEQ. ID. NO. 16 13 (APO-1/CD95 (Fas)-associated phosphatase)” 3 770394 “Fc fragment of IgG, receptor, transporter, alpha” Hs.160741 0.47 +− 0.03 SEQ. ID. NO. 20 5 377461 “caveolin 1, caveolae protein, 22 kD” Hs.281621 0.45 +− 0.03 SEQ. ID. NO. 19 6 357031 “tumor necrosis factor, alpha-induced protein 6” Hs.29352 0.44 +− 0.03 SEQ. ID. NO. 18 7 43733 “glycogenin 2” Hs.58589 0.42 +− 0.03 SEQ. ID. NO. 21 9 52076 “olfactomedin related ER localized protein” Hs.74376 0.38 +− 0.02 SEQ. ID. NO. 13 10 814260 “follicular lymphoma variant translocation 1” Hs.74050 0.36 +− 0.02 SEQ. ID. NO. 17 11 755599 “interferon induced transmembrane protein 1 (9-27)” Hs.146360 0.35 +− 0.02 SEQ. ID. NO. 25 13 377731 “glutathione S-transferase M5” Hs.75652 0.34 +− 0.02 SEQ. ID. NO. 23 14 1473131 “transducin-like enhancer of split 2, homolog of Hs.173063 0.34 +− 0.02 SEQ. ID. NO. 15 Drosophila E(sp1)” 15 823928 “glutathione S-transferase theta 2” Hs.1581 0.32 +− 0.02 SEQ. ID. NO. 153 16 1435862 “antigen identified by monoclonal antibodies Hs.177543 0.32 +− 0.02 SEQ. ID. NO. 22 12E7, F21 and O13” 17 812965 “v-myc avian myelocytomatosis viral oncogene Hs.79070 0.32 +− 0.02 SEQ. ID. NO. 82 homolog” 18 841641 “cyclin D1 (PRAD1: parathyroid adenomatosis Hs.82932 0.31 +− 0.02 SEQ. ID. NO. 5 1)” 19 208718 “annexin A1” Hs.78225 0.29 +− 0.02 SEQ. ID. NO. 2 20 713922 “glutathione S-transferase M1” Hs.278633 0.29 +− 0.02 SEQ. ID. NO. 152 21 291756 “tubulin, beta, 5” Hs.108014 0.29 +− 0.02 SEQ. ID. NO. 1 23 1323448 “cysteine-rich protein 1 (intestinal)” Hs.17409 0.28 +− 0.02 SEQ. ID. NO. 112 24 308497 “KIAA0467 protein” Hs.11147 0.28 +− 0.02 SEQ. ID. NO. 24 25 789091 “H2A histone family, member L” Hs.28777 0.28 +− 0.02 SEQ. ID. NO. 359 26 1471841 “ATPase, Na+/K+ transporting, alpha 1 Hs.190703 0.27 +− 0.02 SEQ. ID. NO. 202 polypeptide” 27 178825 “neurogranin (protein kinase C substrate, RC3)” Hs.26944 0.26 +− 0.02 SEQ. ID. NO. 360 28 810504 “proteolipid protein 2 (colonic epithelium- Hs.77422 0.25 +− 0.02 SEQ. ID. NO. 154 enriched)” 29 740554 “Homo sapiens mRNA; cDNA DKFZp434I0812 Hs.263671 0.25 +− 0.02 SEQ. ID. NO. 158 (from clone DKFZp434I0812); partial cds” 30 24415 “tumor protein p53 (Li-Fraumeni syndrome)” Hs.1846 0.25 +− 0.02 SEQ. ID. NO. 188 31 811108 “thyroid hormone receptor interactor 6” Hs.119498 0.25 +− 0.02 SEQ. ID. NO. 118 32 770868 “NGFI-A binding protein 2 (ERG1 binding Hs.159223 0.25 +− 0.01 SEQ. ID. NO. 190 protein 2)” 35 80338 “selenium binding protein 1” Hs.7833 0.24 +− 0.01 SEQ. ID. NO. 14 38 212640 “Rho GTPase activating protein 4” Hs.3109 0.24 +− 0.01 SEQ. ID. NO. 108 39 417226 “v-myc avian myelocytomatosis viral oncogene Hs.79070 0.24 +− 0.01 SEQ. ID. NO. 81 homolog” 40 742132 “interferon-stimulated protein, 15 kDa” Hs.833 0.23 +− 0.01 SEQ. ID. NO. 140 41 365826 “growth arrest-specific 1” Hs.65029 0.23 +− 0.01 SEQ. ID. NO. 59 42 161993 “CCAAT/enhancer binding protein (C/EBP), Hs.99029 0.23 +− 0.01 SEQ. ID. NO. 166 beta” 43 811000 “lectin, galactoside-binding, soluble, 3 binding Hs.79339 0.23 +− 0.01 SEQ. ID. NO. 6 protein (galectin 6 binding protein)” 44 768205 “homeo box D9” Hs.236646 0.22 +− 0.01 SEQ. ID. NO. 361 48 345232 “lymphotoxin alpha (TNF superfamily, member Hs.36 0.22 +− 0.01 SEQ. ID. NO. 362 1)” 49 586854 “CGI-119 protein” Hs.25615 0.22 +− 0.01 SEQ. ID. NO. 201 52 744417 “carnitine acetyltransferase” Hs.12068 0.21 +− 0.01 SEQ. ID. NO. 363 53 364934 “death-associated protein kinase 1” Hs.153924 0.21 +− 0.01 SEQ. ID. NO. 12 54 809694 “cellular retinoic acid-binding protein 1” Hs.7678 0.21 +− 0.01 SEQ. ID. NO. 364 55 491565 “Cbp/p300-interacting transactivator, with Hs.82071 0.21 +− 0.01 SEQ. ID. NO. 365 Glu/Asp-rich carboxy-terminal domain, 2” 56 1470048 “lymphocyte antigen 6 complex, locus E” Hs.77667 0.21 +− 0.01 SEQ. ID. NO. 366 57 814266 “protein kinase C, zeta” Hs.78793 0.21 +− 0.01 SEQ. ID. NO. 367 58 296030 “ESTs” Hs.10362 0.21 +− 0.01 SEQ. ID. NO. 368 59 379708 “chromodomain helicase DNA binding protein 3” Hs.25601 0.21 +− 0.01 SEQ. ID. NO. 176 60 755506 “annexin A4” Hs.77840 0.20 +− 0.01 SEQ. ID. NO. 177 61 39796 “3-hydroxymethyl-3-methylglutaryl-Coenzyme A Hs.831 0.20 +− 0.01 SEQ. ID. NO. 369 lyase (hydroxymethylglutaricaciduria)” 62 741885 “transcription factor binding to IGHM enhancer Hs.274184 0.20 +− 0.01 SEQ. ID. NO. 370 3” 63 271102 “copper chaperone for superoxide dismutase” Hs.5002 0.20 +− 0.01 SEQ. ID. NO. 371 64 470261 “SMA3” Hs.251397 0.20 +− 0.01 SEQ. ID. NO. 372 66 745343 “regenerating islet-derived 1 alpha (pancreatic Hs.1032 0.20 +− 0.01 SEQ. ID. NO. 85 stone protein, pancreatic thread protein)” 67 563673 “antiquitin 1” Hs.74294 0.20 +− 0.01 SEQ. ID. NO. 10 68 39093 “methionine aminopeptidase; eIF-2-associated Hs.78935 0.20 +− 0.01 SEQ. ID. NO. 63 p67” 75 234376 “Homo sapiens mRNA; cDNA DKFZp564F112 Hs.166361 0.19 +− 0.01 SEQ. ID. NO. 373 (from clone DKFZp564F112)” 76 810133 “ESTs” Hs.10362 0.19 +− 0.01 SEQ. ID. NO. 374 78 815239 “Rho guanine nucleotide exchange factor (GEF) Hs.252280 0.19 +− 0.01 SEQ. ID. NO. 161 1” 80 172751 “amyloid beta (A4) precursor protein-binding, Hs.4880 0.18 +− 0.01 SEQ. ID. NO. 375 family A, member 1 (X11)” 81 289645 “amyloid beta (A4) precursor-like protein 1” Hs.74565 0.18 +− 0.01 SEQ. ID. NO. 4 84 769579 “mitogen-activated protein kinase kinase 2” Hs.72241 0.18 +− 0.01 SEQ. ID. NO. 376 85 1422723 “interferon-induced protein 35” Hs.50842 0.18 +− 0.01 SEQ. ID. NO. 377 86 296880 “membrane protein, palmitoylated 1 (55 kD)” Hs.1861 0.18 +− 0.01 SEQ. ID. NO. 378 87 744052 “nuclear receptor subfamily 1, group H, member Hs.100221 0.18 +− 0.01 SEQ. ID. NO. 379 2” 88 782503 “Homo sapiens clone 23716 mRNA sequence” Hs.12214 0.18 +− 0.01 SEQ. ID. NO. 7 89 1434905 “homeo box B7” Hs.819 0.18 +− 0.01 SEQ. ID. NO. 178 90 212542 “Homo sapiens mRNA; cDNA DKFZp586J2118 Hs.21851 0.18 +− 0.01 SEQ. ID. NO. 53 (from clone DKFZp586J2118)” 91 506548 “regulator of G-protein signalling 10” Hs.82280 0.18 +− 0.01 SEQ. ID. NO. 380 93 768443 “microsomal glutathione S-transferase 1” Hs.790 0.18 +− 0.01 SEQ. ID. NO. 381 94 75923 “Human zinc finger protein mRNA, complete Hs.78765 0.18 +− 0.01 SEQ. ID. NO. 382 cds” SEQ. ID. NO. 97 1475595 “alkaline phosphatase, liver/bone/kidney” Hs.250769 0.17 +− 0.01 SEQ. ID. NO. 383 99 231355 “vesicle-associated membrane protein 2 Hs.194534 0.17 +− 0.01 SEQ. ID. NO. 384 (synaptobrevin 2)” 100 841620 “dihydropyrimidinase-like 2” Hs.173381 0.17 +− 0.01 SEQ. ID. NO. 8 101 1456900 “dipeptidase 1 (renal)” Hs.109 0.17 +− 0.01 SEQ. ID. NO. 385 103 773246 “ring finger protein 1” Hs.35384 0.17 +− 0.01 SEQ. ID. NO. 386 104 191743 “ESTs” Hs.94814 0.17 +− 0.01 SEQ. ID. NO. 387 105 265874 “nuclear factor I/C (CCAAT-binding Hs.184771 0.17 +− 0.01 SEQ. ID. NO. 388 transcription factor)” 106 767345 “ESTs, Moderately similar to I59372 cadherin 12 - Hs.44898 0.17 +− 0.01 SEQ. ID. NO. 389 human [H. sapiens]” 107 729964 “sphingomyelin phosphodiesterase 1, acid Hs.77813 0.17 +− 0.01 SEQ. ID. NO. 390 lysosomal (acid sphingomyelinase)” 108 768644 “zona pellucida glycoprotein 3A (sperm Hs.250867 0.17 +− 0.01 SEQ. ID. NO. 391 receptor)” 111 858469 “thrombospondin 3” Hs.169875 0.17 +− 0.01 SEQ. ID. NO. 392 112 756556 “complement component 1 inhibitor Hs.151242 0.17 +− 0.01 SEQ. ID. NO. 65 (angioedema, hereditary)” 113 190887 “myeloid differentiation primary response gene Hs.82116 0.17 +− 0.01 SEQ. ID. NO. 169 (88)” 114 1475730 “chaperonin containing TCP1, subunit 6A (zeta Hs.82916 0.17 +− 0.01 SEQ. ID. NO. 393 1)” 115 137158 “chromogranin A (parathyroid secretory protein Hs.172216 0.17 +− 0.01 SEQ. ID. NO. 394 1)” 116 897774 “adenine phosphoribosyltransferase” Hs.28914 0.17 +− 0.01 SEQ. ID. NO. 395 120 757248 “calpain, large polypeptide L3” Hs.40300 0.17 +− 0.01 SEQ. ID. NO. 396 124 811920 “interleukin 11 receptor, alpha” Hs.64310 0.16 +− 0.01 SEQ. ID. NO. 397 125 824602 “interferon, gamma-inducible protein 16” Hs.155530 0.16 +− 0.01 SEQ. ID. NO. 84 126 150702 “homeo box B5” Hs.22554 0.16 +− 0.01 SEQ. ID. NO. 398 127 37553 “protein phosphatase 2A, regulatory subunit B′ Hs.236963 0.16 +− 0.01 SEQ. ID. NO. 399 (PR 53)” 128 139957 “hypothetical protein FLJ11181” Hs.28472 0.16 +− 0.01 SEQ. ID. NO. 400 130 343646 “v-ski avian sarcoma viral oncogene homolog” Hs.2969 0.16 +− 0.01 SEQ. ID. NO. 401 131 1031748 “synovial sarcoma, X breakpoint 3” Hs.178749 0.16 +− 0.01 SEQ. ID. NO. 402 132 166236 “glucose-6-phosphate dehydrogenase” Hs.80206 0.16 +− 0.01 SEQ. ID. NO. 403 133 740801 “branched chain keto acid dehydrogenase E1, Hs.78950 0.16 +− 0.01 SEQ. ID. NO. 404 alpha polypeptide (maple syrup urine disease)” 134 120468 “excision repair cross-complementing rodent Hs.59544 0.16 +− 0.01 SEQ. ID. NO. 405 repair deficiency, complementation group 1 (includes overlapping antisense sequence)” 137 785967 “erythrocyte membrane protein band 4.1-like 2” Hs.7857 0.16 +− 0.01 SEQ. ID. NO. 406 139 361943 “Meis1 (mouse) homolog” Hs.170177 0.16 +− 0.01 SEQ. ID. NO. 407 140 810551 “low density lipoprotein-related protein 1 (alpha- Hs.89137 0.16 +− 0.01 SEQ. ID. NO. 206 2-macroglobulin receptor)” 141 841698 “exostoses (multiple) 1” Hs.184161 0.16 +− 0.01 SEQ. ID. NO. 408 142 753104 “dopachrome tautomerase (dopachrome delta- Hs.240217 0.16 +− 0.01 SEQ. ID. NO. 409 isomerase, tyrosine-related protein 2)” 143 878798 “beta-2-microglobulin” Hs.75415 0.16 +− 0.01 SEQ. ID. NO. 410 145 811900 “lymphotoxin beta receptor (TNFR superfamily, Hs.1116 0.16 +− 0.01 SEQ. ID. NO. 411 member 3” 146 741831 “phospholipid transfer protein” Hs.154854 0.15 +− 0.01 SEQ. ID. NO. 412 147 549146 “stimulated trans-acting factor (50 kDa)” Hs.68054 0.15 +− 0.01 SEQ. ID. NO. 413 149 841340 “ATP-binding cassette, sub-family B Hs.158164 0.15 +− 0.01 SEQ. ID. NO. 414 (MDR/TAP), member 2” 153 42576 “ubiquitin-activating enzyme E1 (A1S9T and Hs.2055 0.15 +− 0.01 SEQ. ID. NO. 415 BN75 temperature sensitivity complementing)” 154 53039 “carbohydrate (keratan sulfate Gal-6) Hs.104576 0.15 +− 0.01 SEQ. ID. NO. 416 sulfotransferase 1” 155 308163 “ESTs” Hs.84520 0.15 +− 0.01 SEQ. ID. NO. 57 157 949938 “cystatin C (amyloid angiopathy and cerebral Hs.135084 0.15 +− 0.01 SEQ. ID. NO. 417 hemorrhage)” 158 166195 “ribonuclease/angiogenin inhibitor” Hs.75108 0.15 +− 0.01 SEQ. ID. NO. 418 159 239611 “hemoglobin, epsilon 1” Hs.117848 0.15 +− 0.01 SEQ. ID. NO. 419 160 36950 “phosphofructokinase, liver” Hs.155455 0.15 +− 0.01 SEQ. ID. NO. 420 161 82903 “TAP binding protein (tapasin)” Hs.179600 0.15 +− 0.01 SEQ. ID. NO. 141 162 183440 “arylsulfatase A” Hs.88251 0.15 +− 0.01 SEQ. ID. NO. 421 163 787857 “syntaxin 5A” Hs.154546 0.15 +− 0.01 SEQ. ID. NO. 422 164 840821 “signal sequence receptor, delta (translocon- Hs.102135 0.15 +− 0.01 SEQ. ID. NO. 423 associated protein delta)” 165 760148 “uroporphyrinogen decarboxylase” Hs.78601 0.15 +− 0.01 SEQ. ID. NO. 424 166 1434948 “HIV TAT specific factor 1” Hs.171595 0.15 +− 0.01 SEQ. ID. NO. 425 167 897788 “protein tyrosine phosphatase, receptor type, F” Hs.75216 0.15 +− 0.01 SEQ. ID. NO. 9 168 810124 “platelet-activating factor acetylhydrolase, Hs.6793 0.15 +− 0.01 SEQ. ID. NO. 426 isoform Ib, gamma subunit (29 kD)” 169 50359 “mannose phosphate isomerase” Hs.75694 0.15 +− 0.01 SEQ. ID. NO. 427 170 221826 “guanine nucleotide binding protein (G protein), Hs.1686 0.15 +− 0.01 SEQ. ID. NO. 428 alpha 11 (Gq class)” 171 753587 “butyrophilin, subfamily 3, member A3” Hs.167741 0.15 +− 0.01 SEQ. ID. NO. 429 172 839980 “glucose-6-phosphatase, transport (glucose-6- Hs.26655 0.15 +− 0.01 SEQ. ID. NO. 430 phosphate) protein 1” 173 33327 “Homo sapiens mRNA for KIAA1232 protein, Hs.11101 0.15 +− 0.01 SEQ. ID. NO. 431 partial cds” 174 711961 “general transcription factor IIF, polypeptide 1 Hs.68257 0.15 +− 0.01 SEQ. ID. NO. 432 (74 kD subunit)” 175 809910 “interferon induced transmembrane protein 3 (1- Hs.182241 0.15 +− 0.01 SEQ. ID. NO. 55 8U)” 180 172783 “hypothetical protein FLJ10390” Hs.133475 0.15 +− 0.01 SEQ. ID. NO. 433 182 1374571 “paired basic amino acid cleaving enzyme (furin, Hs.59242 0.14 +− 0.01 SEQ. ID. NO. 434 membrane associated receptor protein)” 183 138936 “erythrocyte membrane protein band 7.2 Hs.160483 0.14 +− 0.01 SEQ. ID. NO. 435 (stomatin)” 186 795321 “mannosidase, alpha, class 2A, member 2” Hs.182923 0.14 +− 0.01 SEQ. ID. NO. 436 188 263727 “DNA segment, single copy probe LNS- Hs.178112 0.14 +− 0.01 SEQ. ID. NO. 437 CAI/LNS-CAII (deleted in polyposis” 189 75009 “EphB4” Hs.155227 0.14 +− 0.01 SEQ. ID. NO. 438 190 435953 “inositol 1,4,5-triphosphate receptor, type 3” Hs.77515 0.14 +− 0.01 SEQ. ID. NO. 144 191 782335 “ESTs” Hs.38270 0.14 +− 0.01 SEQ. ID. NO. 439 194 754600 “nuclear factor I/X (CCAAT-binding Hs.35841 0.14 +− 0.01 SEQ. ID. NO. 440 transcription factor)” 195 213890 “2,4-dienoyl CoA reductase 1, mitochondrial” Hs.81548 0.14 +− 0.01 SEQ. ID. NO. 441 197 1472735 “metallothionein 1E (functional)” Hs.74170 0.14 +− 0.01 SEQ. ID. NO. 442 199 781097 “reticulon 3” Hs.252831 0.14 +− 0.01 SEQ. ID. NO. 443 200 810057 “cold shock domain protein A” Hs.1139 0.14 +− 0.01 SEQ. ID. NO. 105

Alternatively, the genes expressed in the Tables 6 through 9 that are expressed in high levels in the specific cancers can be used as targets for designing vaccines for therapy and for making specific antibodies against and used to target these cancers. Also these genes or their protein products can be inhibited via a variety of methods including oligonucleotide DNA antisense, RNAi (making double stranded siRNA inhibitors, and drugs including small molecules and therefore be be used for treatment of these cancers. Genes found in this manner, such as those shown in Tables 6 through 9 can be used in microarrays. For example, microarrays including any combination of at least one of the 200 genes from Table 5 can be fabricated.

Alternatively, Table 10 shows 19 genes that were found using a method of the invention and are involved with signal transduction. Signal transduction proteins can be important targets for therapy since they pass on signals from the outside of the cell to the nucleus to either survive or proliferate. Of this list of genes only the first (clone ID 200814 (SEQ. ID. NO. 94) has been previously used as a specific target for leukemia/lymphoma therapy. The remainder of the genes are novel targets. For example, FGFR4 (SEQ. ID. NO. 71), a tyrosine kinase receptor that is expressed during myogenesis and prevents terminal differentiation in myocytes, was found to be highly expressed only in RMS, and in particular not in normal muscle. The relatively strong differential expression of FGFR4 (SEQ. ID. NO. 71) in RMS was confirmed by immunostaining of tissue microarrays. The high expression of FGFR4 (SEQ. ID. NO. 71) in most cases of RMS suggests that it may be relevant to the biology of this tumor, it is also expressed in some other cancers. This suggests that, FGFR4 (SEQ. ID. NO. 71) expression in RMS is of biological and therapeutic interest.

TABLE 10 Genes involved with signal transduction name CloneID diagnosis summaryfunction SEQ. ID. NO. membrane metallo- 200814 BL Enkephalinase; membrane zinc SEQ. ID. NO. 94 endopeptidase metalloendopeptidase, may (neutral inactivate peptide endopeptidase, hormones|Proteome enkephalinase, CALLA, CD10) protein tyrosine 897788 NOTBL Receptor-type protein tyrosine SEQ. ID. NO. 9 phosphatase, phosphatase F; interacts with the receptor type, F insulin receptor; has Ig-like and FN-III repeats in the extracellular domain|Proteome protein kinase, 609663 BL* Type II regulatory beta subunit of SEQ. ID. NO. 95 cAMP-dependent, cAMP-dependent protein kinase regulatory, type II, (PKA)|Proteome beta annexin A1 208718 EWS* Annexin I (lipocortin 1); Ca2+- SEQ. ID. NO. 2 dependent phospholipid-binding protein, inhibits phospholipase A2 and has anti-inflammatory activity|Proteome interleukin 4 714453 RMS_BL Subunit of the interleukin 4 SEQ. ID. NO. 83 receptor receptor; member of the cytokine receptor family|Proteome recoverin 383188 NB* Recoverin; calcium-binding SEQ. ID. NO. 38 protein that activates guanylate cyclase activity|Proteome fibroblast growth 784224 RMS* Fibroblast growth factor receptor SEQ. ID. NO. 71 factor receptor 4 4; receptor tyrosine kinase, preferentially binds acidic FGF; contains three extracellular immunoglobulin-like domains|Proteome transducin-like 1473131 EWS* Enhancer of split groucho 2; SEQ. ID. NO. 15 enhancer of split 2, possibly functions during homolog of epithelial differentiation; Drosophila E(sp1) transducin-like, similar to Drosophila E(spI) m9/10, which is required for cell fate decisions|Proteome tumor necrosis 357031 EWS* Similar to CD44; binds SEQ. ID. NO. 18 factor, alpha- hyaluronate and may be involved induced protein 6 in cell-cell communication during the immune response|Proteome ras homolog gene 768370 NOTBL Ras-related GTP binding protein SEQ. ID. NO. 46 family, member B of the rho subfamily, member B; may regulate assembly of actin stress fibers and focal adhesions; very strongly similar to murine Arhb|Proteome insulin-like growth 245330 RMS Insulin-like growth factor II SEQ. ID. NO. 78 factor 2 (somatomedin A); member of the (somatomedin A) insulin protein family|Proteome hematopoietic cell- 767183 BL Contains a helix-turn-helix DNA SEQ. ID. NO. 91 specific Lyn binding domain and an SH3 substrate 1 domain|Proteome dihydropyrimidinase- 841620 EWS_NB Member of the SEQ. ID. NO. 8 like 2 dihydropyrimidinase family|Proteome amyloid beta (A4) 323371 NOTBL Amyloid beta precursor protein SEQ. ID. NO. 27 precursor protein (protease nexin-II); cell surface (protease nexin-II, protease inhibitor; reduces Alzheimer disease) Cu|Proteome interferon induced 755599 EWS* Interferon-inducible SEQ. ID. NO. 25 transmembrane transmembrane protein 1; protein 1 (9-27) involved in relaying antiproliferative and homotypic adhesion signals|Proteome secreted frizzled- 82225 NB* Secreted frizzled-related protein SEQ. ID. NO. 42 related protein 1 1; may have an anti-apoptotic function and inhibit Wnt protein activity; strongly similar to murine Sfrp1|Proteome death-associated 364934 EWS* Death associated protein kinase 1; SEQ. ID. NO. 12 protein kinase 1 serine/threonine kinase regulated by calmodulin, may mediate apoptosis induced by interferon- gamma; has ankyrin repeats|Proteome lectin, galactoside- 811000 EWS_NB Mac-2-binding protein; potent SEQ. ID. NO. 6 binding, soluble, 3 immune stimulator; contains a binding protein macrophage scavenger receptor cysteine-rich domain|Proteome insulin-like growth 2907511 RMS Member of the insulin-like SEQ. ID. NO. 444 factor binding growth factor binding family of protein 5 proteins; may bind to and modulate insulin-like growth factor activity|Proteome

We then determined the classification error rate using increasing numbers of these ranked genes. The classification error rate minimized to 0% at 96 genes, see FIG. 5. The 10 dominant PCA components for these 96 genes contained 79% of the variance in the data matrix. Using only these 96 genes, we recalibrated the ANN models and again correctly classified all 63 samples, see FIG. 6. Moreover, multidimensional scaling (MDS) analysis using these 96 genes clearly separated the four cancer types, see FIG. 7. The top 96 discriminators represented 93 unique genes, see FIG. 8, as IGF2 was represented by three independent clones and MYC by two.

Of the 96 genes, 13 were anonymous expressed sequence tags (ESTs); 16 genes were specifically expressed in EWS, 20 in RMS, 15 in NB and 10 in BL. Twelve genes were good discriminators on the basis of lack of expression in BL and variable expression in the other three types. One gene (EST; Clone ID 295985 (SEQ. ID. NO. 26)) discriminated EWS from other cancer types by its lack of expression in this cancer. The remainder of the genes was expressed in two of the four cancer types. To our knowledge, of the 61 genes that were specifically expressed in cancer type, 41 have not been previously reported as associated with these diseases. These 41 genes can be seen in Table 2 given above.

Example 5 Diagnostic Classification and Hierarchical Clustering

The diagnostic classification capabilities of these ANN models were then tested on a set of 25 blinded test samples. Samples were classified to a diagnostic category if they received the highest vote for that category. As this classifier had only four possible outputs, all samples were classified to one of the four categories. We therefore established a diagnostic classification method based on a statistical cutoff to enable us to reject a diagnosis of a sample classified to a given category. If a sample falls outside the 95th percentile of the probability distribution of distances between samples and their ideal output (for example for EWS it is EWS=1, RMS=NB=BL=0), its diagnosis is rejected.

TABLE 11 Sample ANN committee vote ANN ANN Histological Source label EWS RMS NB BL classification diagnosis diagnosis label Source Test 1 0.01 0.07 0.76 0.06 NB NB NB-C IMR32 ATCC Test 2 0.67 0.06 0.08 0.09 EWS EWS EWS-C CHOP1 NCI Test 3 0.11 0.17 0.16 0.11 RMS — Osteosarcoma-C OsA-Cl ATCC Test 4 0.00 0.95 0.06 0.03 RMS RMS ARMS-T ARMD1 CHTN Test 5 0.11 0.11 0.25 0.10 NB — Sarcoma-C A204 ATCC Test 6 0.98 0.04 0.10 0.03 EWS EWS EWS-T 9608P053 CHTN Test 7 0.05 0.02 0.05 0.93 BL BL BL-C EB1 ATCC Test 8 0.00 0.05 0.94 0.04 NB NB NB-C SMSSAN NCI Test 9 0.22 0.60 0.03 0.06 RMS — Sk. Muscle SkM1 CHTN Test 10 0.10 0.68 0.11 0.04 RMS — ERMS-T ERDM1 CHTN Test 11 0.39 0.04 0.28 0.15 EWS — Prostate Ca.-C PC3 ATCC Test 12 0.89 0.05 0.14 0.03 EWS EWS EWS-T SARC67 CHTN Test 13 0.20 0.7 0.03 0.05 RMS — Sk. Muscle SkM2 CHTN Test 14 0.03 0.02 0.90 0.07 NB NB NB-T NB3 DZNSG Test 15 0.06 0.03 0.05 0.91 BL BL BL-C EB2 ATCC Test 16 0.03 0.02 0.93 0.05 NB NB NB-T NB1 DZNSG Test 17 0.01 0.90 0.05 0.03 RMS RMS ARMS-T ARMD2 CHTN Test 18 0.06 0.04 0.04 0.88 BL BL BL-C GA10 ATCC Test 19 0.99 0.02 0.04 0.05 EWS EWS EWS-T ET3 CHTN Test 20 0.40 0.30 0.10 0.06 EWS — EWS-T 9903P1339 CHTN Test 21 0.81 0.19 0.12 0.04 EWS EWS EWS-T ESZ3 MSkCC Test 22 0.01 0.88 0.09 0.04 RMS RMS ERMS-T ERMD2 CHTN Test 23 0.07 0.08 0.70 0.06 NB NB NB-T NB2 DZNSG Test 24 0.05 0.87 0.06 0.03 RMS RMS ERMS-T DMS4 MSKCC Test 25 0.05 0.02 0.89 0.06 NB NB NB-T NB4 DZNSG Source label refers to the original name of the sample as designated by the source. Histological diagnosis is defined as cancer type suffixed with -T for a tumor sample and -C for a cell line. Normal skeletal muscle (Sk. Muscle) is also included in the test set. The ANN classification as determined by the committee vote is bolded. NCI: National Cancer Institute, National Institutes of Health, ATCC: American Type Culture Collection, MSkCC: Memorial Sloan-Kettering Cancer Center, CHTN: Cooperative Human Tissue Network, DZNSG: German Cancer Research Center, Heidelberg.

The test samples contained both tumors (5 EWS, 5 RMS and 4 NB) and cell lines (1 EWS, 2 NB and 3 BL). The ability of these models to reject a diagnosis on 5 non-SRBCTs was also tested (consisting of 2 normal muscle tissues (Tests 9 and 13) and 3 cell lines including an undifferentiated sarcoma (Test 5), osteosarcoma (Test 3) and a prostate carcinoma (Test 11)). Using the 3750 ANN models calibrated with the 96 genes, we correctly classified 100% of the 20 SRBCT tests (FIG. 6 and Table 11) as well as all 63 training samples, see Table 4. Three of these samples, Test 10, Test 20 and EWS-T13 were correctly assigned to their categories (RMS, EWS and EWS respectively), having received the highest vote for their respective categories. However, their distance from a perfect vote was greater than the expected 95th percentile distance (FIG. 6); therefore, we could not confidently diagnose them by this criterion. All of the five non-SRBCT samples were excluded from any of the four diagnostic categories, since they fell outside the 95th percentiles. Using these criteria for all 88 samples, the sensitivity of the ANN models for diagnostic classification was 93% for EWS, 96% for RMS and 100% for both NB and BL. The specificity was 100% for all four diagnostic categories.

Also, hierarchical clustering using the 96 genes, identified from the ANN models, correctly clustered all 20 of the test samples (FIG. 9). Moreover, the two pairs of samples that were derived from two cell lines, BL-C2 and C4 (ST486) and NB-C2 and C7 (GICAN), were adjacent to one another in the same cluster.

Example 6 Expression of FGFR4 on SRBCT Tissue Array

To confirm the effectiveness of the ANN models to identify genes that show preferential high expression in specific cancer types at the protein level, we performed immunohistochemistry on SRBCT tissue arrays for the expression of fibroblast growth factor receptor 4 (FGFR4 (SEQ. ID. NO. 71)). This tyrosine kinase receptor is expressed during myogenesis but not in adult muscle, and is of interest because of its potential role in tumor growth and in prevention of terminal differentiation in muscle. Moderate to strong cytoplasmic immunostaining for FGFR4 (SEQ. ID. NO. 71) was seen in all 26 RMSs tested (17 alveolar, 9 embryonal). We also observed generally weaker staining in EWS and BL in agreement with the microarray results, except for one of anaplastic large cell lymphoma that was strongly positive (data not shown).

As such, the foregoing description of the exemplary embodiments of the invention has been presented for the purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed. Many modifications and variations are possible in light of the above teaching. It is intended that the scope of the invention be limited not with this detailed description, but rather by the claims appended hereto. The present invention is presently embodied as a method, apparatus, and a computer data product containing a computer program for classifying and diagnosing disease using artificial neural networks.

The above specification, examples and data provide a complete description of the manufacture and use of the composition of the invention. Since many embodiments of the invention can be made without departing from the spirit and scope of the invention, the invention resides in the claims hereinafter appended. 

1. A selection of genes expressed in a cancer cell, said gene selection functioning to characterize the cancer when the expression of said gene selection from said cancer cell is compared to the expression of an identical selection of genes from a noncancerous cell.
 2. The gene selection of claim 1, wherein said cancer to be identified is neuroblastoma.
 3. The gene selection of claim 1, wherein said cancer to be identified is rhabdomyosarcoma.
 4. The gene selection of claim 1, wherein said cancer to be identified is Burkitt's.
 5. The gene selection of claim 1, wherein said cancer to be identified is Ewing family of tumors.
 6. The gene selection of claim 1, wherein said genes are chosen from table
 5. 7. The gene selection of claim 1, wherein said genes are chosen from table
 2. 8. The gene selection of claim 1, wherein said genes are chosen from table 2b.
 9. The gene selection of claim 1 comprising at least 9 genes chosen from table
 5. 10. The gene selection of claim 9, wherein said at least 9 genes are selected from the top ranked genes.
 11. The gene selection of claim 2, wherein said gene selection comprises at least one of the genes with the following Image Id.: 8 12105 (SEQ. ID. NO. 32), 383188 (SEQ. ID. NO. 38), 82225 (SEQ. ID. NO. 42), 878280 (SEQ. ID. NO. 33), 135688 (SEQ. ID. NO. 44), 308231 (SEQ. ID. NO. 39), 486110 (SEQ. ID. NO. 45), 377048 (SEQ. ID. NO. 40), 784257 (SEQ. ID. NO. 34), 395708 (SEQ. ID. NO. 30), 292522 (SEQ. ID. NO. 36), or 813266 (SEQ. ID. NO. 47).
 12. The gene selection of claim 3, wherein said gene selection comprises at least one of the following genes with the following Image Id.: 244618 (SEQ. ID. NO. 77), 298062 (SEQ. ID. NO. 74), 324494 (SEQ. ID. NO. 62), 122159 (SEQ. ID. NO. 66), 788107 (SEQ. ID. NO. 52), 377671 (SEQ. ID. NO. 68), 784224 (SEQ. ID. NO. 71), 293500 (SEQ. ID. NO. 80), 42558 (SEQ. ID. NO. 79), 246377 (SEQ. ID. NO. 51), 809901 (SEQ. ID. NO. 67), 769959 (SEQ. ID. NO. 69), or 755750 (SEQ. ID. NO. 49).
 13. The gene selection of claim 4, wherein said gene selection comprises at least one of the following genes with the following Image Id.: 609663 (SEQ. ID. NO. 99, or 868304 (SEQ. ID. NO. 86).
 14. The gene selection of claim 5, wherein said gene selection comprises at least one of the following genes with the following Image Id.: 770394 (SEQ. ID. NO. 20), 866702 (SEQ. ID. NO. 16), 357031 (SEQ. ID. NO. 18), 377461 (SEQ. ID. NO. 19), 52076 (SEQ. ID. NO. 13), 1473131 (SEQ. ID. NO. 15), 208718 (SEQ. ID. NO. 2), 80338 (SEQ. ID. NO. 14), 377731 (SEQ. ID. NO. 23), 814260 (SEQ. ID. NO. 17), 364934 (SEQ. ID. NO. 12), 755599 (SEQ. ID. NO. 25), 291756 (SEQ. ID. NO. 1), 308497 (SEQ. ID. NO. 24), or combinations thereof.
 15. A product of the gene selection of claim 1, wherein said product is mRNA, proteins, cDNA, DNA, antibodies, vaccine, or combinations thereof.
 16. A selection of genes expressed in a cancer cell, said gene selection functioning to characterize the cancer when the expression of said gene selection from said cancer cell is compared to the expression of an identical selection of genes from a different type of cancer cell.
 17. The gene selection of claim 16, wherein said cancer to be identified is neuroblastoma.
 18. The gene selection of claim 16, wherein said cancer to be identified is rhabdomyosarcoma.
 19. The gene selection of claim 16, wherein said cancer to be identified is Burkitt's.
 20. The gene selection of 16, wherein said cancer to be identified is Ewing family of tumors.
 21. The gene selection of claim 16, wherein said genes are chosen from table
 5. 22. The gene selection of claim 16, wherein said genes are chosen from table
 2. 23. The gene selection of claim 16, wherein said genes are chosen from table 2b.
 24. The gene selection of claim 16 comprising at least 9 genes chosen from table
 5. 25. The gene selection of claim 24, wherein said at least 9 genes are selected from the top ranked genes.
 26. The gene selection of claim 17, wherein said gene selection comprises at least one of the genes with the following Image Id.: 812105 (SEQ. ID. NO. 32), 383188 (SEQ. ID. NO. 38), 82225 (SEQ. ID. NO. 42), 878280 (SEQ. ID. NO. 33), 135688 (SEQ. ID. NO. 44), 308231 (SEQ. ID. NO. 39), 486110 (SEQ. ID. NO. 45), 377048 (SEQ. ID. NO. 40), 784257 (SEQ. ID. NO. 34), 395708 (SEQ. ID. NO. 30), 292522 (SEQ. ID. NO. 36), or 813266 (SEQ. ID. NO. 47).
 27. The gene selection of claim 18, wherein said gene selection comprises at least one of the following genes with the following Image Id.: 244618 (SEQ. ID. NO. 77), 298062 (SEQ. ID. NO. 74), 324494 (SEQ. ID. NO. 62), 122159 (SEQ. ID. NO. 66), 788107 (SEQ. ID. NO. 52), 377671 (SEQ. ID. NO. 68), 784224 (SEQ. ID. NO. 71), 293500 (SEQ. ID. NO. 80), 42558 (SEQ. ID. NO. 79), 246377 (SEQ. ID. NO. 51), 809901 (SEQ. ID. NO. 67), 769959 (SEQ. ID. NO. 69), or 755750 (SEQ. ID. NO. 49).
 28. The gene selection of claim 19, wherein said gene selection comprises at least one of the following genes with the following Image Id.: 609663 (SEQ. ID. NO. 99, or 868304 (SEQ. ID. NO. 86).
 29. The gene selection of claim 20, wherein said gene selection comprises at least one of the following genes with the following Image Id.: 770394 (SEQ. ID. NO. 20), 866702 (SEQ. ID. NO. 16), 357031 (SEQ. ID. NO. 18), 377461 (SEQ. ID. NO. 19), 52076 (SEQ. ID. NO. 13), 1473131 (SEQ. ID. NO. 15), 208718 (SEQ. ID. NO. 2), 80338 (SEQ. ID. NO. 14), 377731 (SEQ. ID. NO. 23), 814260 (SEQ. ID. NO. 17), 364934 (SEQ. ID. NO. 12), 755599 (SEQ. ID. NO. 25), 291756 (SEQ. ID. NO. 1), 308497 (SEQ. ID. NO. 24), or combinations thereof. 30.-31. (canceled)
 32. A method of targeting a product of at least one of the genes in table 5 or table 10 comprising the step of administering a therapeutic agent having a therapeutic effect on said gene product.
 33. The method of claim 32, wherein said at least one gene is chosen from table
 2. 34. The method of claim 32, wherein said at least one gene is chosen from table 2b.
 35. The method of claim 32, wherein said gene product is chosen from the group consisting of: DNA, mRNA, proteins, and combinations thereof.
 36. The method of claim 32, wherein said therapeutic agent is delivered to a cancer cell.
 37. The method of claim 32, wherein said therapeutic agent is delivered in the vicinity of a cancer cell.
 38. The method of claim 32, wherein said therapeutic agent is chosen from the group consisting of: vaccines, antibodies, oligonucleotide DNA antisense, RNAi, chemical molecules, proteins, inhibitors, antagonists, and combinations thereof.
 39. (canceled)
 40. The method of claim 32, wherein said cancer is neuroblastoma.
 41. The method of claim 40, wherein said genes are selected from the group consisting of those with the following Image Id.: 812105 (SEQ. ID. NO. 32), 383188 (SEQ. ID. NO. 38), 82225 (SEQ. ID. NO. 42), 878280 (SEQ. ID. NO. 33), 135688 (SEQ. ID. NO. 44), 308231 (SEQ. ID. NO. 39), 486110 (SEQ. ID. NO. 45), 377048 (SEQ. ID. NO. 40), 784257 (SEQ. ID. NO. 34), 395708 (SEQ. ID. NO. 30), 292522 (SEQ. ID. NO. 36), 813266 (SEQ. ID. NO. 47), and combinations thereof.
 42. The method of claim 40, wherein said genes are selected from table
 6. 43. The method of claim 32, wherein said cancer is rhabdomyosarcoma.
 44. The method of claim 43, wherein said genes are selected from the group consisting of those with the following Image Id.: 24461 8 (SEQ. ID. NO. 77), 298062 (SEQ. ID. NO. 74), 324494 (SEQ. ID. NO. 62), 122159 (SEQ. ID. NO. 66), 788107 (SEQ. ID. NO. 52), 377671 (SEQ. ID. NO. 68), 784224 (SEQ. ID. NO. 71), 293500 (SEQ. ID. NO. 80), 42558 (SEQ. ID. NO. 79), 246377 (SEQ. ID. NO. 51), 809901 (SEQ. ID. NO. 67), 769959 (SEQ. ID. NO. 69), 755750 (SEQ. ID. NO. 49), and combinations thereof.
 45. The method of claim 43, wherein said genes are chosen from table
 7. 46. The method of claim 32, wherein said cancer is Burkitt's.
 47. The method of claim 46, wherein said genes are selected from the group consisting of those with the following Image Id.: 609663 (SEQ. ID. NO. 95), 868304 (SEQ. ID. NO. 86), and combinations thereof.
 48. The method of claim 46, wherein said genes are chosen from table
 8. 49. The method of claim 32, wherein said cancer is a Ewing family tumor.
 50. The method of claim 49, wherein said genes are selected from the group consisting of those with the following Image Id.: 770394 (SEQ. ID. NO. 20), 866702 (SEQ. ID. NO. 16), 357031 (SEQ. ID. NO. 18), 377461 (SEQ. ID. NO. 19), 52076 (SEQ. ID. NO. 13), 1473131 (SEQ. ID. NO. 15), 208718 (SEQ. ID. NO. 2), 80338 (SEQ. ID. NO. 14), 377731 (SEQ. ID. NO. 23), 814260 (SEQ. ID. NO. 17), 64934 (SEQ. ID. NO. 12), 755599 (SEQ. ID. NO. 25), 291756 (SEQ. ID. NO. 1), 308497 (SEQ. ID. NO. 24), and combinations thereof.
 51. The method of claim 49, wherein said genes are chosen from table
 9. 52.-58. (canceled)
 59. The method of claim 32, wherein said genes are selected from the group consisting of those with the following Clone ID: 383188 (SEQ. ID. NO. 38), 82225 (SEQ. ID. NO. 42), 811000 (SEQ. ID. NO. 6), and combinations thereof.
 60. (canceled)
 61. The method of claim 32, wherein said genes are selected from the group consisting of those with the following CloneID: 714453 (SEQ. ID. NO. 41), 784224 (SEQ. ID. NO. 71), 245330 (SEQ. ID. NO. 78), 2907511 (SEQ. ID. NO. 444), and combinations thereof.
 62. (canceled)
 63. The method of claim 32, wherein said genes are selected from the group consisting of those with the following Clone Id.: 200814 (SEQ. ID. NO. 94), 609663 (SEQ. ID. NO. 99), 714453 (SEQ. ID. NO. 83), 768370 (SEQ. ID. NO. 46), 841620 (SEQ. ID. NO. 8), 323371 (SEQ. ID. NO. 27), and combinations thereof.
 64. (canceled)
 65. The method of claim 32, wherein said genes are selected from the group consisting of those with the following Clone Id.: 208718 (SEQ. ID. NO. 2), 1473131 (SEQ. ID. NO. 15), 357031 (SEQ. ID. NO. 18), 755599 (SEQ. ID. NO. 25), 364934 (SEQ. ID. NO. 12), 811000 (SEQ. ID. NO. 6), and combinations thereof.
 66. A method of using a selection of genes expressed in a cell having a particular type of cancer, said gene selection functioning to characterize the particular type of cancer when the expression of said gene selection from said cell is compared to the expression of an identical selection of genes from a cell without that particular type of cancer for diagnosing said particular type of cancer.
 67. The method of claim 66, wherein said method utilizes at least one gene from table
 5. 68. The method of claim 66, wherein said method utilizes at least one gene from table 2b.
 69. The method of claim 66, wherein said cell without that particular type of cancer is a noncancerous cell.
 70. The method of claim 69, wherein said method utilizes at least one gene product.
 71. The method of claim 70, wherein said at least one product is chosen from the group consisting of: proteins, mRNA, DNA, and combinations thereof.
 72. The method of claim 66, wherein said particular type of cancer is neuroblastoma.
 73. The method of claim 72, wherein said at least one gene is chosen from table
 6. 74. The method of claim 66, wherein said particular type of cancer is rhabdomyosarcoma.
 75. The method of claim 74, wherein said at least one gene is chosen from table
 7. 76. The method of claim 66, wherein said particular type of cancer is Burkitt's.
 77. The method of claim 76, wherein said at least one gene is chosen from table
 8. 78. The method of claim 66, wherein said particular type of cancer is Ewing family of tumors.
 79. The method of claim 78, wherein said at least one gene is chosen from table
 9. 80. A device for carrying out the method of claim 66 chosen from the group consisting of: protein arrays, cell arrays, a device to detect single polymorphisms in disease conditions, devices containing metaphase BAC genomes, cDNA arrays, and oligonucleotide arrays. 